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ABSTRACT 
The United States Pharmacopoeia/National Formulary (USP/NF) sets the standards 
and maintains monographs for the evaluation of tablets. These include Official Tests for 
uniformity of dosage units and disintegration testing, and Unofficial Tests for mechanical 
strength (hardness, crushing strength) and resistance to abrasion (friability). Current 
methods of analyzing tablet hardness involve the indirect measurement of the mechanical 
strength of a tablet through destructive and time-consuming procedures. Near-infrared 
reflectance spectroscopy (NIRS) is gaining acceptance in the pharmaceutical industry as a 
non-invasive and non-destructive method for the analysis of finished dosage forms and raw 
materials. This investigation outlines methods used to evaluate various tablet parameters 
using NIRS and the achievement of successful predictions of those parameters. NIR 
models for tablet hardness and density were developed for 15% and 20% 
hydrochlorothiazide and 2% and 6% chlorphenirarnine maleate in a 0.5% magnesium 
stearate and rnicrocrystalline cellulose matrix. NIR calibration models for tablet hardness 
were developed for flat-faced and convex round tablets containing 6% chlorphenirarnine 
maleate and 0.5% magnesium stearate, with either rnicrocrystalline cellulose or dibasic 
calcium phosphate dihydrate. Although the NIR response to changing hardness was the 
same regardless of the drug, separate models were required for tablets of different 
geometries. Scored tablets also required formulation specific calibrations for NIR hardness 
determination. Models for upper and lower compression forces were developed for flat-
faced round tablets containing 6% chlorphenirarnine maleate and 0.5% magnesium stearate, 
with either rnicrocrystalline cellulose or dibasic calcium phosphate dihydrate. NIRS 
prediction of these parameters was at least as precise as the reference hardness test. 
Calibration of compression forces was successful for rnicrocrystalline cellulose-based 
tablets, but not for the more variable dibasic calcium phosphate dihydrate systems. The 
methods described in this investigation may serve as a model for the future acceptance of 
NIRS as an alternative to current compendia! methods for tablet hardness. 
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PREFACE 
This document was prepared in the format of the manuscript plan in accordance to 
section l 1-3 of the Graduate Manual at the University of Rhode Island. The dissertation is 
divided into three sections. 
Section I contains a general introduction to the objectives of my research. Section 
II consists of the main body of this dissertation. This section is composed of four 
manuscripts, written in the format required for each scientific journal to which they were 
submitted. An addendum to Manuscript I was inserted between Manuscripts I and II. An 
addendum to Manuscript IV was included following Manuscript IV. A statement of overall 
conclusions for the entire dissertation is also included in this section. Section III contains 
three appendices which include additional information and experimental details useful to the 
understanding of the work in section II. A bibliography follows Section III, citing all 
sources used to create this document. 
iv 
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SECTION! 
INTRODUCTION 
Near-Infrared Reflectance Spectroscopy (NIRS) is becoming a valuable analytical 
tool in the pharmaceutical industry. NIRS involves the multidisciplinary approaches of the 
analytical chemist, statistician and computer programmer. The term "chemometrics" refers 
to the use of knowledge from other disciplines to derive meaningful chemical information 
from samples of varying complexity. Chemometrics is defined' as the chemical discipline 
that uses mathematical, statistical and other methods employing formal logic to: a) design 
or select optimal measurement procedures and experiments, and, b) provide maximum 
relevant chemical information by analyzing chemical data. Chemometrics has found 
widespread use in analytical chemistry and is relied upon for the development of NIRS 
methods. Numerous types of NIRS problems are studied with qualitative and quantitative 
chemometric methods. 
In the NIR region, the radiation can penetrate compacted materials, such as tablets, 
providing a vast amount of spectral information about the sample. When used in 
reflectance mode, the NIR light beam is scattered from powder samples after its molecules 
have absorbed it selectively. The unabsorbed radiation then passes to the several detectors 
mounted at an angle to the path of the incident rays. The analysis takes approximately 40 
seconds per sample. Application of a math treatment, such as second derivative, prepares 
the raw spectral data for use in a regression and subsequent development of a calibration 
equation. This type of treatment results in a data file which will yield more information 
more easily than a raw data file. 
Official Standards for the evaluation of tablets are prescribed by the United States 
Pharmacopoeia2 (USP) and other compendia and include uniformity of dosage units 
(weight variation, content uniformity) and disintegration testing. Unofficial tests include 
those for mechanical strength (hardness, crushing strength) and resistance to abrasion 
(friability). Tablet hardness or crushing strength is an indication of the mechanical strength 
2 
of a tablet. Hardness has also been associated with other tablet properties, such as density 
and porosity'. 
Tablet hardness depends on the weight of material and the space between the upper 
and lower punches at the moment of compression. Inconsistent hardness values are likely 
to result from variation in these parameters. A tablet should be no harder than necessary 
for adequate handling and shipping. If the tablet is too hard, it may not disintegrate in the 
required amount of time. lf it is too soft, it may not withstand the rigors of shipping, 
handling and dispensing, and may crumble easily. In production, a hardness of four 
kilograms (or kilopons) is considered to be minimum for a satisfactory tablet4 • 
Variation in tablet hardness may be caused by poor mixing, poor flow, unequal 
length punches, or a variation in the size and distribution of granules being compressed. 
Poor mixing of a formulation may lead to poor flow of material, since lubricants and 
glidants may not have been thoroughly distributed. Poor flow may cause improper filling 
of the dies, resulting in weight and hardness variation. A slight variation in the lengths of 
the lower punches can lead to variation in the fill volume and affect tablet hardness. 
Finally, if there are too many large granules present, the proportion of large and small 
particles may change the fill weight in each die' . 
Results of mechanical tests give an indication of how the tablet will behave during 
handling. The crushing strength of a tablet (axial or radial) has been described as a 
function of the compressional pressure employed during its compaction•. The mechanical 
strength of a tablet plays an important role in the development and control procedures. 
Crushing strength is the most widely used test of mechanical strength. It is defined as the 
compression force which, when applied diametrically to a tablet, just fractures it7. 
The Erweka Hardness Tester, which is commonly used in the pharmaceutical 
industry, measures horizontal crushing strength by applying a load at 90° to the longest 
axis. This type of hardness tester is subject to two sources of inherent error: ( 1) the 
possibility of an incorrect zero and (2) a scale that does not accurately indicate the true load 
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applied. Other commercially used instruments include the Strong-Cobb, Monsanto and 
Pfizer hardness testers. Variations in crushing strength values obtained from different 
types of hardness testers are due to inaccuracies in instrument scale values, incorrect zero 
adjustment, and varying methods of applying the load. This necessitates calibration when 
comparing results from different types of testers. The physical dimensions and shape of 
the tablet may also contribute to the property of crushing strength. 
The conventional methods of hardness testing for tablets also involve a subjective, 
operator error. The scale on the Erweka Hardness Tester is divided into segments of 0.25 
kg units. Very often, the sample under evaluation may produce a reading that falls in 
between two divisions and it is up to the operator to decide upon the result. Consistency in 
reading the scale is very important. It is imperative that an accurate and reliable method of 
testing be used to evaluate tablet hardness. 
There is reason to believe that the NIR signal would vary if the compression force 
used to manufacture tablets was changed. Many drug attributes, such as particle size, 
density, moisture content and surface area can have a direct effect on the compaction 
process. Current "wet" methods of analyzing tablets involve the indirect measurement of 
the mechanical strength of a tablet through destructive and time-consuming procedures. 
Many of these tests do not give an entirely accurate indication of how the tablet will behave 
during handling. 
Intuitively, a harder tablet would have a smoother surface, thus changes in hardness 
(compression force) would be expected to alter the NIR spectra. Presumably, increased 
compression force causes a harder tablet to be smoother, thus causing less light scattering, 
leading to greater absorbance and a higher baseline8. However, not all of the tablets within 
a batch or between batches would have the same hardness properties. It is not known to 
what extent it would be feasible to develop standard procedures to quantify compaction 
force. The use of NIRS could provide an alternative method of quantifying the compaction 
properties of a tablet. 
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HYPOTHESIS TESTED IN THIS Ph.D. PROJECT 
There is considerable interest in the area of quantification and prediction of tablet 
parameters using near-infrared spectroscopy (NIRS)9·w If certain process parameters 
were altered, a change in the NIR spectra of the sample would be expected. It has been 
shown that the NIR signal is modified by changes in particle size, morphology and 
crystallinity. 11 For instance, a very rough surface of many small particles would enhance 
scattering and absorption of infrared radiation. Thus we can conclude that changes in 
compression force may have a substantial effect on the intensity of the NIR signal of a drug 
in a tablet. 
The current literature contains no data that indicates to what extent the NIR signal is 
modified by the compression force used to manufacture the tablet. Questions remain as to 
what extent NIRS can be used for finished dosage forms. If a relationship between the 
compression force and the NIR spectra cannot be established, then NIRS would be of 
limited value. 
The hypothesis to be tested in this research is that NIRS can be utilized for the 
nondestructive determination of tablet hardness in a manufacturing environment, and offers 
potential as an alternative to traditional methods of hardness testing. Although this project 
is limited to a small number of drugs and matrices, it is hoped that the general principles 
will be applicable to many or all drugs. Thus, it is hoped that the project will be of material 
value in advancing the possible use of NIRS for compendia! standards. 
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OBJECTIVES 
The objectives of this research project were: 
1) To evaluate the utility of Near-Infrared Reflectance Spectroscopy (NIRS) for the 
measurement of tablet hardness. 
2) To describe the relationship between NIR signal and tablet compaction force or 
hardness. 
3) To compare traditional "wet" methods of tablet analysis to NIRS methods and 
calibrate a NIRS instrument to tablet hardness. 
4) To develop a NIRS method of quantifying the compaction properties of a tablet, 
which might replace or augment existing compendia] tests and demonstrate the 
potential utility of the technique as an alternative to current methods of tablet 
hardness testing. 
5) To examine the effect of tablet geometry and excipient matrix on the 
NlR/compression force relationship. 
6) To evaluate any differences in NIR response due to scoring of a tablet. 
7) To examine the utility of NIRS as a quality control mechanism in determining 
adherence to batch requirements for hardness. 
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SECTION II 
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Manuscript I 
Pharmaceutical Uses Of Near-Infrared Spectroscopy 
*published in Drug Development and Industrial Pharmacy 21 (9) I 071- l 090 ( 1995). 
Abstract 
Near-infrared spectroscopy (NIRS) has been used extensively in the food and 
agricultural industries for the past twenty years. Recent technological advances have made 
NIRS an attractive analytical method for use in the pharmaceutical industry. NIRS has 
been shown to be useful as a qualitative and a quantitative method. A review of 
pharmaceutical applications of NIRS as well as quality control and regulatory issues is 
presented. 
Introduction 
In recent years, near-infrared spectroscopy (NIRS) has become an important 
analytical technique in industry. It bas been used extensively in the food and agricultural 
industries for the determination of moisture, protein and starch content in grains'. The use 
of NIRS to solve pharmaceutical problems is increasing because of technological advances 
in NIR analytical instrumentation and computer software. Though the spectroscopy itself 
is not new, its applications and its use of chemometrics are new and innovative. 
It is now recognized that NIRS offers significant advantages for a broad range of 
quantitative applications. NIRS is a rapid analytical technique that uses the diffuse 
reflectance of a sample at several wavelengths to determine the sample's quantitative 
composition. Sophisticated software stores calibration equations which correspond to the 
spectral features of a sample. In the pharmaceutical industry, NIRS has been shown to be 
useful in determining the percentage of active ingredient as well as in identifying specific 
tablet formulations . NIRS has potential as both a qualitative and quantitative method in the 
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pharmaceutical industry'. Other pharmaceutical uses include raw material identification3 as 
well as monitoring content uniformity in powder mixing operations•. 
The NIR region of the infrared spectra was discovered by William Herschel in the 
early 1800's. It deals with the absorption of electromagnetic radiation in the range of 800 
to 2500 nm' . The segment from 1100 to 2500 nm is known as the Herschel region, and is 
the range most often used in the analysis of pharmaceutical products. 
NIR is more often used as a secondary analytical technique than a primary technique. 
When used as a primary technique, standards are prepared from reference materials, just as 
they are for other primary analytical techniques. A library of known spectra is created, then 
the instrument response is plotted for each sample, yielding a calibration curve. 
Sophisticated mathematical techniques are applied to the data via computer software, and 
the results may be calculated within a few minutes. 
Historical Background 
Near Infrared Spectroscopy (NIRS) has been used in the food industry for over 
twenty years to determine the components of feeds and grains. A major stimulus to interest 
in analytical applications of NIRS has been the success achieved in the analysis of 
agricultural products. Pioneering work by Karl Norris and coworkers at the United States 
Department of Agriculture (USDA) resulted in the development of methods for 
determination of components of forage crops. Norris is credited as with being the first to 
use NIRS to analyze chemically complex solid samples. He was also the first to utilize 
multivariate methods of analysis for quantifying the complex NIR spectra6 . NIR 
reflectance spectra are widely accepted in the food and grain industry for the determination 
of protein, fat, moisture, and other factors. It is also used for compositional analysis of 
dairy products and meats. 
Before 1990, most publications on NIRS concerned applications in the agriculture and 
food industries. NIRS research is ongoing in nearly all analytical disciplines. Since 1990, 
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more NIRS papers were published in the field of general chemistry than in the field of 
agriculture 7 . 
Many of the well known analytical meetings, such as PittCon, Federation of 
Analytical Chemistry and Spectroscopy Societies (FACSS), American Association of 
Pharmaceutical Sciences (AAPS) and Eastern Analytical Society (EAS) have recently 
included technical sessions and posters involving NIRS . In October, 1993, the 
Association of Analytical Chemists (AOAC) held a special symposium on Pharmaceutical 
Process Control and Quality Assessment by Non-Traditional Means. The conference, the 
first of its kind, consisted solely of topics relating to applications of NIRS in 
pharmaceutical manufacturing and the use of neural networks in drug fingerprinting. 
It is anticipated that adoption ofNIRS methods and related technologies will be 
explosive because they offer the potential for major improvements in quality control, record 
keeping, and control of product uniformity . However, the requirements for pharmaceutical 
quality control are more severe than in other fields . Analytical methods are required to be 
extremely accurate, specific and precise. In addition, since active components are often 
present in small quantities, the methods must be very sensitive. Absorption in the near 
infrared region is generally weak, which is an advantage for major components since no 
sample dilution is needed. However concentrations of minor components are often at or 
near the detection limit of the instrument' . 
Fundamentals And Instrumentation 
Theory 
NIRS deals with the absorption of electromagnetic radiation in the range of 700 to 
2500 nm9 . It is a rapid analytical technique, using the diffuse reflectance of a sample at 
several wavelengths to determine the sample's composition. 
The absorption of infrared radiation is the result of transitions between molecular 
vibrational and rotational states (twisting, bending). Upon interaction with infrared 
radiation, portions of the incident radiation are absorbed at specific wavelengths. One of 
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the features of an infrared spectrum is that absorption in a specific region can be correlated 
to functional groups in the molecule (e.g., fingerprint region 7690-15,380 nm). Multiple 
vibrations occur simultaneously and produce a complex absorption spectrum that is 
uniquely characteristic of the functional groups that make up the molecule and of the overall 
configuration of the molecule. 
The NIR region of the spectrum contains overtones and combination bands which are 
mainly due to hydrogen vibrations (OH, CH, NH). These overtones and combination 
bands are much weaker than the fundamental vibrations, so the molar absorptivities are 
between 10 and 1000 times smaller than those of the corresponding infrared bands. Due to 
the smaller molar absorptivities, it is possible to use undiluted samples and obtain 
remarkable depth of penetration into solid samples. The NIR range is adequate for 
studying most organic compounds. 
There are some important differences between the near infrared region and other 
infrared (IR) spectrophotometry. Conventional laboratory IR instruments can operate in 
either the near, mid, and far IR regions, depending on the energy source and the detectors 
used. The wavelength range used for NIR is just beyond the visible end of the 
electromagnetic spectrum, from about 700 nm to 2500 nm. Other regions of the IR 
spectrum are referred to in terms of wavenumbers. Thus the near infrared region is from 
14,300 to 4000 cm-I, the mid infrared range is 4000 to 200 cm- I, and the far infrared range 
is from 200 to 10 cm- I. 
Instrumentation 
NIR instrumentation comprises four categories: monochromator, filter, selective 
diode, and Fourier-transform near-infrared (FT-NIR). Most laboratory NIR instruments 
depend on the dispersion-type monochromator for generating the monochromatic beam. 
Holographic gratings, which are produced by a photo etching process, have replaced the 
old mechanically grooved and replicated gratings. The newer gratings are easier to 
manufacture and cost less than their predecessors. 
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The energy sources used in most NIR instruments are long-lasting, tungsten-halogen 
lamps with quartz envelopes. A lamp which is used for 40 hours per week may be 
expected to last approximately 100 weeks. Detectors may be silicon photo voltaic sensors 
(360 to 1000 nm range) or lead sulfide (900 to 2600 nm range). Both types integrate 
diffusely reflected light. 
NIR radiation is readily scattered by particles, making reflectance analysis an ideal 
technique for the analysis of solids. When the light from a NIR source is directed on a 
sample, both specular and diffuse reflected light are generated by the sample. However, 
only the diffuse reflected light contains the desired chemical information. An integrating 
sphere is used to segregate the diffuse and specular reflectance and to focus the diffuse 
reflected radiation onto the detector. A scanning grating monochromator between the 
source and the sample is used to obtain the desired spectrum. 
Instrumentation developed for NIRS can be implemented either at-line, where a 
technician routinely extracts a sample from the process stream and transfers it to the 
instrument; on-line, where the sample is moved automatically to the instrument mechanical 
device; or in-line, where a fiber optic probe is place directly in the process stream. 
Since ordinary glass is transparent in the NIR wavelength range, the optical 
components of NIR instrumentation don't have to be made of fragile materials. This lack 
of response by glass as well as quartz enables these materials to be used as transparent 
containers and also permits the use of optical fibers to transmit the spectra. ' 0 Glass cannot 
be used in instruments designed for the mid and far IR regions. 
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Marketed Equipment And Suppliers 
Phannaceutical Applications 
NIRSysterns of Silver Spring, Maryland (formerly Pacific-Scientific) supplies most 
of the NIR laboratory instrumentation used by the pharmaceutical industry. These 
instruments are scanning monochromators with interchangeable ("modular") sampling 
systems that include transmission, reflectance, and fiber optic models. NIRSystems 
manufactures a Rapid Content Analyzer™, which can be fitted with specially designed 
sample holders to analyze the contents of transdermal patches, tablets, capsules, and 
various pharmaceutical packaging. The company, a division of the Swedish company 
Perstorp Analytical, specializes in process and laboratory instrumentation primarily for 
food and agricultural, pharmaceutical, chemical , and polymer applications. 
Process and Laboratory Applications 
NIR instruments are manufactured for use in process, at-line, on-line and laboratory 
applications. Bran & Luebbe Analyzing Technologies, of Buffalo Grove, IL is a German-
based company that supplies NIR instruments for use in raw materials release and 
identification. Buehler also supplies instruments for raw materials release and 
identification. Other manufacturers of NIR instrumentation include the following: 
ABB Process Analytics, Lewisburg, WV 
Axiom Analytical, Irvine, CA 
Dickey-John, Auburn, IL 
Guided Wave, Inc., El Dorado Hills, CA 
Infrared Engineering, Inc., Waltham, MA 
Katrina, Inc., Hagerstown, MD 
LT Industries, Inc., Rockville, MD 
Ocean Optics, Dunedin, FL 
Perkin-Elmer, Pomona, CA 
Trebor Industries, Inc., Gaithersburg, MD 
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Calibration 
NIR instruments collect full spectra of a sample and use the statistical technique of 
chemometrics to infer physical and chemical parameters from a spectral scan. 
Chemometrics is a technique which links analytical information to properties other than 
concentration of chemical species. Chemometric methods are applied to the design and 
implementation of analyses so that the most efficient and informative experiments are 
carried out. They are also applied to the experimental results to enhance accuracy in 
interpretation. Calibration techniques, such as multiple linear regression (MLR), principal 
components regression (PCR) and partial least squares (PLS) may be utilized via the 
instrument software, and are linear functions of the reflectance of absorbance. 
A calibrated mathematical model is created to calculate the parameters. Calibration 
involves taking spectra from a great many samples varying over the measurement range and 
also measuring the desired parameters. A rugged chemometric model for a complex sample 
may require thousands of samples taken from all possible situations, in and out of 
specification, that it may encounter. Samples selected for calibration must contain all the 
variables affecting the chemical and physical properties of the samples to be analyzed. In 
order to characterize each source of variation, it is recommended that 15 to 20 samples be 
run for each variable. 
Because NIR bands are mixtures of overtones and combinations, the intensity of 
the absorbance at any particular wavelength does not necessarily respond linearly to a 
change in concentration. In the case of a mixture, band mixing may further disrupt any 
linear relationship between the intensity and the concentration. For these reasons, the 
simple application of Beer's Law (A= ebc, where A= absorbance, e =absorptivity, b = 
path length, and c =concentration) to NIR bands may not generate equations suitable for 
quantitation. 
To avoid this problem, ca]jbration equations are generated using multiple regression 
techniques. A series of samples representing the concentration range of interest are selected 
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and their spectra obtained. This group of spectra is divided into two groups: a calibration, 
or training set and a test, or prediction set. The spectra of the calibration set are used to 
correlate the constituent of known concentration with those of the prediction set. 
The quality of the calibration equation is detennined by a number of factors, 
including the multiple correlation coefficient (MCC), the F-value, and the standard error of 
estimation (SEE). These parameters are measures of the fit between the actual training set 
concentrations and the values predicted by the calibration equation. Ideally, it desirable to 
obtain a MCC value as close to 1.0 as possible, indicating 100 % correlation. The value of 
the SEE should be as minimal as possible, since it indicates the standard deviation of the 
differences between the actual and predicted values for the calibration set. 
One of the major drawbacks of NIRS is the degree of difficulty in calibration of the 
instruments. A calibration is required for each constituent in the sample. The mathematical 
models used can depend critically on the character of the sample, its preparation, and 
operator technique. Laboratories that analyze many samples will be the most satisfied users 
of this technique; labs that analyze only a few samples a week may have trouble justifying 
the setup time. 
Another issue is that of "transferability" of the calibration model, including 
transferable correlation coefficients, that would be usable on all instruments. A model built 
on extensive samples and spectra is much more readily transferable than one developed 
with only a few samples. Although some progress has been made in making calibration 
transfers between instruments, the situation is far from ideal, and careful monitoring is 
needed to obtain satisfactory results. 
QC and Regulatory 
The pharmaceutical industry's interest in NlR technology is in the production of 
better products at a lower cost, while the regulatory interest is in product control and 
uniformity and the detection of deviations from the approved formulations. 
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Validation of a NIRS method is necessary for acceptance by regulatory bodies. The 
error of the primary method must be well known. Accuracy, linearity, reproducibility, 
specificity, sensitivity, and robustness of the method must be demonstrated . The accuracy 
of the NIR results is obtained by comparison with the reference analytical method. 
Specificity of the method can be determined through the use of instrument software which 
qualifies the sample. Since sample placement is an important source of error, the same 
sample should be measured, removed and remeasured several times to determine 
reproduciblity. Robustness of the assay may be tested by varying the operating conditions. 
The major pharmacopoeias allow manufacturers to use alternative analytical 
methods for compliance testing. However, these alternatives must be validated in order to 
demonstrate that they arrive at the same conclusions as the conventional methods. Official 
approval of a NIR method requires acceptable performance using different instruments with 
the same samples. This may be difficult because there is no agreed upon model for 
instrument calibration; each company uses its own model and each type of sample requires 
a different model. It is usually necessary to customize a model to a particular sample and 
instrument. It may be possible to satisfy in-house quality control specifications for product 
consistency within one facility . However, these results must be reproducible at other 
manufacturing sites. 
The United States Food and Drug Administration (U.S.F.DA.) recently approved 
(May 1992) the use of a NIRS method in place of compendia! methods for moisture 
content, identification and assay for ampicillin trihydratel 1. This was the first time the 
U.S.F.D.A. approved the use of a NIRS method for release testing of a bulk 
pharmaceutical product for human consumption. The method was developed at Gist-
brocades bv, a Netherlands-based pharmaceutical company. Validation studies using the 
NIR method showed that it offered faster and more accurate results, eliminated the use of 
solvents, and produced no waste products. This approval is likely to be followed by other 
computer-based technologies which will rapidly come into use in the pharmaceutical 
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industry. It is anticipated that "adoption of these technologies will be explosive because 
they offer the potential for major improvements in the control of product uniformity and 
quality and better record-keeping ... " at a significantly lower cost 12. 
Canada's pharmaceutical regulatory agency, the Health Protection Branch (HPB), 
recently (December, 1993) approved the use of a NlR method for identification of raw 
materials and packaging components developed at Merck Frosst Canada, Inc. to repl ace 
compendia! methods of identification 13. The submitted method utilized a database of 
reference spectra of 185 different raw materials and packaging components. It contained 
examples of successful identification and differentiation between HDPE (high-density 
polyethylene) and LDPE (low-density polyethylene) using NlRS. 
Pharmaceutical Applications 
Moisrure Determination 
The classical methods for water determination are based on weight loss by drying 
or on Karl-Fischer Titration. The presence of water is indicated by a NlR absorption band 
in the 1900 to 2000 nm region due to the combination of fundamental bending and 
stretching vibrations of the OH bond. Moisture levels in grains I 4 have been measured 
using the OH absorption at 1950 nm. The absorption maximum and peak shape depend on 
the degree of hydrogen bonding occurring within the environment where the water is 
located. The stronger the hydrogen bond, the longer the wavelength of the NlR absorption 
maximum. 
The physical and chemical properties of water and their functions of temperature 
were determined by NIRS by Lin and Brown15. Properties determined included density, 
refractive index, dielectric constant, surface tension , ionization constant, as well as various 
thermal and thermodynamic properties. It was concluded that NIRS, when used with 
multivariate regression, can be used as a simple, fast and universal approach for the 
simultaneous determination of the physical and chemical properties of water. 
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NIR methods for the determination of water in freeze-dried products were 
developed by Jones, et al 16. The authors were able to analyze 40 samples per hour using 
this method, and found good agreement (correlation coefficients up to 0.95) between NIR 
predicted values and the Karl Fischer reference values. It was concluded that the NIR 
method provided more accurate and precise data than Karl Fischer titration since it avoided 
the need to open the vials and risk contamination from atmospheric moisture. 
Kamat, et al 17 reported a method of determining residual moisture in lyophilized 
sucrose through the intact glass vials. The peaks attributable to water appeared at 1450 and 
1940 nm. Results indicated a water concentration in the range of 0.72 to 4.74 % with an 
RSD of 6.7 %. A prediction error of0.27% was reported with a single scan. 
Sinsheimer and Poswatk18 measured the 1900 nm moisture band in solids, solvent 
systems, and a micellar system of dioctyl sodium sulfosuccinate (DSS). For solvent 
systems, they concluded that the range of conforrnity to Beer's Law is limited to the lower 
concentrations in weakly basic solvents. 
Boehm and Liekmeierl 9 studied the moisture content of solid dyes and organic 
solvents. They identified three working ranges for quantitative water determination (Table 
I). Nonpolar, organic solvents, such as carbon tetrachloride, were analyzed at 2400 nm, 
the most sensitive band. An indigo dye was analyzed at the 1900 nm wavelength. 
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Table I. Working ranges for quantitative water determination with NJRS 19 
Absorption bands 
(nm) 
1400 
1900 
2700 
20 
Working range for 
_<lllantitative analysis 
0.1 to5% 
0.02 to 0.5 % 
10to200J>I>..m 
NIRS was applied by Corti, et aJ20 to the analytical control of the active ingredient 
and water content of tablets of ranitidine chlorhydrate. The maximum acceptable water 
content for ranitidine tablets was 2 %. The reference value using the Karl Fischer 
(reference) method was I %. Comparison of NIRS values to Karl Fischer values indicated 
higher errors occurring with samples having a water content of less than I % (by reference 
method). None of the NIRS values exceeded 2 %. 
Solid dosage forms 
Current methods of tablet analysis are destructive in nature, and do not allow for 
100% quality control testing. NIRS is a non-invasive and non-destructive method which, 
in theory, would allow 100% inspection of every tablet. It is theoretically possible to 
determine the amount of drug in every tablet in every batch, and check to ensure that a 
tablet is placed in its correct container. In this respect, NIRS is attractive from both a 
quality control and a regulatory perspective. In addition to being a non-destructive method, 
other advantages of NIRS over other quantitative methods include relative ease of sample 
preparation and fast analysis. 
Several authors have reported methods for the identification of active components in 
tablet2 l,22 and liquid23 dosage forms, as well as for raw material identification24. 
A general method for the rapid verification of identity and content of solid dosage 
forms was devised by Ryan, et al25. The authors evaluated the use of mid (MIRS) and 
near inf rared spectrometers to analyze tablet and capsule dosage forms containing either 
lovastatin, simvastatin, enalapril, finastride, or placebo in the range of 0.2 to 40 mg of 
drug. The minimum amount of active drug (in the presence of excipients) detected by both 
methods was I% (w/w). It was reported that NIRS could not allow for differentiation 
between an a-hydrogen atom on the lovastatin ester group and an additional a -methyl 
group in simvastatin. However, the MIRS method was able to distinguish between the two 
structures, since it is well suited for structural elucidation and identification of compounds. 
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Lodder and Hieftje26 described a NIRS method of analysis of intact aspirin tablets. 
The method involved the use of a double-reflecting aluminum sample holder which 
preserved the integrity of the tablet during the analysis. 
Lodder, et at27 reported a NIRS method for the detection of adulterated 
nonprescription drugs. This work was triggered by the 1982 incidents28. of potassium 
cyanide-laced Extra Strength Tylenol® capsules in the Chicago area that resulted in seven 
deaths The adulterants tested included potassium cyanide, sodium cyanide, ferric oxide, 
aluminum metal shavings, arsenic trioxide, and sodium fluoride. The detection limit for 
potassium cyanide was 2.6 mg, or two orders of magnitude less than the lowest reported 
lethal dose in humans (2.941 mg/kg, or 306 mg for a 70 kg person). One shortcoming of a 
NIRS method in this situation is that it is not possible to predict what contaminant might be 
placed in a particular product. The authors' results indicated that a variety of contaminants 
could be detected in intact capsules by using four wavelengths. 
Drennen and Lodder29 developed a non-destructive NlRS assay for determination 
of the degradation products for intact aspirin tablets. The authors concluded that the 
salicylic acid formed by hydrolysis of aspirin significantly changed the spectrum of aspirin 
tablets after exposure to moisture and that this correlation to salicylic acid resulted from 
salicylic acid formation rather than a correlated process. The mass of salicylic acid formed 
by hydrolysis in intact aspirin tablets was measured by NIRS with a reported error of 
0.04% of the total tablet mass (400 ppm). 
Ciurczak30 reported a powder mixing study which utilized NIRS to check for 
homogeneity. For this study, aspirin and vitamin 812 were the active ingredients. 
Aliquots were taken at various times and analyzed via NIRS. A comparison was made 
between visual matching, spectral matching and principal component analysis. Visual 
matching provided an approximation, while spectral matching (using computer software) 
gave somewhat better results. Principal component analysis was the more rigorous 
method, in that it was able to distinguish between the penultimate and the true final mix. 
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The author suggested that the use of NIRS could save many hours of analysis time in a 
routine mixing study. 
Ciurzcak, et aJ3 I described a method of determination of the mean particle size of 
pure, granular substances. The method is based on the theories of reflected light, namely 
the Kubeika-Munk equation, 
where K is the absorption coefficient and S is the scattering coefficient. Reflectance, R , 
increases as the mean particle size decreases, while R decreases as the absorptivity 
increases. Graphs were constructed from log ~ values and used to assess the particle size 
of pure samples of ascorbic acid, aspirin, and aluminum oxide. The absorbance values for 
each spectrum at 1658 nm (the major peak) were plotted against the absorbance values at 
1784 nm (the baseline), resulting in a linear plot with a correlation coefficient of 0.99999. 
The authors concluded that this method could be used as a quality control tool when new 
materials are received. 
The suitability of NJRS as an alternative to several compendia! methods has been 
demonstrated by Plugge and Van Der Vlies 32,33 with ampicillin trihydrate. Their work led 
to the U.S.F.D.A.'s acceptance of NIRS as an official method of testing for the 
identification, water content and assay of ampicillin trihydrate. The NJR method was 
compared to a hydroxyl amine colorimetric method as described in the Code of Federal 
Regulations (CFR). Other workers34,35 have reported the development of NJR methods 
for quality control in pharmaceutical analysis, but this was the first time that a regulatory 
agency approved the use of a NIR method for release testing of a bulk pharmaceutical 
product for human consumption. The U.S.F.D.A. has accepted NJRS as the official 
method for determination of the lincomycin content in an agricultural mixture containing 
soybean meal 36, but until 1992 there had not been any approved pharmaceutical uses. 
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Liquid Dosage Forms 
Dubois, et al37 reported a method of detennination of five components in a liquid 
formulation of otic drops. The product contained two active components (phenazone and 
lidocaine), two solvents (ethanol and glycerol) and one antioxidant (sodium thiosulfate). 
Results indicated that the NIRS method was well suited to the quantitation of both of the 
solvents and one of the active compounds (phenazone). The concentration oflidocaine in 
the fonnulation (I %) was at the detection limit of the instrument, thus the accuracy of the 
method was insufficient. 
Kumar and Raghunathan38 used NJRS to examine the nature of the water pool 
fonned in the reverse micellar system, lecithin/nonpolar solvent/water. The three nonpolar 
solvents used in the study were benzene, carbon tetrachloride and cyclohexane. The NIR 
spectra indicated the presence of two types of water in the lecithin reverse micellar 
solutions. One was water-dispersed in the organic phase and the other was water-
solubilized in the reverse mi cellar interior. Results revealed that the amount of water 
present in the organic phase was negligible at all water concentrations in all three solvents. 
Grant, et al 39 investigated the quantitative analysis of solutions containing various 
concentrations of sodium hydroxide, sodium chloride and sodium carbonate using NIRS. 
It was observed that the addition of these salts caused changes in the absorption spectrum 
of water, even though sodium carbonate and sodium chloride do not themselves absorb in 
the NJR region. 
Other Possible Uses 
The hydroxyl value is an indicator for the stages of an esterification reaction. 
Hansen reported a NIRS method by which the shifting of the hydroxyl value of a reaction 
could be monitored 40_ This work suggests that it may be possible to monitor the 
degradation of a reaction, and possibly be useful in stability testing of raw materials. 
Tudor, et al 4 1 investigated the use of near-infrared Fourier-transfonn (Ff) Raman 
spectroscopy in the molecular structural analysis of drugs and biomedical polymers. The 
24 
authors developed a technique by which the concentration of a drug within a polymer 
vehicle could be determined over a wide drug concentration range. The Ff-Raman 
spectrum of diclofenac dispersed in a sodium alginate matrix was monitored, as well as the 
spectrum of the alginate alone. It was concluded that this method illustrated the potential 
for quantification of degradation kinetics in certain polymers using Ff Raman infrared 
spectroscopy. 
Conclusion 
Recently, there has been a large increase in the amount of research in the near 
infrared region. NIRS bas been shown to be a valuable tool for a number of important 
applications. It bas gained official acceptance in the food and agricultural industries, and is 
now becoming more recognized in the pharmaceutical industry. Specially designed 
instrumentation for use in the pharmaceutical industry has become more widely available, 
and is made more powerful by software improvements. 
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Addendum to Manuscript I 
The importance of NIRS may be affirmed by its increasing appearance in the 
literature. NJRS has been used to measure such properties as sample composition and 
identification 1, moisture content2,3, content unifonnity4, homogeneity of mixing5 , and 
degradation products6. Other reports? of pharmaceutical uses of NJRS describe a 
method to screen tablets in the development of a new coating process. Since reflective 
techniques are sensitive to surface texture8·9, NIRS is also suitable for particle size 
measurements. A comprehensive review was written by WeyerlO, citing 164 NJRS 
references in agriculture and chemical processing. Workman 11 outlined 156 references to 
the use of NIR for process applications, including pharmaceutical uses. McClure 12 
described NIRS instrumentation in great detail and discussed several engineering and 
agricultural applications. 
Since 1990, NIRS has received more attention from the pharmaceutical industry, 
as noted by several reviews describing useful applications. Mac Donald and Prebblel 3 
presented an overview ofNJRS in the pharmaceutical industry, and included results of 
their own experiments with identification, blending, and water detennination. Aldridge, 
et al 14 described a NJRS method for nondestructive identity testing of blister packed 
tablets. The NlR method required only seven minutes to analyze ten tablets, compared to 
only 40 tablets per day using conventional TLC. 
In the food industry, NJRS has been used for the qualitative determination of 
hardness I 5, 16 of wheat kernels. Wheats are classified as hard or soft according to their 
milling performance. Hard wheats produce larger, more angular particles during the 
grinding process than soft ones. This angling occurs because hard wheats have cleavage 
planes associated with the cell walls in the endosperm; the cells come away more cleanly 
and remain more intact 17. Soft wheats fracture at random, frequently across cell walls, 
resulting in fragments containing mainly starch. NIRS can be used to discriminate hard 
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and soft wheat kernels through differences in particle size of ground meal . The ground 
meal from the hard varieties reflects less energy than soft ones ground in the same 
fashion IS. 
Calibration Transfer Between Instruments 
In a recent commentary stemming from the 1995American Chemical Society 
Meeting at the short course on practical NIR (the first NIR short course offered by the 
A.C.S.), consultant Emil Ciurczak stated that " it is more important for instruments to 
perform in a reproducible manner than for them to represent absolute values of some 
mythical standard." l 9 In other words, Ciurczak stressed that it is doesn't matter that a 
single wavelength of one instrument may be 2 nm off from an absolute standard, as long 
as it always identifies that point the same way every time. The National Institute of 
Standards and Technology (NIST) in Gaithersburg, MD has no single standard available 
for wavelength accuracy in transmission NIRS. A reflectance standard exists but has not 
yet been widely accepted. The reflectance standard is based on polystyrene, however, 
and consistency in batches of such polymers has not yet been achieved. At this time, the 
responsibility of establishing proper calibration is on the manufacturer of the instrument. 
Bouveresse and Massart20 described a modified algorithm for standardizing NIR 
spectrophotometric instruments. The authors used locally weighted regression, which 
gives more weight to the standardization samples which are in the same spectral intensity 
range as the samples to be predicted and less weight to the samples farthest from this 
range. This approach enabled standardization of samples of a different nature. 
Standards for Quantitative NIR Analysis 
The American Society for Testing and Materials (ASTM) recently published an 
official document2 l providing a guide to spectroscopists for the multivariate calibration of 
infrared spectrometers. The scope of the publication, entitled "Standard Practices for 
Infrared, Multivariate, Quantitative Analysis", includes the use of multivariate 
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calibrations for the determination of physical or chemical characteristics of materials. The 
practice applies to the near-infrared (780 to 2500 nm) through the mid-infrared (4000 to 
400 cm- 1) spectral regions. This document is the first official standard for the application 
of chemometric multivariate analysis to near-IR and IR instruments22. 
Validation of NIRS Methods 
Validation aspects of a NIRS method are similar to those of other analytical 
methods. The principal elements of ensuring linearity, accuracy, selectivity and 
reproducibility of a quantitative method are required. The validation process determines 
the amount of error due to variation between the values in the population. It is used to 
check for the existence of a relationship between the calibration set and the validation set. 
Calibration models are developed by regression analysis to determine the 
relationship between calibration set spectra and the constituent value of interest for those 
samples. Partial Least Squares (PLS) is a useful type of regression for small populations 
and involves application of a series of simple linear regressions. Using cross validation 
in a PLS regression, the sample population is separated into several segments, usually 
four, then one segment is validated as an unknown against the remaining segments. The 
segment that is validated is sequentially moved through the entire population until all the 
samples in the population are fully validated. The procedure results in the calculation of 
the mean square error of cross validation (MSECV) for the population. In other words, 
the program will determine the numberof factors (a factor is equivalent to a sample in the 
file) required to characterize a sample set without overtitting it. Overtitting the population 
would render the calibration incapable of predicting analytical results on samples outside 
the population. 
When cross validation is performed on a sample set that required (e.g.) six 
factors, four lines result on the plot of MSECV versus factors. The number of factors 
that will overtit the spectra is indicated at the point on the plot where the line points 
upward. The ideal number of factors will be displayed to the left of that point, at the 
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factor where the plot is closest to the x-axis. Of the values reported in the regression 
results, a critical value to examine is the ratio of the current MSECV to the minimum 
MSECV. It is recommended that this ratio be as close to 1.25 (not 1.00 or equal to the 
lowest value) as possible to determine the correct number of factors. This is in contrast to 
other regression procedures where the point of highest correlation is the value of 
interest23. 
Manufacturers of NIRS instrumentation include software packages which allow 
the operator to predict analytical results on data files that have been stored, thus allowing 
for validation of the calibration equation, and testing for errors in the developed 
calibration. This enables calibration equation performance testing in terms of precision. 
If the laboratory values relevant to the sample spectra were entered into the computer file, 
performing the prediction function on the data results in the calculation of predicted 
results and residual values. This may be followed by a statistical summary (see Appendix 
I for definition of terms used in statistical summary report) which includes bias, standard 
deviation of differences, root mean square, and standard error of bias, as well as slope 
and intercept information. Using this information, the operator can determine if there is a 
bias or slope difference between a calibration set of samples, or a slope difference 
between a calibration set of samples and a validation set. Slope variations indicate that the 
calibration samples and the prediction samples are quite different, more than just a bias 
offset, and that this calibration is not applicable to this type of sample. It is not acceptable 
practice to make a slope adjustment to a calibration. 
A bias may be observed when the NlR instrument values are consistently higher 
or consistently lower than the laboratory values. This translates to a shift in the Y-
intercept of a plot of NIR versus lab values (the slope may not be affected). The ideal 
situation is when this plot shows points scattered evenly along a line that is 45° to the x-
axis, thus zero bias. A bias adjustment is required when the value for the bias is more 
than double the standard error of the bias in the positive or negative direction. 
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The main problem associated with using empirical models is that they are based 
on correlation rather than causation24 . Construction of these models involves finding 
measurements that simply correlate well with an analyte. The validity of these models 
depends the ability of the calibration set to accurately represent the samples in the 
prediction set. A good rule of thumb is to make sure that any type of variation observed 
in the prediction set also varies in the calibration set over the same range as the variation 
occurring in the prediction set25. Usually, the complete prediction set is not available at 
the same time as the creation of the calibration set, and unusual phenomena may be 
associated with some of the prediction samples. 
One source of prediction error is the inherent accuracy and precision of the 
reference method used. If the reference method produces erroneous analyte values that 
are consistently high or low, this bias will be reflected in the prediction results. Imprecise 
(but accurate) reference values may also increase prediction error, in a nonsystematic 
way. Thus it is very important to minimize the errors in the reference values that are to be 
used to create an empirical model. 
Other sources of prediction error relate to the reproducibility, stability and 
repeatability of the NIR instrument. Reproducibility (precision) is validated by making 
repeated measurements of the same sample, removing it between runs. Small changes in 
conditions may occur due to multiple insertions of a sample onto the instrument. Stability 
refers to similar changes that may occur over a longer period of time (hours or days). 
Repeatability refers to the instrument's ability to generate consistent measurements under 
the same conditions (without removing the sample from the instrument}, over a relatively 
short period of time (seconds or minutes). All of these factors must be addressed to 
assure the validity of the NIR calibration model. 
Current NIR News 
In 1995, the European Patent Office26 granted a patent to Dr. Paul Aldridge of 
Pfizer Central Research in Groton, Connecticut for an Apparatus for mixing and detecting 
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on-line homogeneity. This patent involves the use of a NIR fiber-optic probe interfaced 
on-line with a blender. Sekulic, et a127 recently described the use of this Apparatus for 
on-line monitoring of powder blend homogeneity . An S.-quart twin-shell V-blender was 
interfaced with a fiber optic probe at the axis of rotation. Spectra were collected at 
prescribed intervals, and data analysis was performed by a series of software packages. 
Variability in the NIR spectra as a function of time was measured, and it was shown that 
this variability reached a minimum sooner than traditional blending times suggest. 
Official approval of a NIR method as an alternate method for identification and 
assay of tablets was granted in June 1995 to Glaxo Wellcome in the United Kingdom28. 
The company received official approval from the Medicines Control Agency (MCA) for 
the use of NJR as an alternate method for identification and assay of Zovirax® 200 mg 
tablets. The MCA is the agency within the U. K. Department of Health which is 
responsible for licensing of medicinal products, inspection and enforcement. The 
quantitative calibration was developed in the Analytical Development Laboratories and is a 
four-factor PLS equation. 
Update on mannfacturers of NIRS instrnment hardware and software 
An extensive product review of recent NIR technology was published by 
Noble29. Enormous progress has been achieved in chemometrics and computing power, 
making many new applications possible. There are over twenty manufacturers of NIR 
spectrophotometers in the United States. There are many more vendors of sampling 
components and software packages for data analysis. Multivariate calibration methods 
are essential for quantitative NlR analysis. Most instrument vendors offer software that 
is capable of using multivariate algorithms, such as partial least-squares (PLS), 
multilinear regression (MLR) and principal component analysis (PCA). Some of the 
vendors also license software from third-party vendors of statistical analysis software. 
The best known third-party packages include Pirouene (lnfometrix, Seattle, WA), 
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MATLAB (The Mathworks, Inc., South Natick, MA), WbCalc and Grams 386 (Galactic 
Induslries, Salem, NH). 
Conclusions 
Although the use of NIRS methods in the pharmaceutical industry is increasing, 
many scientists are reluctant to accept it as a viable alternative to current testing methods. 
The process of developing a calibration and selecting a model is challenging project, as is 
the validation of the method. Traditionally, pharmaceutical scientists are not trained in 
chemometric methods, and this remains a stumbling block to the understanding and 
implementation of NlR technology. Instrument manufacturers and software vendors are 
aware of this, and now design their products in more user-friendly ways than before. It 
will be several more years before sufficient data is published to convince the skeptical that 
NlRS is a usable and extremely useful technology. 
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Manuscript II 
A Feasibility Study of the Effect of Compression Force on the Near-
Infrared Spectra of Tablets 
*presented at4Pharma Conference, March 1995 
1. 1 Abstract 
The primary objective of this research was to evaluate the utility of near-infrared 
reflectance spectroscopy (NlRS) for measuring tablet hardness. Flat, white tablets with no 
orientation (scoring, etc.) were manufactured on a Stokes Rotary Tablet Press. The 
formulations evaluated were: 1) placebo matrix (microcrystalline cellulose and magnesium 
stearate), 2) hydrochlorothiazide (HCTZ) 15 % with placebo matrix, and (3) 
chlorpheniramine maleate (CTM) 2 % with placebo matrix. Five or six levels of tablet 
hardness (2 to 12 kg) were used for each formulation. Tablets were evaluated by 
conventional USP testing methods for weight, hardness, thickness and friability. NlR 
reflectance analysis was performed on 20 tablets from each batch using a NTRSystems 
Rapid ContentT>• Analyzer. Tablet evaluations showed hardness variation of 5-10% and 
weight variation of< l %. NlR analysis of these tablets showed an upward shift in the 
raw spectra with increasing hardness. Softer tablets had more variable spectra. Principal 
component analysis correctly (by distance) identified tablets that were two hardness units 
apart. Results confirmed that there is a difference in raw NlR spectra due to changes in 
tablet compression force. 
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1. 2 Introduction 
Near-infrared reflectance spectroscopy (NIRS) bas received widespread attention as a 
nondestructive method for the rapid measurement of the composition of many 
products 1·2.3 . NIRS determines these parameters through the measurement of diffuse 
reflectance. Diffuse reflectance is light that bas been transmitted through a portion of the 
sample and emerges from the illuminated surface due to internal light scattering4 . This 
type of reflectance is affected by the absorbance and light-scattering properties of the 
product. 
Current methods of tablet hardness testing, drug identity and content are destructive in 
nature and may not always give an accurate representation of the batch being evaluated. 
NlRS is a noninvasive and nondestructive method that, in theory , would allow for 100% 
testing. In this respect, NIRS is attractive from both a quality control and a regulatory 
perspective. 
The purpose of this study was to investigate the feasibility of NIRS for the 
measurement of tablet hardness. 
1 . 3 Experimental 
1 .3.1 TabletManufacture 
Half-inch round, flat-faced tablets were manufactured using one of the sixteen stations 
of a Stokes B-2 Rotary Tablet Press. Hydrocblorothiazide and chlorpheniramine maleate 
were the active components chosen for the formulations, in addition to microcrystal line 
cellulose(Avicel® PH 102, FMC Corporation) and magnesium stearate. Both are relatively 
low-dosage drugs and would thus not be expected to interfere with the process of direct 
compression. The components of each formulation (Table 1) were accurately weighed on a 
Mettler balance for a batch size of one kilogram. Each blend was mixed for ten minutes in 
a Turbula mixer, then transferred to a labeled plastic bag to await compressing. 
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Table I. Formulations used in feasibility study. 
Formulation Comj>onents Percent 
placebo blend Avicel® PHI02 99.5 % 
magnesium stearate 0.5 % 
HCTZ 15% hydrochlorothiazide 15.0 % 
Avicel® PH I 02 84.5 % 
mllgDesium stearate 0.5 % 
CTM2% chlorpheniraminemaleate 2.0 % 
Avicel® PH102 <rl.5 % 
magnesium stearate 0.5 % 
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Tablet hardness was varied to achieve a range of 2 to 12 kilograms (kg) as measured 
by the Erweka Hardness Tester. (Note: I kg is equivalent to I kilopon, a commonly used 
hardness unit). Approximate batch size was 300 tablets for each of five to six levels of 
hardness . 
Tablets were evaluated for weight, hardness, friability and thickness. Twenty tablets 
from each batch were weighed using a Mettler balance. The thickness of five tablets from 
each batch was measured using an Ames Dial Comparator (B. C. Ames Co., Waltham, 
MA, Model No. 3). Thickness data was converted from inches to millimeters using 
Microsoft® Excel. The conversion equation was: (25.4 mmlin) x (#Ames lines x 100) x 
(0.001 inch/line). 
Hardness testing was performed on twenty tablets from each batch using an Erweka 
Hardness Tester. Hardness data were subject to a two-sided T-tesl using Mini tab® 
(Version 8, Addison-Wesley Publishing Co.) to rule out equal means between hardness 
levels. Randomness of the sample selection process was tested by applying a 
nonparametric runs test Hardness values were expressed in kilograms. 
Friability testing was performed using a Roche Friabilator. Twenty tablets from each 
batch were weighed on a Mettler balance before and after undergoing four minutes (100 
revolutions) in the friabilator. The weight difference was calculated and expressed in terms 
of percent loss due to abrasion or fracture. 
1 .3.2 Near-Infrared Analysis 
A NIRSystems Rapid Content Analyzer® Model 5000 was used for the analysis of 
tablet samples. This instrument consists of a reflectance detector module and a 
monochromator module (Figure I) The reflectance module consists of detectors sited at a 
45° angle to the light incident on the sample (Figure 2), which reduces the effect of 
specular, or stray, energy reaching the detectors. The reflectance detector module is 
equipped with a sample holder specifically designed to bold tablets. Figure 3 is a schematic 
drawing of the sample holder, which includes the iris. The lever shown at the bottom, 
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right comer in the diagram is used to control the width of the iris, thus centering a tablet of 
practically any diameter on the detector surface. 
The instrument was interfaced with a Compaq Presario personal computer installed 
with NSAS TM (Near-Infrared Spectral Analysis Software) version 3.13 and JQ2TM 
(Identify , Qualify and Quantify) Chemometric Software version 1.13 (NIRSystems, Silver 
Spring, MD). A color monitor and dot matrix printer were also part of the system. 
PrintAPlot® software version 3 .0 (Insight Development Corporation, San Ramos, CA) 
was used to create color output files for spectral plots. Plots were downloaded to a laser 
printer in a remote location. 
NTR reflectance parameters were set at32 scans per sample in the range of 1100 to 
2500 nm. A ceramic (Coor' s Standard) reference scan was taken before each set of 
samples. Single tablet NTR scans were run on 20 samples from each batch of tablets. The 
sample to be measured was placed directly above the detector surface and centered with the 
iris. Before positioning each sample, the detector surface was gently cleaned of debris. 
Each sample scan took approximately 42 seconds to complete. 
Reflectance spectra were collected for the active components (in powder form), the 
individual excipients used in the blends, and the powdered blends before compaction. The 
sample to be measured was loosely packed into a 50 ml glass beaker, up to a volume of20 
ml. The beaker was tapped lightly three times to level the powder surface. The spout of 
the beaker was aligned the same way for each sample. The sample was scanned once, then 
tapped three times on the counter, and rescanned, with the spout shifted 45' from the 
original alignment A third scan was taken after the beaker was tapped and rotated another 
45' . The same beaker was used for all components. The three scans were averaged and 
overlayed on a plot. 
A spectral Ii brary of each "product" (batch) was created through the use of JQ2TM . 
Spectral data from each hardness level of HCTZ tablets were entered into the HCTZ 
product library. Likewise, CTM spectral data were entered into the CTM product library. 
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Through the software's internal validation program, principal components were calculated. 
Identification by correlation and by distance was evaluated. "Correlation" is one of the 
modes of spectral matching used by the NSAS software. In correlation mode, the products 
in the spectral library are compared by correlation to see if they match a potential sample for 
analysis. In the "distance" mode, the program uses the distance between the library records 
and potential samples. A minimum of three spectra in the library is required for the 
distance mode to work. 
1.4 Results 
1 .4.1 Results o/Tablet Evaluation 
Tablet weights were very consistent, with a relative standard deviation of less than 1 % 
(most batches had a relative standard deviation of 05% or less). Specifications for tablet 
hardness were set at 10%. Table 2 summarizes the average hardness, weight, thickness 
and friability for the placebo blend. Relative standard deviations (RSD) for the mean 
hardness values for the placebo tablets ranged from 4.50% to 11.2%. 
Table 3 summarizes the average hardness, weight, thickness and friability for HCTZ 
15% tablets. The RSD's for hardness ranged from 3.3% to 14.6%, following a trend of 
increasing variation with a decrease in hardness. The standard error of the Erweka 
Hardness Tester was calculated to be 0.34 kg. 
A summary of average hardness, weight, thickness and friability for CTM 2 % tablets 
appears in Table 4. The RSD' s for hardness ranged from 3 .18% to 8.49%. This 
formulation produced tablets with the least amount of deviation from the target hardness. 
Overall, the variation (RSD) in tablet hardness (Figure 4) was observed to be 
inversely proportional to the hardness value, a trend which was generally reflected in the 
ftiability data (decrease in hardness results in an increase in friability) . It is logical to 
expect that a softer tablet may have more variability with respect to values for hardness. 
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1 .4.2 Results of NIR Analysis 
The raw and second derivative spectra of CTM, Avicel® PHI02 and magnesium 
stearate are shown in Figures 5 and 6. Avicel® and Avicel®-containing blends were of a 
free-flowing and uniform nature. CTM powder contained clumps and was not free-
flowing. Figures 7 and 8 display the raw and second derivative spectra of HCTZ along 
with A vice!® PH 102 and magnesium stearate. HCTZ powder was crystalline, uniform 
and free-flowing. Observation of these spectra show distinctly different patterns or 
fingerprints for each component of the formulations. The second derivative treatment of 
the spectra reduces the contribution of physical characteristics of the components, resulting 
in a smoothing of the data and a reduction of baseline shift and noise. 
The NIR absorbance (log l/R) versus wavelength (run) was plotted for each batch of 
tablets. When the raw spectra from all batches of a blend were overlayed on the same plot, 
a general upward shift in absorbance was observed in response to an increase in hardness. 
Plotting the second derivative spectra at several hardness levels also demonstrated an 
increase in absorbance at the peak maxima, although less obvious. The raw and second 
derivative spectra of the placebo blend tablets at five hardness levels are shown in Figures 9 
and 10, respectively. Figures 11 and 12 are the raw and second derivative spectra of 
HCTZ 15% tablets at five levels of hardness. The raw and second derivative spectra of 
CTM 2% tablets at six hardness levels are shown in Figures 13 and 14. 
Observation of the spectra in Figures 12 and 14 demonstrate the smoothing effect of 
the second derivative math treatment The spectra appear to be nearly superimposed upon 
each other, except for small changes at absorbance maxima. Linear regression was 
performed on the spectral data at absorbance maxima Numerous single wavelengths were 
chosen based on the appearance of an effect from increased tablet hardness. The results of 
these analyses are summarized in Tables 5 and 6. CTM 2% absorbance at eight single 
wavelengths was found to be significantly increased with an increase in tablet hardness. 
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HCTZ 15% absorbance at eight (out of ten wavelengths chosen) was also significantly 
increased in response to an increase in tablet hardness. 
A spectral library was created for each of the two blends containing active 
components, using the second derivative spectra. Each level of hardness represented a 
separate product, from which the calculation of principal components was generated. The 
principal component analysis (PCA) for HCTZ 15% resulted in the successful identification 
of each product by distance. Seven HCTZ 15% samples (47 correct/ 7 incorrect) were 
incorrectly identified when the library was validated by correlation. The correlation method 
also identified four out of ten conflicting pairs of products in this library. This information 
is useful for future updating of the library , since there may be a better set of samples for 
use in this spectral library. 
1.5 Conclusions 
The results of this feasibility study indicate that there is a change in the NIR signal as 
a function of tablet hardness. Three tablet formulations were manufactured of varying 
compression forces and analyzed by NIRS. An increase in tablet hardness resulted in a 
consistent upward shift in NIR absorbance. Tablet samples of different hardness levels 
were successfully differentiated by principal component analysis. NIRS has the potential 
as an altemati ve method of tablet hardness testing. 
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Table 2. Summary of Placebo Matrix Tablet Evaluation 
Lot Mean Mean Weight (g) Mean Thickness Friability 
Number Hardness n=20 (mm) n=S % loss 
(kg) n=20 
KM17 9.625 ± 0.43 0.3233 ± 0.0008 3.81 0.61 
(h=l2kg) (rsd=4.50%) (rsd=0.24 %) 
KM19 8.14±038 0.3246 ± 0.0009 3.99 0.31 
(h=Skg) (rsd=4.73 %) (rsd=0.29 %) 
KM21 6.11 ± 0.34 0.331 ± 0.003 4.14 0.30 
(h=6kg) (rsd=5.56%) (rsd=0.84 %) 
KM23 4.66 ± 0.33 0.333 ± 0.002 4.29 0.45 
(h=4kg) {rsd=7.02 %) (rsd=0.52 % 
KM25 2.09 ± 0.23 0.321 ± 0.001 4.78 2.65 
(h=2kg) (rsd=l 1.2 % ) (rsd=0.34 %) 
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Table 3. Summary of Hydrochlorothiazide 15% Tablet Evaluation 
Lot Mean Hardness Mean Weight (g) Mean Thickness Friability 
Number (kg) n=20 n=20 (mm) n=S % loss 
KM47 10.09 ± 0.52 0.3272 ± 0.0015 3.40 0.15 
(h=l2kg) (rsd=5.2 %) (rsd=0.45%) 
KM45 8.96 ± 0.31 0.3254 ± 0.0013 3.58 0.15 
(h=9kg) (rsd=3.3 %) (rsd=0.41 %) 
KM43 4.85 ± 0.30 0.326 ± 0.0018 3 .94 0.46 
(h=6kg) (rsd=6.1%) (rsd=0.56%) 
KM41 3.46 ± 0.30 0.3264 ± 0.0017 4.19 0.76 
(h=4kg) (rsd=8.5%) (rsd=0.53%) 
KM39 1.61 ± 0.24 0.325 ± 0.0015 4.79 2.30 
(h=2kg) (rsd=l4.6%) (rsd=0.46%) 
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Table 4. Summary of Chlorpheniramine Maleate 2% Tablet Evaluation 
Lot Mean Hardness Mean Weight (g) Mean Thickness Friability 
Number (kg) n=20 n=20 (mm) n=S % loss 
KM51 11.2 ± 0.36 0.3239 ± 0.0016 3.91 0.08 
(h=l2kg) (rsd=3.18 %) (rsd=0.49%) 
KM53 9.49 ± 0.44 0.326 g ± 0.002 4.06 0.15 
(h=9.5kg) (rsd=4.6 %) (rsd=0.49 %) 
KM61 7.58 ± 0.49 0.326 ± 0.001 4.27 0.15 
(h=8kg) (rsd=6.53 %) (rsd=0.44 %) 
KM55 6.31 ± 0.47 0.325 ± 0.002 4.47 0.31 
(h=6kg) (rsd=7.5 %) (rsd=0.68 %) 
KM57 4.10 ± 0.30 0.322 ± 0.001 4.80 0.78 
(h=4kg) (rsd=7.32 %) (rsd=0.32 %) 
KM59 2.38 ± 0.20 0.325 ± 0.003 5.33 1.54 
(h=2kg) (rsd=8.49 %) (rsd=0.81 %) 
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Table 5. HCTZ 15%: Linear regression of second derivative absorbance data at single 
wavelengths 
Equation: Hardness= y-iotercept +slope (Abs at x nm) 
Linear Regression ANOVA 
nm Linterce~ sl~ r2 F ...E._ 
1334 - 11 1221 0.524 3.31 0.167 
1364 -0.75 -758 0.239 0.94 0.404 
1396 -28.I 976 0.958 91.56 0.002 
1432 -26. I - 1331 0.975 118.34 0.002 
1800 6.86 -613 0.072 0.23 0.664 
1882 -27.3 614 0.933 56.57 0.005 
2000 -28.9 653 0.933 42.06 0.007 
2218 -27.6 1048 0.933 41.45 0.008 
2270 -19.2 -1143 0.968 90.56 0.002 
2344 -56.6 -1914 0.985 202.98 0.001 
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Table 6. CTM 2% linear regression of second derivative absorbance data at single 
wavelengths 
Equation: Hardness = y-intercept +slope (Abs atx nm) 
Linear Regression ANOVA 
nm ...Y::interce_E! slO£._e r2 F 
_l)_ 
1330 -32.2 2991 0.883 30.18 0.005 
1366 -14.7 -2163 0.631 6.83 0.059 
1396 -51.5 1728 0.957 89.89 0.001 
1434 -40.8 -2034 0.963 104.44 0.001 
1458 -27.9 -55!0 0.987 296.32 0.000 
1926 -59.9 -995 0.918 44.91 0.003 
2018 -64.9 1794 0.973 142.61 0.000 
2102 -78.9 -2478 0.923 47.63 0.002 
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Figure 3. Diagram of sample holder for Rapid Content Sampler.Lever at bottom right is 
used to control the iris opening for centering tablets. 
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Figure 4. Percent variation in hardness versus tablet hardness. 
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Mannscript III 
Near-Infrared Spectroscopy as a Non-Destrnctive Alternative to 
Conventional Tablet Hardness Testing 
*presented at AAPS Tenth Annual Meeting November 1995 poster session 
1.1 Abstract 
In the present study, near-infrared reflectance spectroscopy (NIRS) was used to 
evaluate and quantify the effect of compression force on the NIR spectra of tablets. Flat, 
white tablets with no orientation (scoring, etc.) were manufactured on a Stokes Rotary 
Tablet Press. NIRS was used to predict tablet hardness on the following four 
formulations: hydrochlorothiazide (HCTZ) 15 % and 20% in a placebo matrix 
(microcrystalline cellulose and magnesium stearate), and chlorpheniramine maleate (CTM) 
2 % and 6% in a placebo matrix . Five or six levels of tablet hardness from 2 to 12 kg were 
used for each formulation. Twenty tablets from each batch were evaluated by conventional 
USP methods for weight, hardness, thickness and friability . This laboratory tablet data 
was compared to NIR reflectance data using an NIRSystems Rapid Content Sampler. 
Multiple linear regression and partial least squares regression techniques were used to 
determine the relationship between tablet hardness and NIRS spectra. An increase in tablet 
hardness produced an upward shift (increase in absorbance) in the NIRS spectra. A series 
of equations was developed by calibrating tablet hardness data against NIR reflectance 
response for each formulation. The results of NIRS hardness prediction were at least as 
precise as the laboratory hardness test (SE= 032). A method is presented which has the 
potential as an alternative to conventional hardness testing of tablets. 
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1 . 2 Introduction 
A variety of chemometric and statistical techniques are used in modem 
spectroscopic methods to extract useful information from raw spectroscopic data. Linear 
calibration methods such as multiple Ii near regression (MLR), principal component analysis 
(PCA) and partial least squares regression (PLS) are commonplace in near-infrared 
spectroscopy, as well as in NMR and UV/VIS methods. A discussion of these 
mathematical techniques may be found in various other references I • 2. Multivariate 
calibration is a process for creating a model that correlates component concentrations or 
properties to the absorbance of a set of known reference samples. The reference method is 
the analytical method that is used to determine the reference component concentration or 
property values that are used in the calibration. The mathematical expression relating 
component properties to absorbance is known as a calibration model. The calibration 
process is one of the most important steps in NIR analysis. Errors in NIR prediction most 
often arise from errors in the reference method, instability of the NIR instrument, and 
inappropriate choice of the calibration model. 
With sophisticated computer software, the general analyst may use these calibration 
algorithms with relative ease. Using the NIR spectral software, the analyst can acquire 
spectra, correlate them to laboratory data, develop a calibration equation and apply that 
equation to similar, new samples to predict constituent concentrations or properties. 
A feasibility study was previously performed (Manuscript U) in order to investigate 
the effect of tablet hardness on the NIR spectra. Results of the initial work indicated that 
there is a detectable shift in the NIR spectra in response to a change in tablet hardness for a 
given formulation. These results were promising enough to warrant further investigation 
of the NIR method. The purpose of this study was to calibrate a NIR instrument to tablet 
hardness and demonstrate the potential utility of the technique as an alternative to current 
methods of tablet hardness testing. 
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1. 3 Experimental 
1.3. 1 Tablet Manufacture 
Table 1 lists the formulations used for this study. The components of each 
formulation were accurately weighed on a Mettler balance for a total weight of one 
kilogram. Each formulation was blended for ten minutes in a Turbula T2C shaker/mixer, 
then transferred to a labeled plastic bag to await compressing. 
Tablets were manufactured by direct compression using one of the sixteen available 
stations of a Stokes B2 Rotary Tablet Press. One-centimeter tooling was used to make flat, 
white tablets having no orientation or scoring. The target tablet weight was 324 mg and the 
batch size was approximately 300 tablets. The tablet press was monitored until the desired 
level of hardness was achieved. Five to six hardness levels, with target hardness levels of 
2, 4 , 6, 8, 10, and 12 kilograms on the Erweka Hardness Tester (which measures crushing 
strength), were used for each of the four formulations, for a total of27 batches of300 
tablets each. 
1.3 .2 Evaluation ofTablets 
Twenty tablets from each batch were evaluated for weight, hardness, thickness and 
friability. The USP tolerances for weight variatioo3 allow a percentage difference of 7.5 
for an average tablet weight of 130 to 324 mg. Tablets weighing more than 324 mg may 
differ by no more than 5%. The USP requires that twenty tablets be individually weighed 
and their average weights calculated. The weights of no more than two of the tablets may 
differ from the average weight by more than the prescribed percentage. No single tablet 
weight may differ by more than double that percentage. In this study, the target weight 
was 324 mg+/- 5.0o/o. Tablet thickness and friability were measured according to the 
protocol described in Manuscript II . 
Tablet hardness was measured using the Erweka Hardness Tester. Hardness 
testing was performed on twenty tablets from each batch after all non-destructive physical 
tests were completed. This order of testing allowed direct correlation of data to a specific 
67 
Table I. Composition of tablet formulations manufactured for NIR analyses. 
Formulation Com.J!.onents Percent 
Placebo Blend Avicel® PH102 99.5 % 
magnesium stearate 0.5 % 
HCTZ 15% hydrochlorothiazide 15.0 % 
Avicel® PHI02 84.5 % 
magnesium stearate 0.5 % 
HCTZ20% hydrochlorothiazide 20.0 % 
Avicel® PH102 79.5 % 
magnesium stearate 0.5 % 
CTM2% chlorpheniramine maleate 2.0 % 
Avicel® PHJ02 97.5 % 
magnesium stearate 0.5 % 
CTM6% chlorpheniramine maleate 6.0 % 
Avicel® PH102 93.5 % 
magnesium stearate 0.5 % 
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tablet sample. Hardness specifications are generally chosen by tbe manufacturer, based on 
tbe desired performance of tbe tablet. For this study, the desired tolerances for hardness 
were set at+/- 10.0%. 
The mean, standard deviation and relative standard deviation (RSD) were calculated 
for weight, hardness and thickness for each batch using Microsoft® Excel. The laboratory 
values for tablet hardness were entered into the NSAS™ computer files for the 
corresponding NIR spectra. 
Tablet density (weight per volume) values were calculated with Microsoft® Excel 
(Version 5.0, Microsoft Corporation, USA) using equation ( l): 
de 
. g weight(g) 2 
nslly --3 ~ x ;rr 
· cm thickness(cm) equation (I), 
where r = radius of 0.5 cm. 
The RSD of tbe density values were tabulated and compared with the RSD of the laboratory 
hardness values. The calculated density values were entered into the NSAS™ computer 
files for the corresponding NIR spectra. For practical purposes, surface porosity was 
disregarded, i.e., it was assumed that the tablets were flat. 
The standard error (standard deviation) was calculated for each laboratory 
(reference) method. The overall and single product values for tbe reference standard errors 
were used for comparison to the NIR standard errors. 
1 .3.3 Near-Infrared Spectroscopic Analysis 
A NIRSystems Rapid Content Analyzer® Model 5000 was used for the analyses of 
tablet samples. This instrument and corresponding setup were described in Manuscript II. 
NIR reflectance parameters were set al 32 scans per sample in the range of 1100 lo 2500 
nm. A ceramic (Coor's Standard) reference scan was taken before each set of samples. 
Single tablet NIR scans were run on 20 samples from each batch of tablets. The sample to 
be measured was placed directly above the detector surface and centered witb the iris. 
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Before positioning each sample, the detector surface was gently cleaned of debris. Each 
sample scan took approximately 42 seconds to complete. For each sample tablet, the lab 
hardness value for the corresponding NTR spectra was entered into the computer as the 
constituent value for hardness. The NIR spectral data were mathematically transformed to 
their second derivative spectra using a segment of 20 and a gap of 0. The segment size 
refers to the number of wavelengths the computer averages into one data point to improve 
the signal to noise ratio. Gap size is the distance in nanometers between wavelength 
segments. These two parameters will vary according to the math treatment in use. 
Of the twenty spectra collected per batch, thirteen spectra per batch were selected 
for inclusion in the calibration set. To test for bias in the data, several calibration sets were 
created for each formulation , either by random computer selection or simply using the first 
thirteen spectra. The remaining seven spectra were used to create a validation sample set. 
Each of the HCTZ calibration sets contained a total of 65 samples ( 13 x 5 hardness levels), 
while the CTM calibration sets contained 78 samples (13 x 6 hardness levels). The placebo 
calj bration sets contained 72 samples ( 13 x 4 hardness levels). 
Multilinear regression (MLR) and partial least squares (PLS) regression were 
performed on the second derivative of the calibration spectra using NSAS™ . MLR utilizes 
one or more wavelengths in the development of a calibration model , whereas PLS involves 
the use of the full spectrum. Tablet hardness data was calibrated with NIR data and 
equations were developed for the various formulations. Numerous calibration equations 
were generated with each regression type. PLS was used with cross validation (segment 
size of four) and a maximum number of eight factors. The equations were deemed to be 
initially acceptable if they had a correlation coefficient of 0.95 or better and a standard error 
of estimation (SEE) of 0.32 to 0.5 kg. Further statistical analysis (root mean square error, 
bias, multiple correlation coefficient) was performed using NSAST>• when each calibration 
equation was applied to a validation set of tablet spectra. These statistics describe the 
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ability of the equation to predict the hardness of the samples. The definitions of these 
statistical terms are listed in Appendix 1. 
Validation of each model was performed by applying it to a set of validation (or 
prediction) samples to test the model's predictive ability. These predicted values were then 
statistically compared to laboratory hardness values measured for these samples and 
checked for agreement of the model with the reference method. The standard error of 
prediction (SEP), also known as the RMS error, was also calculated. 
J .3 .4 Effect of Sample Position on NIR Spectra 
A validation study was undertaken to evaluate the effect of sample position on the 
resulting NlR spectra. A comparison was made between spectra taken from (A) one tablet 
in ten positions without the use of the iris, which is normally used to center the tablet 
before analysis, (B) ten tablets in one position, both sides, using iris, and (C) one tablet 
scanned 20 times using iris. 
In Part A, one tablet was scanned in ten positions on the instrument's detector 
surface without the use of the iris. Samples 2 through 10 were scanned with an edge of the 
tablet touching the approximate center area of the detector surface. Figure 1 illustrates the 
approximate placement of each tablet sample on the detector surface. All positions were in 
reference to the center position, which was located by the iris. The positions were 
identified as follows: 1) approximate center of detector surface, 2) above center at 12 
o' clock or O°, 3) 45°, 4) 90°, 5) 135°, 6) 180°, 7) 225°, 8) 270°, 9) 315° and 10) 12 
o'clock again (360°). 
In Part B, one tablet was scanned twenty times in the center position. The tablet 
was scanned, removed, then repositioned between scans using the iris to center the tablet 
on the detector surface. 
In Part C, twenty tablets were scanned once using the iris to position the sample in 
the center of the detector surface. 
71 
Figure 1. Diagram of tablet position in reference to center position on NIR detector 
( surface. Center position was determined using the iris. 
I 
0,360' 
315' 
270' 90' 
135' 
180' 
72 
1.4 Results 
The tablets used in this study were manufactured by direct compression. This is the 
simplest tablet production method and has several advantages over wet granulation 
methods. It is an economical method, since few processing steps are involved in 
comparison to wet granulation. No moisture is involved in the preparation of the blends 
for direct compression, thus the tablets made from this process tend to be more stable than 
those produced by wet granulations. However there are several d.isadvantages to direct 
compression methods. There are relatively few crystalline substances that may be directly 
compressed. Also, many products contain a low effective dose of the active drug, which 
may be difficult to adequately distribute throughout the tablet matrix. Another disadvantage 
of direct compression is that a limited amount of active ingredient may be incorporated into 
the matrix (usually no more than 30% ). This is a major limitation when formulating high 
dose products. 
A relationship between NIR signal and tablet hardness or compaction force was 
established for four tablet formulations containing active drugs, and for one placebo 
formulation. The same excipient matrix was used for the entire study. 
1.4.1 Results of Physical Testing of Tablets 
Results of tablet evaluations for hydrochlorothiazide 15% (HCTZ), 
chlorpheniramine maleate 2% (CTM) and placebo blends were previously reported in 
Manuscript 11. Tables 2 and 3 summarize the results of physical testing of HCTZ 20 % and 
CTM 6 %,respectively. Tablet weights for all batches were very consistent, with a relative 
standard deviation of less than 0.6 %. Friability was observed to increase in response to a 
decrease in tablet hardness. The properties of all batches fell within acceptable performance 
guidelines. 
The mean values for tablet hardness were generally lower than the target hardness 
value for each batch (Table 4). An exception to this occurred with the placebo blend, 
where batches in the 4, 6, and 8 kg range were higher than the target values. One other 
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Table 2. Summary of hydrocblorothiazide 20% tablet evaluation. 
Lot Mean Hardness Mean Weight (g) Mean Thickness Friability 
Number (kg) n=20 n=20 (mm) n=S % loss 
KM65 1.26 ± 0.13 0.3324 ± 0.00078 
(h=2kg) (rsd=l0.1%) (rsd=0.24 %) 
KM67 2.66 ± 0.25 0.333 ± 0.001 4.06 0.80 
(h=4kg) (rsd=9.52%) (rsd=0.20%) 
KM69 4.38 ± 0.31 0.3323 ± 0.00067 3.71 0.80 
(h=6kg) (rsd=7.1%) (rsd=0.20%) 
KM71 6.93 ± 0.52 0.3313 ± 0.00064 3.43 0.25 
(h=9kg) (rsd=7.5%) (rsd=0.19%) 
KM73 8.06 ± 0.51 0.3310 ± 0.00107 3.43 0.09 
(h=12kg) (rsd=6.36%) (rsd=0.32%) 
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Table 3. Summary of chlorpheniramine maleate 6% tablet evaluation. 
Lot Mean Hardness Mean Weight (g) Mean Thickness Friability 
Number (kg) n=20 n=20 (mm) n=S % loss 
KM77 8.26 ± 0.28 0.339 ± 0.001 3.84 0.02 
(h=l2kg) (rsd=3.33 %) (rsd=0.28 %) 
KM79 7.61±0.29 0.3296 ± 0.0007 3.91 0.01 
(h=lOkg) (rsd=3.76 %) (rsd=0.20 %) 
KM81 5.16 ± 0.26 0.3324 ± 0.001 4.09 0.14 
(h=8kg) (rsd=5.04 %) (rsd=0.3 1 %) 
KM83 4.41 ± 0.23 0.3293 ± 0.0007 4.39 0.24 
(h=6kg) (rsd=5.29 %) (rsd=0.22 %) 
KM85 2.74 ± 0.22 0.3312 ± 0.0011 4.65 0.57 
(h=4kg) (rsd=8.l %) (rsd=0.33 %) 
KM87 1.31 ± 0.16 0.3303 ± 0.0012 5.18 2.02 
(h=2kg) (rsd=l2.2 %) (rsd=0.37 %) 
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Table 4. Comparison of mean tablet hardness with target hardness. 
Product Mean hardness Target hardness % Difference 
(kg) (~ 
Placebo 9.625 12 19.79 
8.14 8 -1.75 
6.ll 6 -1.83 
4.66 4 -16.50 
2.09 2 -4.50 
HCTZ 15% 10.09 12 15.92 
8.96 9 0.44 
4.85 6 19.17 
3.46 4 13.50 
1.61 2 19.50 
CTM2% 11.2 12 6.67 
9.49 9.5 0.11 
6.31 6 -5.17 
4.1 4 -2.50 
2.38 2 -19.00 
7.58 8 5.25 
HCTZ20% 1.26 2 37.00 
2.66 4 33.50 
4.38 6 27.00 
6.93 9 23.00 
8.06 12 32.83 
CTM6% 8.26 12 31.17 
7 .61 JO 23.90 
5.16 8 35.50 
4.41 6 26.50 
2.74 4 3 l.50 
1.31 2 34.50 
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exception was in the CTM 2% batches having target hardnesses of 2, 4, and 6. These 
differences may have been due to environmental conditions, since all the hardness data was 
not collected on the same day as the tablet manufacture. HCTZ 20o/o and CTM 6% tablets 
were manufactured during the months of April and May, when ambient humidity is 
generally higher. The other three formulations were manufactured during the months of 
January and February, when ambient conditions are relatively dry . Although all batches 
were stored in tightly closed plastic containers, ambient conditions in the laboratory change 
frequently and may have resulted in increased uptake of moisture by the samples. No 
relationship was found between the deviation from target values and the "age" of the 
samples on the day of testing. 
Overall, the relative standard deviation (RSD) for lab hardness values ranged from 
3.23 to 13.24%. For each formulation , the RSD was found to increase as the average 
hardness decreased. The RSD for hardness was plotted against the age of the tablet, 
relative to the time that hardness data was collected (Figure 2). No relationship was found 
between RSD for hardness and the age of the sample. However, when the age of the 
product was plotted (Figure 3) against the percentage difference from the target hardness, 
there was a linear relationship (r2= 0.586). In Figure 4, the data was plotted and 
regression was performed by product. No correlation between age and percentage 
difference from the target hardness was found for the single products HCTZ 20o/o (r2= 
0.047) or CTM 2% (r2= 0.00). Io Figure 5, we find similar behavior between both HCTZ 
products and CTM 6%. The overall r2 for both HCTZ products was 0.82, and 0.83 for 
CTM 6% alone. Similar slope values resulted when both HCTZ products (slope= 0.446) 
were compared with the CTM 6% (slope= 0.531) formulation. Although inconsistent 
between products, this evidence suggests that tablet hardness may change over time, and 
hardness data should be collected immediately after tablet manufacture for the most accurate 
results. 
Figure 2. Product age versus percent standard deviation in hardness. 
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Figure 3. Product age versus deviation from target hardness (data from all four 
formulations included). 
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Figure 4. Product age versus deviation from target hardness: data separated by product to 
determine individual regression coefficients. 
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Figure 5. Product age versus deviation from target hardness: HCTZ data grouped together 
for regression and compared to CTM 6% regression. 
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A linear relationship was observed between tablet hardness and calculated density 
values for each batch. Table 5 summarizes the regression and correlation coefficients for 
each batch. (Detailed calibration results are given in Appendix C.) Hardness versus 
density values for the CTM 2% and 6% tablets were plotted in Figures 6 and 7. The 
regression equations (r2= 0.980 and 0.956, respectively) were similar, but when plotted 
together (Figure 8) the correlation was reduced to 0.65. A similar trend was observed with 
the HCTZ 15% and 20% data, shown in Figures 9 and I 0. The correlation between 
density and hardness for HCTZ 15% and 20% was r2= 0.962 and 0.938, respectively. 
When all of the HCTZ data was plotted together as in Figure 11 , the r2 dropped to 0.729. 
Figure 12 is a plot of density and hardness values for all four formulations. When from all 
four formulations were plotted together, the r2 was 0.45. As a linear relationship was 
demonstrated between density and tablet hardness for these products, I concluded that it 
would be feasible to develop NIR calibration models for density as well as hardness. 
1 .4.2 Results of NIR Spectral Analysis 
The raw spectra of CTM 6% and HCTZ 20% are illustrated in Figures 13 and 14. 
The corresponding second derivative spectra are displayed in Figures 15 and 16. The 
overall shapes of the spectra are similar between the two formulations, due to the fact that 
the major portion of each formulation was composed of the same matrix. It may be 
observed from the spectra in Figures 15 and 16 that the baseline at 1100 nm starts out quite 
close for all hardness levels, then begins to diverge after about 1500 nm. 
The raw and second derivative spectra ofCTM 2% and HCTZ 15% were given in 
Manuscript II. The second derivative spectra of all four products at a hardness level of 2 
kilograms is shown in Figure 17. The spectral differences between the formulations are 
more obvious in this plot. Each spectrum represents the average spectra of twenty single 
tablets. 
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Table 5. Linear relationship between tablet hardness and calculated density. 
Formulation 
CTM2% 
CTM6% 
CTM2% and6% 
HCTZ 15% 
HCTZ20% 
HCTZ 15% and 20% 
all 4 formulations 
Slope 
0.031 
0.042 
0.029 
0.038 
0.035 
0.036 
0.031 
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Y-Intercept 
0.720 
0.779 
0.790 
0.837 
0.969 
0.899 
0.843 
0.980 
0.956 
0.651 
0.962 
0.938 
0.729 
0.450 
Figure 6. CTM 2% hardness versus density (n=20). 
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Figure 7. CTM 6% hardness versus density (n=20). 
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Figure 8. CTM 2% and 6% combined data: hardness versus density (n=20). 
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Figure 9. HCTZ 15% hardness versus density (n=20). 
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Figure 10. HCTZ 20% hardness versus density (n=20). 
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Figure l l. HCTZ 15% and 20% combined data hardness vsersus density. 
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Figure 12. All CTM and HCTZ data: hardness versus density. 
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Figure 14. Raw NIR spectra of HCTZ 20% tablets at five hardness levels. 
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Figure 15. Second derivative NIR spectra of CTM 6% tablets. 
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Figure 16. Second derivative NlR spectra of HCTZ 20% tablets . 
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Figure 17. Second derivative NIR spectra of HCTZ 15%, HCTZ 20%, CTM 2% and CTM 6% tablets at a 
hardness of approximately 2 kg. 
1 .4.3 Results of Sample Position Study 
Figure 18 illustrates the effect of various sampling positions on the NTR spectra of 
one tablet The resulting spectra cover nearly a four-fold range in absorbance. Without the 
use of the iris to position the sample, even the spectra of the two replicates at 12:00 were 
shifted from one another. The sample scanned in the center position was closest to the 
actual baseline. The remaining samples were grossly shifted upward in relation to the 
center sample. Samples positioned at 180° and 225° were nearly superimposed, as were 
samples at 45" and 270°. It is interesting to note that the second derivative treatment 
(Figure 19) reduced the baseline offset of the samples so that they were almost 
superimposed upon each other. The region from 1476 nm to 1594 nm contained a 
significant amount of variation, as is evident from the plot The standard deviation 
spectrum of these samples appears in Figure 20, where the highest amount of variation 
appears around 1500 nm. It is likely that a loss of spectral information occurs when the 
sample is not reproducibly and accurately positioned. 
There was no significant difference between the raw spectral plots of one tablet 
scanned twenty times (Figure 21) versus twenty tablets scanned once (Figure 22). These 
spectra appear to be one solid line of varying thickness at specific wavelength regions. The 
iris was used on both sets of samples, thus the shapes of the spectra are the same. Figure 
23 and Figure 24 further illustrate the similarity between these two sets of samples. These 
are the standard deviation spectra of the respective sample sets. When superimposed, they 
differ slightly in absorbance, but not in "peak" position. This portion of the study 
demonstrates the precision of the NIR method. Multiple scans of the same sample yielded 
nearly the same results as a single scan of several samples. Overall , using the iris to center 
the tablet dramatically reduced the error due to sample positioning. 
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Figure 18. Raw NlR spectra of one tablet scanned in ten positions. 
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Figure 20. Standard deviation spectra of one tablet scanned in ten positions 
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Figure 21. Raw NIR spectra of one tablet scanned twenty times. 
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Figure 22. Raw NI R spectra of twenty tablets scanned once each. 
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Figure 23. Standard deviation spectra of one tablet scanned twenty times. 
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Figure 24. Standard deviation spectra of twenty tablets scanned once. 
1 .4.4 Results of Calibration Development 
Once a suitable set of calibration models was developed, they were applied to a set 
of validation samples that were part of the original population but not included in the 
calibration set. The choice of the best calibration models was made by comparing statistical 
parameters that were calculated by the NSAS™ software. First, since a NIRS method 
cannot be more sensitive than its primary analytical method6, it is important that the 
standard error of estimation (SEE) of the NIR method be as at least as good as that of the 
primary analytical method. The SEE indicates whether the answers provided by the 
calibration equation will be sufficiently accurate for the purposes for which they are being 
generated. The laboratory standard error on the Erweka Hardness Tester was calculated to 
be 032 kg. Readings may be subjective if the value falls between the 0.25 kg markings on 
the hardness tester. 
The NIR standard error was calculated for each MLR calibration along with the 
slope (k I), intercept (kO) and correlation coefficient (r2). A better correlation coefficient 
and standard error of estimation (SEE) were usually obtained by using more than one 
analytical wavelength in the calibration. Calibration coefficients (slope terms) should be in 
the same range relative to one another, and their values should be under 50()()7. If there is a 
large change in thex value for the calibration set with a relatively large change in 
absorbance (y ), the regression coefficients tend to stay small, indicating a large sensitivity 
and signal-to-noise ratio. On the other hand, a large change in x with a small change in 
absorbance results in large regression coefficients and may indicate low sensitivity and low 
signal-to-noises. 
The validation process involved the calculation of various statistical parameters that 
measure goodness of tit. These parameters (defined in Appendix I) include the ratio of 
bias to standard error of the bias (bias/SEB) and the ratio of standard deviation of the 
difference to root mean square (SDD/RMS). The RMS is close to the standard error of 
prediction (is not n-1); it is the non-bias corrected standard error. Standard deviation of the 
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difference (SDD) is the bias-corrected standard error. The desirable ratio between these 
parameters is 0.9 to 1.0. A rule of thumb for goodness of fit using these parameters is that 
bias/SEB should equal no more than 3.0, and the ratio SDD/RMS should be close to 1.0. 
It is desirable to have the bias and the SEB close to zero. It is also important that the value 
for slope adjustment be close to l.0 as well , since this indicates linearity. Note that it is 
unacceptable to change the slope9, as this indicates that the model does not fit the sample 
population. 
When using PLS, large MSECV (mean square error of cross validation) values 
indicate differences between spectra. The choice of the number of factors to use is based 
on the number of variables present in the formulation. Since we are measuring a physical 
property, rather than a chemical property, choosing the number of factors is not as straight 
forward . The usual practice is to select a model that uses no more than twice the number of 
variables in the formulation. The formulations in this study were composed of one active 
and two excipients, and varied in the level of hardness used in the manufacturing process. 
Therefore, eight factors were chosen as the maximum number allowed in the regression. 
The "mixed" calibrations required more factors, since they included the addition of drug 
concentration as a variable. 
As the current study was extensive in the development of various calibration 
models, only the summary results will appear in the text of this manuscript The reader is 
directed to Appendix 2 for more detailed calibration results, which include wavelength and 
calibration coefficient information for each formulation. 
1.4.4.J Results of HCTZ Calibrations 
Tables 6 and 7 summarize the calibration of HCTZ 15% tablets and HCTZ 20% 
tablets, respectively. Different MLR wavelengths were selected by the computer for 
calibrating each HCTZ formulation. Although it might be expected that the calibration 
wavelengths would be the same for a given drug, it must be reiterated that the equations are 
developed through chemometric methods using the wavelengths having the greatest 
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Table 6. Results of HCTZ 15% hardness calibration/prediction. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
10hcl5ca MLR 65 0.991 0.393 25 0.994 0.332 
2hcl5cal MLR 65 -0.983 0.541 25 0.987 0.535 
3hl5c3 MLR 65 0.996 0.295 25 0.994 0.318 
5hcl5cal MLR 62 0.989 0.445 25 0.992 0.405 
8hcl5cal MLR 65 0.990 0.417 25 0.990 0.419 
*hctl5c2 MLR 65 0.944 l.010 25 0.964 7.410 
*hc20cal4 MLR 61 0.991 0.354 36 0.888 3. 100 
7hcl5pls PLS 63 0.994 0.341 36 0.991 0.399 
pls4hcl5 PLS 62 0.995 0.294 36 0.990 0.403 
plshctl5 PLS 65 0.995 0.310 25 0.994 0.326 
*Calibration model from HCTZ 20% formulation ( 
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Table 7. Results of HCTZ 20% hardness calibration/prediction. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
5hc20cal MLR 65 0.980 0.446 25 0.985 0.479 
6hc20cal MLR 65 0.981 0.442 25 0.986 0.460 
hc20cal3 MLR 64 0.989 0.385 35 0.992 0.366 
hc20cal4 MLR 61 0.991 0.354 35 0.992 0.367 
pls2hc20 PLS 65 0.988 0.414 25 0.985 0.477 
pls3h20 PLS 63 0.990 0.374 25 0.985 0.486 
plshct20 PLS 75 0.991 0.359 25 0.984 0.529 
*plshctl5 PLS 65 0.995 0.310 25 0.987 3.720 
*Calibration model from HCTZ 15% formulation . 
( 
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variation in absorbance. It was possible to preselect the regression wavelengths, but in this 
experiment, the resulting predictions were not generally as good. Calibrations that were 
designed for Herz 15% did not fit data sets from HCTZ 20% samples. 
Table 8 contains a series of Herz 15% calibrations at 2076 nm. The calibration 
sets used to generate these models differed in the manner of sample selection and exclusion 
of outliers. (An outlier is a data point that falls well outside the main population.) The first 
model (hct l Scal) was generated from a sample set that was not randomly selected. The 
first thirteen spectra from each of the five hardness levels were selected for the calibration 
sample set. The next two models were generated from a calibration set that was randomly 
selected. These two models differ in the number of wavelengths used to perform the 
regression. The addition of another wavelength to the model resulted in an improved SEE 
and correlation coefficient. The next set of three models in Table 8 demonstrates the effect 
of deleting outliers from the data set during the calibration process. Again, the SEE was 
improved by the addition of other wavelengths to the model. 
It was not possible to develop acceptable calibrations by combining data from two 
concentrations of the same drug. The models themselves (Table 9) had acceptable 
correlation coefficients, but did not pass the validation process. For example, calibrations 
constructed from HCTZ 15% and 20% data resulted in a high bias value when applied to 
validation sets containing either concentration of drug. Equations developed for HCTZ 
15% were applicable to HCTZ 20% samples (and vice versa) only if an adjustment was 
made to the "bias/slope" value of the calibration. Equations developed for an HCTZ 
formulation did not fit a CTM validation set (and vice versa), unless an adjustment to the 
slope or bias was made. The NSAS" ' software was capable of making this adjustment, 
which resulted in a shift of the plot of lab hardness values versus NIR predicted values. In 
practice, this type of adjustment would not be acceptable, as it indicates that the model does 
not fit the sample population (i .e., the samples are outside the calibration set). 
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Table8. NTR calibration models for HCTZ 15% tablets, where 
Hardness= ko + k1 (AbsA. 1) + k1(AbsA.2) + k3(Abs1..3) 
MLR Calibration 
Cal.file ko k1 k2 kJ A DID molt r SEE 
hctl.5c2# -21.81 511.34 0 0 1998 0.944 1.010 
6hcl.5cal 21.54 -139.21 0 0 1572/1998 -0.985 0.513 
4hc15cal -9.21 235.44 -2027.65 0 1998+1578 -0.959 0.441 
hctl.5cal# -31.17 -1399.01 0 0 2076 -0.984 0.547 
2bcl5cal -29.89 -1345.28 0 0 2076 -0.983 0.541 
5bc15cal -27.78 -992.81 771.80 0 2076+1316 0.989 0.445 
3bl.5cl * -29.37 -1323.68 0 0 2076 -0.991 0.412 
3h15c2* -26.25 -896.24 -1232.31 0 2076+1822 0.994 0.330 
3b15c3 -22.25 -479.63 -2172.43 292.36 2076+1822+1902 0.996 0.295 
7hcl.5cal -2.11 -955.78 0 0 1360+2262 0.990 0.502 
9bcl5cal 71.97 -51.69 0 0 1580/1676 -0.989 0.430 
8bcl5cal -25.11 -1372.35 908.01 0 2320+1328 0.990 0.417 
l0bcl.5ca -12.16 -631.55 -3582.01 0 1520+1576 0.991 0.393 
PLS Calibration 
Cal. file #factors MSECV A. range nm (min) molt r SEE 
pls2bcl5* 4 O.Q3 1100-2500 1.13 0.995 0.301 
pls4bcl5 4 0.03 1300-2350 1.18 0.995 0.294 
7hc15pls 6 0.04 1100-2500 1.21 0.994 0.341 
plshctl5 6 0.04 1100-2500 1.01 0.995 0.310 
3h15pl 4 0.06 1100-2500 1.12 0.996 0.289 
*outliers deleted 
#nonrandom sample selection 
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Table 9. Results of HCTZ 15% and 20% (combined) hardness calibration/prediction. 
Calibration Prediction 
Cal.file Math n r2 SEE n Val.Set r2 SEP 
hcAcall MLR 65 -0.971 0.665 25 HCTZ 15% 0.977 0.713 
hcAcall MLR 65 -0.971 0.665 35 HCTZ20% 0.983 0.508 
hcAcal3 MLR 57 -0.979 0.551 36 HCTZ 15% 0.964 0.822 
bcAcal3 MLR 57 -0.979 0.551 35 HCTZ20% 0.983 0.476 
hcAcal5 MLR 52 -0.984 0.464 36 HCTZl5% 0.909 1.34-0 
hcAcal5 MLR 52 -0.984 0.464 35 HCTZ20% 0.985 0.464 
pls4bcA PLS 59 0.991 0.350 36 HCTZ 15% 0.834 1.600 
pls4hcA PLS 59 0.991 0.350 35 HCTZ20% 0.989 0.394 
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1 .4.4.2 Results ofCTM Calibrations 
Calibration models for CTM 2% and CTM 6% are summarized in Tables 10 and 
11, respectively. Numerous equations were developed at multiple wavelengths for each 
formulation. The computer selected different wavelengths for the two different drug 
concentrations. In general , the addition of wavelengths to the calibration resulted in a 
higher correlation coefficient and a better SEE. However, better predictions (validations) 
resulted from the models that used fewer wavelengths in the multiple regression of both 
CTM 2% and CTM 6% tablets. PLS performed somewhat better than MLR. 
Validation of CTM 2% models resulted in higher (ten-fold) bias values than the 
CTM 6% predictions. This may be a reflection of the higher variability in the laboratory 
hardness data. 
All of the MLR models that were developed for CTM 6% tablets successfully 
predicted their corresponding validation sets. It is evident from Tables 10 and 11 that the 
model with the best SEE may not yield the best prediction results. The best models 
consisted of three or four terms, but the same equations did not yield the best validation 
results. Overall, PLS performed slightly better than MLR for CTM 6% samples. 
Equations developed for combined CTM 2% and 6% samples followed the same 
rule as the combined HCTZ formulations (Table 12). The computer selected wavelengths 
for the combined formulations that were different from those forCTM 2% or CTM 6%. 
1 .4.4.3 Results of"Mixed" Calibrations 
"Mixed" calibrations were developed by performing regression on combined data 
from the four tablet formulations (Table 13). In the process of developing these calibration 
equations, the software defined a significant number of data points as outliers. The 
majority of the outlying points originated from the CTM 2% data. One PLS calibration was 
developed using the data from all four formulations (Table 14). This model only 
marginally fit both sets ofHCTZ validation data and the CTM 6% data. None of the 
developed models fit the CTM 2% data. The best performance was obtained from the 
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Table IO. Results of CTM 2% hardness calibration/prediction. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
ct2cal2 MlR 90 0.991 0.423 42 0.985 0.548 
ct2cal3 MlR 88 0.991 0.411 42 0.985 0.563 
ct2cal4 MlR 88 -0.988 0.482 42 0.980 0.638 
ct2ca15 MlR 88 0 .993 0.372 42 0.985 0 .552 
pls2ctm2 PLS 88 0.987 0.490 30 0.981 0 .650 
pls3ctm2 PLS 88 0 .987 0 .486 30 0.980 0 .658 
pls5ctm2 PLS 75 0.991 0.431 42 0.984 0.552 
pls6ctm2 PLS 75 0.991 0.417 42 0.981 0 .623 
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Table 11. Results of CTM 6% hardness calibration/validation. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
c6sscall MLR 78 -0.989 0.365 42 0.986 0.439 
c6sscal2 MLR 78 -0.992 0.318 42 0.990 0.370 
c6ssca13 MLR 78 0.993 0.298 42 0.992 0.336 
c6sscal5 MLR 78 0.994 0.271 42 0.991 0.340 
c6sscal7 MLR 78 0.994 0.285 42 0.994 0.287 
c6sscal9 MLR 78 0.993 0.291 42 0.994 0.288 
*ctm2cal MLR 90 -0.986 0.510 30 0.979 4.000 
plslctm6 PLS 78 0.997 0.204 30 0.991 0.365 
pls2ctm6 PLS 77 0.996 0.224 30 0.991 0.360 
pls3ctm6 PLS 77 0.994 0.272 42 0.991 0.356 
*plsctm2 PLS 90 0.988 0.474 30 0.978 5.380 
*Calibration model from CTM 2% formulation 
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Table 12. Results of CTM 2% and 6% (combined) hardness calibration/prediction. 
(l 
Calibration Prediction 
Cal.file Math n r2 SEE Val. set n r2 SEP 
ct26cal3 MLR 78 0.954 0.887 CTM6% 42 0.955 0.834 
ct26cal3 MLR 78 0.954 0.887 CTM2% 42 0.967 0.929 
ct26cal4 MLR 78 0.971 0.710 CTM6% 42 0.945 0.862 
ct26cal4 MLR 78 0.971 0.710 CTM2% 42 0.980 0.659 
ct26cal4 MLR 78 0.971 0.710 both 84 0.967 0.762 
ct26ca15 MLR 78 0.944 0.982 both 84 0.941 1.010 
ctm26cal MLR 78 0.968 0.746 CTM6% 42 0.948 0.833 
ctm26cal MLR 78 0.968 0.746 CTM2% 42 0.976 0.705 
c26plsl PLS 78 0.991 0.412 CTM6% 42 0.979 0.683 
c26plsl PLS 78 0.991 0.412 CTM2% 42 0.985 0.451 
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Table 13. Results of"mixed" hardness calibration/prediction. 
Calibration Prediction 
Cal.file Math n r2 SEE n Val.File r2 SEP 
mix2plsl PLS 199 0.991 0.3686 42 CTM6% 0.989 0.416 
mix2plsl PLS 199 0.991 0.3686 42 CTM2% 0.827 2.770 
mix2plsl PLS 199 0.991 0.3686 25 HCTZ 15% 0.992 0.379 
mix2plsl PLS 199 0.991 0.3686 25 HCTZ20% 0.984 0.485 
mix2call MLR 208 -0.95 0.832 42 CTM6% 0.978 0.817 
mix2call MLR 208 -0.95 0.832 25 HCTZ 15% 0.934 1.080 
mix2call MLR 208 -0.95 0.832 25 HCTZ20% 0.971 0.755 
mix2cal2 MLR 199 -0.963 0.709 42 CTM6% 0.978 0.844 
mix2cal2 MLR 199 -0.963 0.709 25 HCTZ20% 0.971 0.731 
mix2cal3 MLR 199 -0.938 0.637 42 CTM6% 0.981 0.723 
mix2cal3 MLR 199 -0.938 0.637 25 HCTZ 15% 0.953 0.920 
mix2cal3 MLR 199 -0.938 0.637 25 HCTZ20% 0.983 0.589 
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Table 14. "Mixed" hardness calibration models developed using the indicated products. 
MLR 
CTM 2,6 and HCTZ 15,20 
Cal.file k (O) k(l) k(2) A.nm mult r SEE 
I not saved -18.73 -211133 0 1586 -0.877 1.39 
2 not saved* -22.48 -4567. 17 0 1820 -0.903 1.17 
*deleted outlier.;(CTM 2% 12kg) 
CTM 6 and HCTZ 15, 20 
Cal.file k(O) k(l) k(2) A.nm mult r SEE 
mix2call -22.24 -4550.70 0 1820 -0.950 0.832 
mix2cal2* -21.90 -4489.33 0 1820 -0.963 0.709 
ntix2cal3 -28.12 -3104.72 -436.49 1820+2344 -0.938 0.637 
CTM 2, 6 onl;i: 
Cal.file k(O) k(l) k(2) A.nm mult r SEE 
ctm26call -33.12 -5821.95 0 1824 -0.951 0.912 
ctm26cal2 -20.65 -9243.32 1510.45 1824+2324 0.968 0.746 
PLS 
CTM 2,6 and HCTZ 15,20 
Cal. file # factors MSECV (min) A. range nm mult r SEE 
mix2plsl 13 0.05 1.19 1100-2500 0.991 0.369 
CTM 2, 6 onl;i: 
Cal. file # factors MSECV (min) A. range nm mult r SEE 
c26plsl 11 0.06 1.18 1100-2500 0.991 0.412 
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HCTZ 15% data, which resulted in a SEE of0.379 when predicted with the PLS model. 
For practical purposes, the use of this type of mixed calibration is not viable due to the 
relatively high standard errors; the majority of these calibrations have SEE's which are 
higher than the reference SE for the Erweka hardness tester. 
In theory, it might be expected that mixed calibrations would work on a global scale 
since there is no analytical wavelength for hardness. The effect of changing hardness is 
seen as an overall spectral effect. The instrument selects the wavelength(s) having the 
highest correlation coefficient in the wavelength region selected. Other factors, such as 
sensitivity plots and loadings aid in the selection of the appropriate wavelength(s) in a case 
where the computer chooses a wavelength that is unrelated lo the constituent of interest. 
The instrument evaluates the overall spectral variation- changing the hardness in a specific 
formulation has an overall effect on the spectra, which may vary between formulations. 
Although the present study did not find a universal calibration equation for 
hardness, it was found that the NIR signal responded in the same way to a change in 
hardness, regardless of the drug. A change in hardness caused a shift in the spectra at 
several common wavelengths for each formulation. Upon observation of the average 
second derivative spectra of each batch of tablets, it was noted that all four formulations 
demonstrated a shift in the spectra at 1330, 1366, 1396, 1432, 1882 and 1926 nm. The 
spectral bands at 1432 nm and 1926nm are characteristic of the water content in the 
sample. Absorbance changes at these wavelengths suggest changes in moisture content 
due to changes in tablet compaction forces. Since all four formulations were composed of 
the same excipient matrix, similarities in the general peak shape would be expected. 
1 .4.4.4 Results of Placebo CalibraJions 
The results of MLR and PLS calibrations and validations for the placebo tablets are 
summarized in Table 15. Several multiple term models were developed using MLR. The 
best MLR model utilized three wavelengths and resulted in multiple correlation coefficient 
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Table 15. NIR hardness calibration/validation of placebo tablets. 
Calibration Prediction 
Cal.file Math n r2 SEE n Val.Set r2 SEP 
pl3cl MLR 52 0.990 0.400 28 placebo 0.974 0.676 
p13cl MLR 52 0.990 0.400 26 placebo* 0.986 0.537 
p13c2 MLR 49 0.993 0.338 28 placebo 0.975 0.669 
p13c2 MLR 49 0.993 0.338 26 placebo* 0.986 0.493 
pl3c2 MLR 49 0.993 0.338 25 placebo* 0.988 0.438 
pl4cl MLR 49 0.991 0.383 28 placebo 0.978 0.627 
pl4cl MLR 49 0.991 0.383 24 placebo* 0.991 0.398 
pl4cl MLR 49 0.991 0.383 30 CTM2% 0.887 3.860 
pl4cl MLR 49 0.991 0.383 35 HCTZ20% 0.928 2.330 
pl2p2 PLS 47 0.994 0.314 28 placebo* 0.988 0.495 
pl2p3 PLS 47 0.992 0.345 28 placebo 0.964 0.840 
pl2p3 PLS 47 0.992 0.345 25 placebo* 0.987 0.528 
pl2p4 PLS 47 0.991 0.359 28 placebo 0.986 0.536 
pl2p5 PLS 45 0.994 0.301 28 placebo 0.987 0.533 
pl2p6 PLS 45 0.993 0.329 28 placebo 0.985 0.557 
pl2p7 PLS 42 0.994 0.295 28 placebo 0.986 0.546 
pl2p8 PLS 42 0.989 0.382 28 placebo 0.984 0.561 
Legend: 
* outliers deleted from validation set 
PLS Partial Least Squares 
MLR Multiple Linear Regression 
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of 0.993 and a SEE of 0338. PLS produced slightly better SEE values. Validation of 
both types of models resulted in marginally acceptable predictions. Overall, linearity was 
not as good as it was for other formulations. Calibrations of the placebo formulations were 
constructed from only four levels of hardness. Better performance could likely be achieved 
by including more data in the models. 
1.4.4.5 Results of Density/NJR Calibration 
Calibrations were also developed for the four formulations using the calculated 
tablet density versus NIR signal. The models themselves were much better than those 
developed using hardness data. One factor that might be expected to contribute to this 
improvement is the degree of variability in the laboratory measurements. Relative standard 
deviations (fable 16) in laboratory hardness measurements were 3 to 13% compared with 
errors in density of only 0.2 to l.0%. In evaluating the laboratory hardness data, a trend 
was observed in the percentage standard deviation: as hardness was decreased, percentage 
variation increased. This effect was not observed with the calculated tablet density data. 
In order to evaluate the performance of the NIR determination of density, the NIR 
values were compared to the reference SE for density, i.e., the laboratory values. The 
overall reference SE for density was 6.67 x l Q-3 (giml). The calculation of the SE for 
density is dependent on the precision of the weight and thickness measurements. These 
measurements are generally very good, due to the quality of the tablet press tooling and the 
accuracy of the balance. 
Numerous one and two-term density calibration models were developed for each of 
the four products and are summarized in Tables 17 to 20. ln general, the SEE's were three 
to four times greater than the reference SE for density measurement. PLS models were 
slightly better in terms of linearity and SEE. CTM 2% calibrations developed using MLR 
had only slightly higher SEE values (0.018) in comparison to the reference SE value of 
0.013. PLS models for CTM 2% resulted in SEE values of approximately 0.011. 
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Table 16. Comparison of% standard deviation between tablet hardness data and density 
calculations. 
Product Density SD% Hardness SD% 
hct20 4kg 0.298 9.77 
hct20 6kg 0.201 7.06 
hct20 9.Skg 0.311 7.51 
hct20 12k_g_ 0.438 6.35 
mean 0.312 7.67 
hct15 2kg 0.370 13.24 
hctl5 4kg 0.510 9.31 
hctl5 6kg 0.625 6.12 
hctl5 9kg 0.466 3.42 
hctl5 12~ 0.450 4.98 
mean 0.484 7.41 
ctm2 12kg 1.000 3.23 
ctm2 9.Skg 0.470 4.60 
ctm2 6kg 0.690 7.90 
ctm2 4kg 0.370 8.29 
ctm2 2kg 0.930 8.57 
ctm2 8k_g_ 0.510 6.92 
mean 0.662 6.59 
ctm6 12kg 0.284 3.33 
ctm6 IOkg 0.262 3.76 
ctm6 8kg 0.310 5.04 
ctm6 6kg 0.220 5.29 
ctm6 4kg 0.330 8.10 
ctm6 2~ 0.370 12.17 
mean 0.2% 6.28 
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Table 17. NIR density calibration/prediction results for HCTZ 15% tablets. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
c l MLR 65 -0.985 0.0217 36 0.967 0.0335 
c3 MLR 65 -0.994 0.0135 36 0.981 0.0263 
c2 MLR 65 0.995 0.0127 36 0.980 0.0266 
pl PLS 65 0.997 0.0109 36 0.981 0.0252 
p2 PLS 63 0.997 0.0098 36 0.981 0.0252 
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Table 18. NlR density calibration/prediction results for HCTZ 20% tablets. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
cl MLR 52 -0.974 0.0178 28 0 .960 0 .0220 
c2 MLR 52 0.989 0.0119 28 0.980 0.0156 
c3 MLR 52 0.968 0.0197 28 0 .966 0.0203 
o4 MLR 52 0.983 0.0144 28 0.978 0.0167 
pl PLS 52 0 .997 0.0062 28 0.994 0.0083 
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Table 19 NIR density calibration/prediction results for CTM 2% tablets. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
cl MLR 78 0.978 0.0204 42 0.976 0.021 
c2 MLR 78 0.987 0.0159 42 0.983 0.018 
c3 MLR 78 0.982 0.0182 42 0.982 O.oJ8 
c4 MLR 78 -0.982 0.0187 42 0.978 0.020 
pl PLS 78 0.994 0.0112 42 0.990 0.014 
p2 PLS 77 0.993 0.0118 42 0.988 0.015 
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Table 20. NIR density calibration/prediction results for CTM 6% tablets. 
Calibration Prediction 
Cal.file Math n r2 SEE n r2 SEP 
cl MlR 78 -0.978 0.0224 42 0.978 0.022 
c2 MlR 78 0.983 0.0200 42 0.983 0.020 
c3 MLR 78 0.983 0.0195 42 0.978 0.022 
c4 MLR 78 0.986 0.0179 42 0.991 0.015 
pl PLS 78 0.996 0.0104 42 1.000 0.011 
p2 PLS 76 0.996 0.0100 42 0.994 0.012 
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Overall, PLS models also performed better in the validation process. Although the 
laboratory density values were less variable than the laboratory hardness values, 
calibrations produced from hardness data were more rugged than the density models. and 
were better at predicting hardness. Jn other words. the models based on hardness 
contained built-in variability which contributed to the good prediction ability of the 
hardness calibrations. 
1.5 Conclusions 
This work presents a viable and non-destructive alternative to hardness testing of 
tablets. A method was developed which offers the potential of 100% quality control testing 
for tablet hardness. There is a correlation between the hardness or compression force of a 
tablet and its NIR spectra. As tablet hardness increased, an upward shift in the raw NIR 
spectra was observed. This relationship was modeled by the development of formulation 
specific calibration equations for the determination of hardness via NIRS. The NIR 
method of hardness testing did not suffer from subjective differences in reading the results. 
Because the method is non-destructive. the samples can be further tested or even packaged 
for sale after NIR testing. The use of the iris was important to maintain accurate and 
reproducible sampling technique. 
Equations based on tablet density produced statistically improved models for NIR 
density determination. Predictions based on tablet density had slightly lower multiple 
correlation coefficients than predictions based on tablet hardness. 
In applying multivariate regression techniques. we are assuming that there is an 
equation that will best fit all the data in a set. We also assume that a perfect fit of any model 
to all the data cannot be made because of random errors in the data. Thus. we end up with 
a list of potential equations that fit our criteria (none of them a perfect fit). Each time we 
select a different wavelength, or include additional wavelengths in the model. different 
calibration coefficients result. This reflects the different values of the molar absorptivity 
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( 
(extinction coefficient) at different wavelengths. The calculation for each calibration 
coefficient contains a contribution from each constituent at each wavelength Io. 
It may not be possible, or desirable to develop a single, global equation for the 
evaluation of hardness. Since hardness is a physical property for which there is no single 
analytical wavelength, PLS may be a more reliable approach to calibration. PLS models 
the entire spectra, not just data at specific wavelengths. The goal in developing a global 
calibration is •· ... to cover as broad a range of samples as possible while maintaining 
acceptable accuracy" .1 1 Unique equations that are developed for a particular product can 
secondarily act to identify or qualify the product. In the agricultural industry. a global 
calibration is one that is designed to analyze 90 to 95% of samples of a given product 12. 
Specific calibrations based on a small range of samples typically perform bener than general 
calibrations, provided the samples to be analyzed are represented in the calibration set. 
1. 6 Considerations for future work 
The calibrations developed in this study covered a hardness range of 2 to 12 kg. Jn 
a manufacturing sening, a more realistic range of acceptable hardness values would be+/-
20%, at most. In this situation, a slightly different approach to calibration would be 
required. Rather than manufacturing tablets covering a broad range of hardness values. 
spectral data from several lots of a product would be collected over a period of time. An 
acceptable range of hardness would be identified for the product. and a calibration would 
be developed using the collected data. 
Jn order to fully characterize the potential of NIRS as an alternative to conventional 
hardness testing. several tablet matrices should be evaluated. A comparison of tablets 
produced by direct compression versus wet granulation would be useful in the 
detennination of the extent of NIRS utility for hardness testing. 
In the current study. second derivative data was used to develop the calibration 
models. Derivative spectroscopy is a powerful technique for magnifying the fine structure 
of spectral curves. The result is an enhancement of structure that is offset by a decrease in 
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the signal-to-noise (SIN) ratio. The major advantage is an increase in resolution. which 
may be very useful for resolving bands that are too close to be resolved in their absorption 
spectrum. In the case of a physical property, such as tablet hardness, the use of the second 
derivative spectra may not be desirable since taking derivatives minimizes non-chemical 
composition effects, such as particle size. Since we are interested in a physical property. it 
seems logical to include such influences by using the untreated (raw) spectra. 
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Manuscript IV 
Effect of Matrix and Geometry on the 
Near-Infrared Determination of Tablet Hardness 
1 . 1 Abstract 
The purpose of this study was to evaluate the effect of matrix and geometry on the 
detennination of tablet hardness via near-infrared reflectance spectroscopy (NIRS). A 
secondary objective was to evaluate any differences in NIR response due to scoring of a 
tablet. Flat-faced and convex (scored on one side) tablets were manufactured at five levels 
of compression force, using two excipient matrices. Blend# I consisted of 
chlorpheniramine maleate6%, magnesium stearate 0.5% and microcrystalline cellulose. 
Blend #2 contained chlorpheniramine maleate 6%, magnesium stearate 0.5% and di basic 
calcium phosphate dihydrate. 
Multiple linear regression and partial least squares were used to develop calibration 
models using NIR spectral data and tablet hardness. Differences in these models enabled 
comparisons of matrix and geometry, as well as scoring. NIR absorbance data at several 
individual wavelengths were subject to linear regression and one-way analysis of variance 
in order to assess the potential of hardness prediction at one wavelength. 
Formulation specific calibration models were developed for two tablet matrices and 
two geometries. NIRS calibration models successfully predicted tablet hardness for both 
matrices and both geometries. Absorbance (log I /R) values were higher for convex tablets 
than flat tablets. Scored tablets produced slightly more variable results than nonscored 
tablets . Tablets containing di basic calcium phosphate di hydrate produced more variable 
hardness and spectral results than those containing microcrystalline cellulose. Models 
developed for one fonnulation could not be used to predict hardness in other fonnulations. 
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Models developed for flat tablets could not be used to predict hardness for convex tablets. 
The previously established hardness/NIR relationship was valid for other formulations. 
1. 2 Introduction 
Powdered drugs are generally combined with a number of excipients when 
formulating solid dosage forms , and then processed into convenient forms for drug 
administration. It is important to characterize their fundamental powder and processing 
properties since, in principle, all factors influencing the final compact depend upon them 1 _ 
Consolidation of a particulate solid into a compact or tablet is affected by the way 
the material behaves under an applied pressure. For example, microcrystalline cellulose is 
primarily a deforming material , dicalcium phosphate dihydrate fragments and lactose is an 
intermediate of the two2. Once the particles have been brought sufficiently close together, 
they undergo some form of bonding, such as solid bridge formation, intermolecular forces 
and mechanical interlocking. 
Compressed tablets are characterized by several specifications, including weight , 
hardness, thickness, shape and diameter. The diameter and shape are defined by the 
tooling selected for use in the tablet press. Tablets may be of numerous shapes and their 
surfaces may be flat, concave or convex to varying degrees. Concave punches are used to 
prepare convex tablets. Tablets may also be scored to facilitate breakage into smaller 
doses. These characteristics make the tablets distinctive and identifiable with the 
manufacturer's product' . 
In Manuscript Ill , near-infrared reflectance spectroscopy (NlRS) was used to 
develop calibration models capable of predicting tablet hardness. These models were based 
upon flat faced tablets having no scoring or indentations on their surfaces. and utilized 
tablets made from only one excipient matrix. It is suspected that a convex surface may 
produce a different NIR spectrum in response to changes in compression force. It is also 
suspected that scoring may also affect on the NIR response to hardness, as the surface 
integrity would be different from an nonscored tablet. The effect of matrix on NIR 
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calibration was shown by Corti, et a]4, in the comparison of a powder with a gel 
formulation containing ketoprofen. There are no known studies that examine the effect of 
tablet matrix on NIR calibration efforts. The current study was undertaken to investigate 
the effect of tablet geometry, scoring and excipient matrix on the NlR/compression force 
relationship. 
1 . 3 Experimental 
1 .3. 1 Tablet Manufacture 
Flat faced (FF) round and standard round convex (SRC), half-inch diameter tablets 
were manufactured by direct compression using a Korsch Type PH 106-DMS, six-station 
tablet press, interfaced with Korsch Compression Research System Instrumentation KWS 
506A (courtesy of Pfizer Central Research, Pharmaceutical R & D, Groton, Connecticut.). 
The FF tablets were made first, then the tooling was changed and the SRC tablets were 
made. The SRC tablets were scored on one side only. 
Two formulations were used, differing only in the type of diluent (Table I). The 
first blend contained 93.5 % Emcompress® (dicalcium phosphate dihydrate, Edward 
Mendell Company) and the second contained 93.5% Avicel® PH 102 (microcrystalline 
cellulose, FMC Corporation). Chlorpheniramine maleate (CTM) 6% was the active 
component and each blend was lubricated with 0.5% magnesium stearate (Fisher 
Scientific). The basis for selection of the matrices was the behavior of the diluent when 
compressed. Microcrystalline cellulose compresses due to plastic deformation while 
dicalcium phosphate dihydrate is known to fracture upon compaction. Each blend was 
mixed for ten minutes in a 16-quart, twin shell dry blender (Patterson-Kelley). The 
Emcompress®/CTM blend was screened (20 mesh) after mixing, to reduce lumps of CTM. 
The CTM fortbeAvicel®/CTM blend was screened (20 mesh) prior to mixing. 
The target weight for the CTM/Emcompress® /magnesium stearate tablets was 800 
mg. The target weight for the CTM/Avicel®/magnesium stearate tablets was 540 mg. 
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After adjusting the tablet press for correct target weight, the hardness level was adjusted to 
achieve five different levels for each blend. 
Target hardnesses of 2, 4, 6, 9, and 12 kg (as monitored by a Heberlein , vector-
type Hardness Tester) were used for each combination of blend and geometry for a total of 
20 different batches of tablets. The tablet press was adjusted to the desired hardness level, 
beginning with the lowest level , and monitored for constant tablet hardness. After 
achieving a constant hardness level, the next ten tablets were collected from each batch. in 
order, and stored in labeled Whirl-top® plastic bags. The instrumented tablet press 
recorded compression force data for the first six tablets of the ten collected from each batch. 
Upper and lower compression forces (in kN, or kilonewtons) and ejection force data were 
recorded for each batch. This compression data was correlated to the first six reserved 
tablet samples, for later calibration with NIR data. The tablet press was allowed to 
continue compressing until approximately 200 tablets per batch were manufactured. The 
same process was repeated for the next hardness level. 
Each batch of tablets was labeled according to geometry, matrix and hardness (low 
to high) level. Flat-faced Avicel®/CTM tablets were labeled AF! through AF5. Convex 
Avicel®/CTM tablets were labeled AC! through ACS. Flat-faced Emcompress®/CTM 
were labeled EFI through EF5, and convex Emcompress®'CTM tablets were labeled EC I 
through EC5. 
1.3.2 Near-Infrared Spectroscopic Analysis 
A Perstorp Analytical/NIRSystems Rapid Content Analyzer® Model 5000 was used 
for the analyses of tablet samples. This instrument and corresponding setup was described 
in Manuscript II. 
NIR reflectance parameters were set at 32 scans per sample in the range of 1100 to 
2500 nm. A ceramic (Coor' s Standard) reference scan was taken before each set of 
samples. Near-infrared reflectance measurements were made on the ten reserved tablets 
from each batch. The sample to be measured was placed directly above the detector surface 
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and centered with the iris. Before positioning each sample, the detector surface was gently 
cleaned of debris. Flat faced (FF) tablets were scanned once on each side. Standard round 
convex tablets (SRC) were measured twice, alternately , on each side, and given spectral 
sample names corresponding to score and replicate number. 
J .3.3 Tablet Evaluation 
After completion of the NIR scans, the ten reserved tablets from each batch were 
subjected to weight, thickness and hardness testing using a Vector Systems-3 hardness 
tester, which was interfaced with a Mettler balance, Model AM.SO. The tablets were 
manually added to the hardness tester without regard to the orientation of the scoring on the 
SRC tablets. The order in which the instrument performed these tests was thickness, 
weight, and then tablet hardness. 
The laboratory hardness and compression data were analyzed using Mini tab® 
Statistical Software (Version 8, Student Edition) to test the means. Two-sided I-tests were 
performed between batches and on consecutive hardness levels to test for equal means. 
The individual hardness data was entered into the near-infrared software, NSAS. as 
constituent number one, hardness. The corresponding upper compression force data was 
entered into NSAS as constituent number two. upper kN. Lower compression force data 
was entered into NSAS as constituent number three. lower kN. Thus, there were three 
constituents for each NlR spectrum: hardness (n=lO) , upper punch force (n=6), lower 
punch force (n=6) . 
1 .3.4 Effect of Sample Position ojSRC Tablets on the NIR Spectra 
Reproducibility of sample position is an important factor in NlR analysis. Flat 
faced, round tablets can be reproducibly positioned on the detector surface (this experiment 
was described in Manuscript Ill ) using the iris. However, one might suspect that SRC 
tablets may be subject to more variation in position since the point of contact between the 
tablet and the detector surface is so much smaller than that of a flat faced tablet. Scoring of 
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Table I. Summary of fonnulations used in tablet manufacture. 
Fonnulation 1 
Theoretical Actual 
Chlorpheniraminemaleate 6.0 % 240.0 g 240.0 g 
(CTM) 
Emcom_JJ_ress® 93 .5 % 3740.0_g__ 3740.36_g__ 
M~esi um stearate 0.5 % 20.0....&J 20.0_g__ 
Total 100.0 % 4000.0J:.J 4000.36....&_ 
Fonnulation 2 
Theoretical Actual 
CTM 6.0 % 240.0_.&: 240.0_g__ 
Avicel® PHI02 93 .5 % 3740.0_g__ 3740.3I_g__ 
M~esium stearate 0.5 % 20.0 _g' 20.0 g 
Total 100.0 % 4000.0_g__ 4000.3l_g__ 
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tablets introduces another variable The SRC tablets manufactured for this study were 
scored on one side only , enabling the testing of scored versus nonscored samples. A 
validation study was performed to evaluate the effect of sample position on the NIR spectra 
of SRC tablets. The effect of scoring on reproducible sample positioning was also 
examined in this study. 
Emcompress®/CTM 6%/magnesium stearate SRC tablets (6 kg hardness) were 
chosen for this portion of the study. One tablet was placed in the center sampling position 
using the iris and scanned ten times on each side, removing and flipping the tablet over 
between scans. First the nonscored side of the tablet was scanned, and then the scored side 
was scanned. During the analysis of the scored side, an attempt was made to align the 
score at the same point for each scan. 
Next, one tablet was placed in the center position using the iris. and scanned ten 
times on each side without removing it from the detector surface. The nonscored side was 
run first, followed by the scored side. In the third phase of the study, ten tablets were 
scanned once on each side in the center position, using the iris. 
Finally, one tablet was scanned in ten positions on the detector surface. The 
methods for this study were previously described and illustrated in Manuscript III (Figure I 
in section 1.3.4). Beginning with the center position, the tablet was moved to the 12:00 
(twelve o' clock) position, then rotated to a position 45• from the previous spot. At each 
rotation , one edge of the tablet was touching the center position . The 12:00 position was 
repeated, as position number ten. The resulting spectra were entered into spectral libraries, 
where the mean and standard deviation spectra were extracted for each condition. Standard 
deviation spectra were plotted and compared. 
1.3.5 Near-Infrared Calibrarion of Hardness and Compression Force 
Table 2 summarizes the numerous spectral data sets that were created for the 
calibration process. FF tablet spectral data forthe general calibration was the average of 
two replicates per tablet. SRC data was treated in three separate ways: 1) all four replicates 
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per sample were averaged (two scored replicates and two nonscored replicates from each 
tablet). 2) data from the scored sides (n=2) of the samples were averaged, and 3) data from 
the non-scored sides (n=2) were averaged. The subsets of scored and nonscored data were 
used for separate calibrations. 
Constituent #1 , hardness, was calibrated first. Calibration sets were created from 
the averaged spectra by using the Sample Select function of NSAS T~ , which selected six 
spectra from each level of hardness, based on a "boxcar" distribution. Tbe software selects 
the spectra having the most variation in the set. Thus, tbe calibration set AF contained 
hardness and spectral data from six tablets at each of five hardness levels of flat tablets of 
the A vice!® I chlorpbeniramine/ magnesium stearate blend, for a total of 30 calibration 
samples. The calibration set AC was composed of SRC tablets at five hardness levels, 
containingAvicel® /chlorpheniramine/ magnesium stearate blend. The calibration set EF 
was comprised of flat tablets at five hardness levels. containing Emcompress®/CTM/ 
magnesium stearate blend. The calibration set EC was composed of SRC tablets at five 
hardness levels, containing Emcompress®/CTM/ magnesium stearate. 
A separate calibration set was needed to test the second and third constituents, 
upper and lower compression force. This was because compression data was available for 
only six tablets from each batch. The same sample selection process was followed. except 
four spectra per batch were selected by the computer from the samples having associated 
compression data, and the remaining two spectra from each batch were used in the 
validation (prediction) set. 
Each subset of spectral data was converted to the second derivative. Standard 
multiple linear regression (MLR) and partial least squares regression (PLS) were performed 
on each calibration set. One to three wavelengths were used for each MLR model. PLS 
regression was limited to eight factors and the wavelength range was 1100 to 2500 nm. 
Equations were developed from second derivative and "raw" (untreated) spectral data. 
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Table 2. Summary of spectral data sets for hardness calibration (H-Cal.) and compression 
force (C-Cal.) 
Cal. n per n per n per 
Matrix Cal . group filename hardness H-Cal. Set C-Cal. Set 
level 
Avicel general AC 4 30 
SRC- scored ACS 2 30 
SRC- ACN 2 30 
nonscored 
Flat AF 2 30 20 
Emcompress General EC 4 30 
SRC- scored ECS 2 30 
SRC- ECN 2 30 
non scored 
Flat EF 2 30 20 
138 
Validation sets for hardness were created using the remaining four spectra from 
each batch of tablets (for a total of 20 validation samples per formulation). Validation of 
the models was performed using the Percent Predict function ofNSAsr~. Equations that 
were developed for one calibration set were applied to the corresponding validation set (of 
the same math treatment), as well as validation sets from other blends, to test their fit. 
The subsets of scored and nonscored data were compared chemometrically to detect 
spectral differences. Mean and standard deviation spectra for each subset were calculated 
using the JQ2"' function of NSAS. Standard deviation spectra of raw and second 
derivative data were compared to evaluate differences between scored and nonscored sides 
of the samples. Calibration equations for hardness were also developed for the scored and 
nonscored data, as described above. 
1.4 Results 
1.4.l Resuirs ofTabler Evaiuarion 
The results of the evaluation of physical tablet parameters for Avicel®/CTM FF and 
SRC tablets are summarized in Tables 3 and 4. Emcompress® /CTM FF and SRC tablet 
data are summarized in Tables 5 and 6. All hardness, thickness and weight evaluations 
were completed within one week of the date of tablet manufacture. Good reproducibility 
was achieved in all batches for tablet weight and thickness. Avicel® /CTM tablet weights 
varied from 0.54% to 1.84% (relative standard deviation , RSD) and thickness varied from 
0.59% to 1.42%. Emcompress® /CTM tablet weights varied from 0.30% to 0.49% and 
thickness varied from 1.07% to 2.10%. 
It was generally noted in all formulations that an increase in tablet hardness was 
associated with an increase in variability (RSD). Hardness values for the Avicel® /CTM 
batches varied from 3.3% to 11 .2%. Variation in Emcompress® /CTM tablets ranged from 
1.70% to 10.7%. In the Emcompress® /CTM formulations , data from the two highest 
hardness levels contained several extremely low values which were eliminated from the 
data set (summary table does not include the deleted values). These were: SRC level 4 
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(n==2), SRC level 5 (n==5), FF level 4 (n== I) and FF level 5 (n==4). No outliers were 
initially detected in the A vice!® /CTM hardness data. Hardness testing of scored tablets 
may occasionally result in a false value if the score is aligned with the applied crushing 
force . Orientation of scoring on SRC tablets during hardness testing may have contributed 
to the variability in the hardness data. 
Calculation of the reference standard error for hardness is summarized in Table 7. 
Deletion of outlying hardness values for Emcompress® /CTM FF tablets resulted in a SE of 
0.39 (kg), the same value as A vice!® /CTM FF tablets. The SE for EC tablets was 0.58, 
and for AC it was 0.68. The matrix SE was 0.49 for all Emcompress® /CTM tablets, and 
0.54 for all Avicel®/CTM tablets. The geometry SE for all SRC tablets was 0.63 , and 
0.39 for all flat tablets. The overall SE for all tablets analyzed in the experiment was 0.51 
kg. 
Hardness data from two batches of the Emcompress®/CTM SRC tablets were 
found to have equal means. Hardness level 4 (9.41 ± 0.97 kg) was deterrnined to be not 
significantly different (p== 0.05) from hardness level 5 (9.86 ± 1.29 kg). In contrast to this 
finding , the corresponding upper and lower compression force data did not follow the same 
pattern. The five levels of upper and lower compression force were found to be 
significantly different (p== 0.05) from one another in these batches. 
A comparison of average hardness data was made between FF and SRC tablets at 
each hardness level for both forrnulations (Table 8). In other words, EF data at hardness 
level 1 was compared to EC hardness level I , AF data at hardness level 1 was compared to 
AC hardness level 1, etc. Emcompress/CTM means were equal for hardness levels I 
through 4 . Avicel/CTM means were equal only at hardness level 5. (This was an 
important piece of inforrnation for later spectral comparisons. It might not be useful to 
compare, for example, spectra of EF tablets at hardness level 2 to EC tablets at hardness 
level 2 if the actual hardness means were not equal). 
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Table3. Summary of weight, thickness and hardness data for Avicel/CTM 6% 
/magnesium stearate flat 1/2" round tablets (AF). 
Product Weight (g) Thick (cm) Hardness (kg) 
±St.Dev. (RSD%) ±St.Dev. (RSD%) ±St.Dev. (RSD%) 
AFl 0.539 ± 0.()()<) 0.552 ± 0.005 2.30 ± 0.26 
( 1.666) (0.841) (11.23) 
AF2 0.551 ± 0.005 0.503 ± 0.004 4.23 ± 0.23 
(0.970) (0.888) (5.35) 
AF3 0.550 ± 0.004 0.453 ± 0.003 6.93 ± 0.29 
(0.696) (0.591) (4.20) 
AF4 0.545 ± 0.003 0.410 ± 0.003 9.87 ± 0.33 
(0.546) (0.752) (3.34) 
AF5 0.545 ± 0.008 0.380 ± 0.004 13 .81±0.84 
(1.544) (1.096) (6.10) 
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Table4. 
Product 
ACHl 
ACH2 
ACH3 
ACH4 
ACH5 
Summary of weight, thickness and hardness data for Avicel/CTM 6% 
/magnesium stearate SRC 1/2" round tablets (AC). 
Weight (g) Thick (cm) Hardness (kg) 
± St.Dev. (RSD%) ±St.Dev. (RSD%) ±St.Dev. (RSD%) 
0.540 ± 0.005 0.626 ± 0.008 3.00 ± 0.25 
(0.900) ( 1.220) (8.3 1) 
0.540 ± 0.005 0.552 ± 0.007 6.37 ± 0.26 
(0.890) (1.348) (4.06) 
0.544 ± 0.009 0.523 ± 0.006 8.59 ± 0.78 
(1.612) (1.126) (9.04) 
0.545 ± 0.008 0.490 ± 0.007 12.06 ± 0.84 
(1.410) ( 1.339) (6 .99) 
0.542 ± 0.010 0.472 ± 0.007 14.25 ± 1.27 
( 1.835) ( J.421 ) (8.90) 
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Table5. Summary of weight, hardness and thickness data for CTM 6% 
/Emcompress/Magnesium Stearate flat 1/2" round tablets (EF). 
Product Weight (g) Thick (cm) Hardness (kg) 
±St. Dev. (RSD%) ±St. Dev. (RSD%) ±St. Dev. (RSD%) 
EFHI 0.790 ± 0.003 0.347 ± 0.007 3.37 ± 0.21 
(0.327) (2. 104) (6.23) 
EFH2 0.795 ± 0.002 0.333 ± 0.005 5.89 ± 0.25 
(0.295) (l.544) (4.24) 
EFH3 0.791 ± 0.004 0.325 ± 0.005 8.25 ± 0.14 
(0.489) (1.6 19) (1.70) 
EFH4 0.796 ± 0.004 0.321 ± 0.005 I I.OJ ± 0.49 
(0.473) (l.405) (4.45) 
EFH5 0.799 ± 0.003 0.307 ± 0.004 14.53 ± 0.85 
(0.396) ( l.208) (5.85) 
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Table6. 
Product 
ECHI 
ECH2 
ECH3 
ECH4 
ECH5 
Summary of weight, thickness and hardness data for Emcompress/CTM 6% 
/magnesium stearate SRC 1/2" round tablets. 
Weight (g) Thick (cm) Hardness (kg) 
± St.Dev.(RSD%) ± St.Dev.(RSD%) ± St.Dev.(RSD%) 
0.809 ± .002 0.442 ± 0.008 3.28 ± 0.14 
(0.290) ( J.74) (4.27) 
0.803 ± 0.004 0.424 ± 0.005 6.11±0.21 
(0.458) (J.257) (3.44) 
0.806 ± 0.002 0.417 ± 0.005 7.94 ± 0.29 
(0.301) ( 1.259) (3.60) 
0.809 ± 0.003 0.413 ± 0.004 9.41 ± 0.97 
(0.392) ( 1.074) ( 10.3 I) 
0.811 ± 0.003 0.406 ± 0.005 9.86 ± 1.29 
(0.377) (1.337) (13. 1) 
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Table 7. Calculation of Standard Error(SE) for Pfizer Hardness Tester. Results are in 
kilograms (kg). 
Hardness Level EFsd ECsd AFsd ACsd 
I 0.21 0.14 0.26 0.25 
2 0.25 0.21 0.23 0.26 
3 0.14 0.29 0.29 0.78 
4 0.49 0.97 0.33 0.84 
5 0.85 1.29 0.84 1.27 
SE~oduct 0.39 0.58 0.39 0.68 
SE- Emcom_.£..ress 0.49 SE-Avicel 0.54 
SE flat 0.39 SESRC 0.63 
Overall 
SEE= 0.51 
KEY: EF Emcompress/CTM flat faced tablets 
EC Emcompress/CTM SRC tablets 
AF Avicel/CTM flat faced tablets 
AC Avicel/CTM SRC tablets 
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Table 8. Comparison of hardness means between EF versus EC and AF versus AC tablets 
(as determined by two-sided t-test). 
EF Hardness (kg) EC Hardness (kg) Equal p 
mean ± St.Dev. (RSD) mean± St.Dev. (RSD) Means? 
3.37 ± 0.21 (6.2%) 3.28 ± 0.14 (4.3%) 0.27 
5.89 ± 0.25 (4.2%) 6.11 ± 0.21 (3 .4 %) 0.05 
8.25 ± 0.14 (1.7%) 7.94 ± 0.29 (3.6 %) 0.0099 
11.01 ± 0.49 (4.5%) 9.41 ± o.<n (J0.3%) 0.0018 
14.53 ± 0.85 (5.9%) 9.86 ± 1.29 (13. 1%) 
"' 
AF Hardness (kg) AC Hardness (kg) Equal p 
mean± St.Dev. (RSD) mean± St.Dev. (RSD) Means? 
2.30±0.26(I1.2%) 3.0 ± 0.25 (8.3%) 
"' 
4.23 ± 0.23 (5.4%) 6.37 ± 0.26 (4.1%) 
"' 6.93 ± 0.29 (4.2%) 8.59 ± 0.78 (9.0%) 
"' 9.87 ± 0.33 (3.3%) 12.06 ± 0.84 (7.0%) 
"' 13.81 ± 0.84 (6.1 %) 14.25 ± 1.27 (8.9%) 0.24 
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A comparison of average hardness means was also made between formulations of 
the same geometry and hardness level (Table 9). The purpose of these comparisons was to 
evaluate the spectral differences between excipients (matrices) at one hardness level. Mean 
hardness values for AC and EC were found to be equal at hardness levels I, 2 and 3. 
Mean hardness for AF at level 5 was found to be equal to EF at level 5 (p= 0.13). 
Avicel®/CTM upper (UC) and lower (LC) compression force data is summarized in 
Table 10. Variability (% RSD) in compression data was generally from 2 to 5.7%. UC 
and LC data for Emcompress®/CTM tablets are summarized in Table l l. 
Emcompress®/CTM compression data was less variable than Avicel®/CTM data (0.73 to 
2 .5%) with the exception of EF5, which varied by over 25%. 
In order to achieve the desired levels of tablet hardness, significantly greater 
compression forces were required to compress tablets containing Emcompress®. UC 
forces required for Avicel®/CTM batches ranged from l.8 to 5.1 kN, while those for 
Emcompress®/CTM tablets ranged from 6.7 to 22.7 kN. This was partially due to the fact 
that Emcompress® has a higher bulk density than Avicel®. Particle size distributions al so 
differ between the two excipients. Emcompress® bulk tapped density was reported to be 
0.99 g/ml (per the manufacturer's certificate of analysis). Its density is 2.89 g/cm3. The 
average particle size is 120 to 150 µm. Emcompress® is a crystalline solid or powder, 
consisting of granules of which over 95% are less than 425 µm and less than I 5% are 
under 75 µm. It is not known to be hygroscopic5. Compaction of dibasic calcium 
phosphate takes place primarily by brittle fracture. Due to its abrasive nature, it is 
important to include a lubricant in the tablet formulation . 
Avicel® PH 102 (microcrystalline cellulose) is a crystalline powder composed of 
porous particles. Its bulk density is 0.3 g/ml3 and its density is 1.55 g/cm3. Typical mean 
particle size is 20 to 200 µm. Particle size distribution consists of less than 8% of particles 
greater than 250 µm and over 45% of particles greater than 75µm . The moisture content 
of Avicel® is less than 5.0% but it is known to be hygroscopic6. 
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Table9. Comparison of hardness means between AF versus EF and AC versus EC 
tablets (as determined by two-sided t-test). 
AF Hardness (kg) EF Hardness (kg) Equal p 
mean± St.Dev. (RSD) mean± St.Dev. (RSD) Means? 
2.30 ± 0.26 (11.2%) 3.37 ± 0.21 (6.2%) ;C 
4.23 ± 0.23 (5.4%) 5.89 ± 0.25 (4.2%) ;C 
6.93 ± 0.29 (4.2%) 8.25 ± 0.14 (1.7%) ;C 
9.87 ± 0.33 (3.3%) I I.OJ ± 0.49 (4.5%) ;C 
13.81 ± 0.84 (6.1%) 14.53 ± 0.85 (5.9%) 0.13 
AC Hardness (kg) EC Hardness (kg) Equal p 
mean± St.Dev. (RSD) mean± St.Dev. (RSD) Means? 
3.0 ± 0.25 (83%) 3.28 ± 0.14 (43%) 0.0079 
6.37 ± 0.26 (4.1%) 6.11 ± 0.21 (3.4 %) 0.025 
8.59 ± 0.78 (9.0%) 7.94 ± 0.29 (3.6 %) 0.030 
12.06 ± 0.84 (7 .0%) 9.41 ± 0.97 (10.3%) ;C 
14.25 ± 1.27 (8.9%) 9.86 ± 1.29 (13.1%) ;C 
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Table 10. 
AF-HI 
AF-H2 
AF-H3 
AF-H4 
AF-HS 
AC-HI 
AC-H2 
AC-H3 
AC-H4 
AC-HS 
Avicel/CTM Compression Data Summary (AF= flat faced tablets; AC = 
SRC tablets at hardness levels HI to H5). 
Upper, kN Lower, kN 
Mean St. Dev. % RSD Mean St. Dev. % RSD 
1.789 0.036 2.04 1.066 O.OZ5 2.367 
2.218 0.047 2.109 1.413 0.033 2.344 
2.835 0.060 2.113 1.924 0.041 2.117 
3.520 0.133 3.774 2.491 0.099 3.977 
4.260 0.220 5.162 3.072 0.177 5.755 
1.912 0.054 2.834 1.145 O.o35 3.093 
2.886 0.115 3.977 1.906 0.o75 3.952 
3.465 0.152 4.386 2.368 0.102 4.301 
4.335 0.173 3.982 3.062 0.129 4.212 
5.075 0.1 90 3.736 3.674 0.147 4.007 
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Table 11. 
EC-HI 
EC-H2 
EC-H3 
EC-H4 
EC-HS 
EF-HI 
EF-H2 
EF-H3 
EF-H4 
EF-H5 
Emcompress/CTM Compression Data Summary (EF= flat faced tablets; 
EC= SRC tablets at hardness levels HI to HS). 
Upper, kN Lower, kN 
Mean St. Dev. % RSD Mean St. Dev. % RSD 
6.755 0.133 1.963 4.935 0.064 1.294 
11.633 0.206 1.774 8.417 0.099 1.172 
14.811 0.185 1.249 10.771 0.089 0.823 
17.535 0.210 l.197 12.848 0.102 0.793 
22.661 0.241 1.065 16.779 0.122 0.730 
6.690 0.159 2.377 4.911 0.125 2.542 
10.624 0.201 1.894 7.709 0.112 1.458 
14.148 0.247 l.743 10.219 0.152 1.487 
17.600 0.297 1.690 12.801 0.176 1.378 
21.487 5.482 25.512 15.733 4.060 25.806 
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It must be noted that the formulations chosen for this study were composed of a 
minimum number of components, and thus were not optimized. The goal was to create a 
comparison between blends containing the same concentrations of active and lubricant, so 
as not to introduce additional variables. In practice, it would be unlikely for a tablet to be 
manufactured using over 90% of one major excipient. This factor may be responsible for 
some of the variability in the Emcompress®/CTM hardness data. 
UC force varied from 2.04% to 5.16% for all Avicel®/CTM batches. 
Emcompress®/CTM compression force data was considerably more variable than the 
Avicel®/CTM data. The highest level of compression force for the flat Emcompress®/ 
CTM tablets was responsible for a 25.5% variation; the lower four levels of flat-faced 
tablets ranged from 1.69% to 2.38%. Compression force for Emcompress®/CTM SRC 
tablets varied from 1.07% to 1.96%. 
1 .4.2 Results of NIR Specrral Analysis 
The effect of blending Emcompress® with CTM and magnesium stearate is 
demonstrated in Figure 1. This plot compares the raw NTR spectrum of Emcompress® 
powder (alone) with that of the blended formulation . The spectra have similar shapes 
except for the two small peaks between 2100 and 2300 nm on the blend spectrum. 
In Figure 2, the raw spectrum of the Emcompress®/CTM/magnesium stearate blend 
is plotted with the average spectrum of the FF tablets (n= 10) at each of five hardness 
levels. (Note: unless otherwise indicated. all spectral plots represent the average of I 0 
tablets). This plot demonstrates the effect of varying the compression force on the blend. 
As the hardness (compression force) was increased. the absorbance value also increased. 
The spectrum of the uncompressed powder blend shifted slightly between the spectra of the 
second and third hardness levels. 
Figure 3 is the raw spectrum of the Emcompress®/CTM!magnesium stearate blend 
plotted with the spectra of the SRC tablets at each of five hardness levels. The spectrum of 
the powder blend was in close proximity to the lower level hardness tablets. The powder 
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blend spectrum deviates most from the tablet spectrum in the region of 1100 nm to 
approximately 1900 nm. 
The difference between the flat and SRC Emcompress®/CTM tablets is shown in 
Figure 4. Here, the high and low hardness level tablets of each geometry type were plotted 
together. The two upper spectra compare flat to SRC tablets at hardness level 5. At 
hardness level 5, the mean hardness value for the SRC tablets was 9.86 ± \.29 kg, while 
that of the FF tablets was 145 ± 0.85 kg. Thus, due to the large difference in the hardness 
data at this level, a direct comparison of the spectra based on hardness at this level is not 
possible. The plot at hardness level 5 shows a higher absorbance for the FF tablets in 
comparison to the SRC tablets. At hardness level I, absorbance values are higher for the 
SRC tablets (hardness means were equal at level I}. 
Figure 4 also demonstrates the large increase in absorbance for both tablet shapes 
when the compression force was increased. Hardness level I represents an applied upper 
compression force of 6.76 (± 0.13) kN for both types of tablet geometry. The upper 
compression force at hardness level 5 was 22.66 (± 0.24) kN. 
Observation of the pattern of the spectra in Figure 4 reveals striking similarities 
between FF and SRC tablets. The chemical composition of the sample is responsible for 
the unique spectrum of the formulation. We can see that tablet hardness and geometry do 
not affect this uniqueness; instead, these physical changes are responsible for the drifting 
baseline and ''peak" shifts in the spectra. 
Figures 5 and 6 are the second derivative spectra of FF Emcompress®/CTM tablets 
at five hardness levels in two different wavelength ranges. Each plot illustrates the change 
in absorbance as the tablet hardness is increased. At numerous maxima and minima, there 
appeared to be the same degree of increase in absorbance in response to increasing 
hardness. 
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Figures 7 through 11 compare the raw spectra of FF versus SRC Emcompress®/ 
CTM tablets at each hardness level. Reference to the data in Table 8 will be useful for 
reviewing Figures 7 through 11. As discussed earlier, the mean values for hardness for 
Emcompress®/ CTM tablets were equal for hardness levels I, 2, 3 and 4, and so direct 
comparisons could be made about the effect of tablet geometry . In each of these four plots, 
the absorbance of the SRC tablets was higher in comparison to the FF tablets. It is also 
noted that the FF and SRC spectra partially overlap in the 19<Xl nm region (water band). It 
would be expected to find the same concentration of water in the two batches, since they 
originated from the same blend. However, the maximum absorbance at about 1930 nm 
was higher in the SRC tablets for all but hardness level 3 spectra. In Figure 11. a direct 
comparison could not be made since the mean hardness values at level 5 were not 
equivalent. 
Figure 12 is the raw spectrum of Avicel® /CTM/magnesium stearate powder blend 
plotted with that of the FF Avicel® /CTM/magnesium stearate tablets (n= 10) at five 
hardness levels. In the region of 1100 nm to approximately 2100 nm, the absorbance of 
the powder blend spectrum is much lower than the absorbance of the FF compressed 
tablets. From 2100 nm to 2500 nm, the powder blend spectrum falls much closer to the 
tablet spectrum. In Figure 13 , a similar comparison is made between the powder blend and 
the compressed SRC tablets at five hardness levels. Again, the greatest amount of 
difference is seen from 1100 nm to about 2100 nm, where the powder blend spectrum is 
closer to the tablet spectrum. 
In contrast to the observation of the deviation of powder blends from the tablet 
spectrum (deviation on the left side of the plots), the tablet spectra behaved in the opposite 
fashion. The tablet response to increasing compression force was greatest on the right side 
of the plots. In each of the plots comparing tablet spectra, the raw spectra were often 
indistinguishable in the 1100 nm to 1500 nm region. Increases in absorbance due to 
increasing compression force were not noted until 1500 nm. 
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The raw spectra of FF and SRC Avicel® /CTMJmagnesium stearate tablets are 
compared in Figure 14. The spectra of five hardness levels of SRC tablets were plotted 
against the spectra of five hardness levels of FF tablets. In the region from 1100 nm to 
1500 run, each set of samples was practically overlayed. From approximately 1475 nm. 
the effects of increasing compression force are manifested in the spectra. The maximum 
absorbance of the SRC tablets was greater than that of the FF tablets. 
Figure 15 is a second derivative plot comparing the FF and SRC tablets at the 
highest and lowest hardness levels. The absorbance of the Avicel®/CTM SRC tablets was 
slightly greater than that of the FF tablets. The difference between A vicel®/CTM FF and 
SRC tablets was small in comparison to that seen with the Emcompress®/CTM tablets. 
This expanded view (in the region from 1414 nm to 1646 run) of the derivitized spectrum 
further illustrates the effect of increasing hardness on the NIR spectrum. As previously 
mentioned, derivative treatment of spectral data enhances spectral features, but may 
decrease the signal to noise (SIN) ratio. 
1 .4.3 Results of Sample Position Study 
Emcompress®/CTM 6%/magnesium stearate SRC tablets (6 kg hardness) were 
used to evaluate the effect of various sampling positions on the NIR spectra. Examination 
of the raw spectra of each condition does not initially appear to reveal much information. 
Figures 16 and 17 are equally unexciting in their comparison of scanning a sample with 
replacement versus not moving it between scans. There does not appear to be a difference 
in the two conditions for either scored or nonscored sides of tablets. 
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Figure 18 compares the reflectance spectra (raw data) of one tablet scanned ten 
times on each side without moving it. The upper spectrum is the average of ten scans of 
the scored side of the tablet. The lowermost spectrum is the average of ten scans of the 
nonscored side of the tablet. Observation of the plot shows that the spectra were overlayed 
from 1100 to about 1450 nm, then began to diverge. Beyond 1900 nm, the difference 
between the two spectra was at its maximum. This plot demonstrates slightly higher 
absorbance values for the scored tablet data. 
The standard deviation spectrum is a useful tool for extracting more information 
from the samples. When comparing second derivative data from the scored and nonscored 
sides of the tablet scanned ten times without moving it, there was so little difference that the 
computer could not create a standard deviation plot for either of these conditions. 
Obviously, ten replicates of this type of sample (without moving it) would not be needed in 
a real calibration. 
Figure 19 compares the standard deviation spectrum (second derivative) of a scored 
versus nonscored tablet scanned ten times. There appeared to be more variation in the 
water band for the scored sides of the tablets; the rest of the nonscored spectra are in the 
same range as the scored plot. 
Figure 20 compares the raw spectra of ten scans of a scored side of a tablet versus 
ten scans of a nonscored side of a tablet. The spectrum of the scored side had a slightly 
higher absorbance than that of the nonscored side. 
Figure 21 compares the standard deviation spectrum of scored versus nonscored 
sides of ten tablets scanned once. Figure 22 displays the second derivative transformation 
of the same data. Again, the second derivative treatment reduced much of the apparent 
baseline shift caused presumably by sample placement. There was greater variability in the 
scored data. 
Figure 23 illustrates the difference between the raw spectra often scored tablets 
scanned once and one tablet scanned ten times. The average absorbance spectrum of ten 
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scans of the same tablet was lower than that of ten tablets scanned once each. 
Figure 24 is the second derivative of the standard deviation spectrum comparing 
one scored tablet scanned ten times versus ten scored tablets scanned once each. The 
standard deviation spectrum of the scored tablets under these sampling conditions are 
essentially the same. 
Figure 25 shows the raw spectra of nonscored tablets, comparing one tablet 
scanned ten times versus ten tablets scanned once. The difference was not obvious to the 
naked eye. Figure 26 displays the standard deviation spectra of these conditions. Note the 
vastly greater difference in variation in the spectrum representing the average often tablets 
scanned once (upper spectrum). A second derivative plot of the same samples (Figure 27) 
shows two very different looking spectra. Overall , there was greater variability in the 
average spectrum of ten tablets scanned once each. There is one region of overlap of the 
data in the 1900 to 1-930 nm range, which is due to water content. 
The raw spectrum of one tablet scanned in ten positions on the detector surface is 
shown in Figure 28. The absorbances at 1100 nm ("origin" of the plot) range from -0.102 
to 0.41. demonstrating a five-fold shift in response to a change in sample position. The 
naked eye cannot discern any real differences in the overall shape of the spectra. It is 
noteworthy that the spectra of the two replicates scanned in the 12:00 position (above the 
center) were quite close to each other. Also near the 12:00 spectra were the 135° and 315° 
samples. The spectra of the 45°, 180°, and 270° samples were close to each other, with the 
225° sample not far above it. The sample from the center position was the lowermost 
spectrum in the plot, beginning at an absorbance of -0. I 02. The 90° sample originated at 
approximately 0.130. 
The second derivative spectra of the tablet in ten positions are shown in Figure 29. 
Much of the baseline shift was removed by the derivitization of the spectra. The spectra 
appear to be completely overlayed except for the region from about 1450 nm to 1600 nm. 
Figure 30 is an enlarged view of this wavelength range. There are large differences in 
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Figure 26. Standard deviation spectra (raw data) of I nonscored tablet scanned I 0 times versus 10 tablets scanned 
once each. 
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Figure 27. Standard deviation spectra (second derivative data) of I nonscored tablet scanned IO times versus 10 
tablets scanned once each. 
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Figure 28. Raw NIR spectra of I nonscored tablet scanned once each at ten different positions. 
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Figure 30. En larged view of seco nd derivative NIR spectra of one nonscored tablet scanned ten times. 
absorbance maxima at 1513 nm, 1540 nm, and 1573 nm. It is not known why this region 
was so highly affected by sample position in comparison to the rest of the spectrum. 
The raw spectra in Figure 28 followed a similar panem of presentation to those in 
Figure 4 , where increases in compression force caused the spectra to shift upwards . When 
sample position was changed, the spectra also shifted, although not in a regular, predictable 
manner. Changes in sample position are known to result in this apparent "particle size" 
effect. The difference is that the second derivative of data from Figure 4 were not 
completely overlayed at the absorbance maxima, as they were in Figure 29. This indicates 
that the apparent "particle size" effect from changing hardness could not be entirely 
removed by derivitizing the spectra. 
In summary, the results of the sample position study demonstrate that variability in 
the spectral data may be introduced through slight changes in sample placement. This 
variability was greater in scored than in nonscored tablet data. Much of the variation could 
be reduced by using a second derivative math treatment. The center position was the most 
reproducible sampling position due to the ability to use the iris. 
1 .4.4 Single wavelength regression and analysis of variance 
During NIR analysis of these products, some degree of consistency was observed 
in the spectral response to increasing tablet hardness. For a given formulation , regular 
increases in second derivative absorbance values occurred at several wavelengths in 
response to increasing hardness. For Emcompress®/CTM tablets, these wavelengths were 
1430, 1898, and 1926 nm. A vice!® /CTM tablets demonstrated regular increases in 
absorbance values at 1884, 1926, 2236, and 2270 nm. This portion of the study tested the 
theory that hardness may be measured at a single wavelength. 
Second derivative absorbance values at the specified wavelengths were tabulated for 
each product (n=IO) at all five hardness levels. Linear regression and one-way analysis of 
variance were applied (Minitab®) to the hardness and spectral data to assess their 
relationship. Cricket Graph was used to plot the data at each wavelength. Since NIR is 
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being used to predict tablet hardness from absorbance data, hardness becomes the 
dependent variable (y). Regression data are summarized in Table 12. A linear relationship 
was found to exist for each set of data; in most cases r2 was better than 0.92. 
Graphic representation of the data provides useful information for comparative 
purposes. Data for flat versus SRC Emcompress®/CTM tablets at 1430, 1898, and 1926 
nm are plotted in Figures 31 through 33 . EF regression lines were found to converge with 
EC lines, suggesting different slopes for flat versus SRC tablets at 1430 and 1898 nm. 
Data forflat versus SRCAvicel®/CTM tablets at 1884, 1926, 2236, and 2270 nm 
are compared in Figures 34 through 37. In each case, the regression lines for flat versus 
SRC appeared to be parallel, indicating similar slopes. Slope and intercept data for 
Avicel®/CTM tablets were very similar between flat and SRC data. These data suggest that 
NlR response to increasing compression force is similar for flat and convex Avicel®/CTM 
tablets. 
Figure 38 is a plot of hardness versus second derivative of absorbance for convex 
(SRC) Avicel®/CTM tablets and Emcompress®/CTM tablets at 1926 nm. Figure 39 shows 
the same conditions for the flat tablets. The same set of comparisons was made at 1430 nm 
and is demonstrated in Figures 40 and 41. It is obvious from these plots that the slope and 
intercept values between tablet matrices are quite different, supporting the theory that 
separate calibration models would be needed for hardness prediction of different tablet 
formulations. 
To further investigate the single wavelength regression theory, NSAS was used to 
develop NIR calibrations for each product at each of the aforementioned wavelengths. 
Models were developed for flat, scored, nonscored and mixed (scored/nonscored) tablet 
surfaces. It was surprising to discover that the results of these calibrations were quite 
good. Table 13 summarizes the regression coefficients for Avicel®/CTM tablets. R2 
values ranged from 0.951 to 0.990. Calibration and prediction results for the 
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Table 12. Summary of NIR absorbance versus hardness regression at single 
wavelengths (Hardness= slope x absorbance + intercept). 
Matrix Geometry A.(nm) Slope Intercept r2 F 
Em compress flat 1926 -178.857 -25.698 0.968 1227.30 
SRC 1926 -195.908 -27.083 0.921 479.53 
flat 1898 401.831 -25.420 0.965 1116.32 
SRC 1898 495.077 -30.866 0.922 485.54 
flat 1430 -708.099 -28.579 0.975 1598.79 
SRC 1430 -604.704 -22.839 0.873 281.34 
Matrix Geometry A.(nm) Slope Intercept r2 F 
Avicel flat 1926 - 1560.251 -89.544 0.952 946.18 
SRC 1926 -1574.581 -87.26 0.972 1640.60 
flat 1884 1940.230 -82.792 0.963 1234.28 
SRC 1884 2006.831 -83.026 0.974 1807.90 
flat 2236 2449.174 -100.043 0.926 597.77 
SRC 2236 2669.498 -106.429 0.939 734.63 
flat 2270 -2164.221 -123.169 0.956 1047.55 
SRC 2270 -2419.599 - 134.423 0.962 1207.58 
SRC 1430 -4001.400 -75.550 0.968 1453.27 
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Figure 31. Emcompress®/CTM Flat versus SRC Tablets: Hardness versus second 
derivative (20) absorbance at 1430 nm. 
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Figure 32. Emcompress®/CTM Flat versus SRC Tablets: Hardness versus second 
derivative (20 ) absorbance at 1926 nm. 
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Figure 34. Avicel®/CTM Flat versus SRC Tablets: Hardness versus second derivative 
(20) absorbance at 1884 nm. 
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Figure 35. Avicel®/CTM Flat versus SRC Tablets: Hardness versus second derivative 
(20) absorbance at 1926 run . 
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Figure 36. Avicel®/CTM Flat versus SRC Tablets: Hardness versus second derivative 
(20) absorbance at 2236 run . 
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Figure 37. Avicel®/CTM Flat versus SRC Tablets: Hardness versus second derivative 
(2D) absorbance at 2270 nm. 
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Figure 39. Avicel®/CTM versus Emcompress®/CTM Flat Tablets: Hardness versus 
second derivative (20) absorbance at 1926 run. 
2D-Absorbance at 1926 nm 
o AF hardness y = -1560.25lx - 89.544 r2 = 0.952 
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Figure 40. Avicel®/CTM versus Emcompress®/CTM SRC Tablets: Hardness versus 
second derivative (20 ) absorbance at 1430 nm. 
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Table 13. NSAS Avicel- Summary of nm/hardness regression 
( 
matrix geometry A. (nm) slope intercept r2 
Avicel Flat 1884 1986.326 -84.952 0.980 
Flat 1926 -1598.096 -91.894 0.974 
Flat 2236 2495.963 -!02.083 0.957 
Flat 2270 -2203.484 -125.533 0.975 
Nonscored 1884 1970.873 -80.162 0.982 
Nonscored 1926 - 1541.233 -83.987 0.981 
Nonscored 2236 2629.358 - 103.068 0.951 
Nonscored 2270 -2325.375 -127.233 0.970 
Nonscored 1884+1926 8755.657 -66.458 0.984 
NS/S 1884 1985.744 -81.946 0.987 
NS/S 1926 -1559.371 -86.203 0.986 
NS/S 2236 2603.937 - !03.387 0.969 
NS/S 2270 -2351.095 -130.304 0.983 
Scored 1884 1993.503 -83 .759 0.984 
Scored 1926 - 1561.7 -87.863 0.982 
Scored 2236 2676.638 - !08.485 0.960 
Scored 2270 -2502.612 -141.189 0.980 
Scored 1926+1884 8781.652 -59.469 0.990 
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Avicel®/CTM tablets are summarized in Table 14. Emcompress®/CTM regression 
coefficients are summarized in Table 15. Linearity ranged from 0.912 to 0.983. Validation 
results for Emcompress®/CTM tablets are given in Table 16. Comparison of the Minitab® 
regression results (Table 12) with NSAS results (Tables 13 and 15) reveals slight 
differences in regression coefficients. The primary reason for the differences was that the 
data sets for NSAS calibration were constructed from six spectra rather than ten (Minitab®) 
in order to facilitate the development of validation sets. 
It should be reiterated that tablet hardness is a physical property, and thus a single 
wavelength cannot be assigned exclusively to hardness. The absorbance at 1926 nm is 
associated with water content, yet each formulation demonstrated a regular increase in 
absorbance at 1926 nm in response to increased hardness. Since this pattern of increased 
absorbance occurred at several wavelengths for each product, it may be concluded that one 
or more of these wavelengths could be used to calibrate tablet hardness for a particular 
formulation. Absorbance of interfering substances would have to be evaluated before 
choosing a single wavelength for this application (e.g., 1926 nm may not be a reliable 
single wavelength). 
1.4.5 Calibration ojTabJet Hardness 
The yardstick for comparison of calibration equations is the set of statistics that 
results from the application of the equation to a validation set. The statistical parameters 
used to evaluate calibration models were described in Manuscript Ill. 
The standard error (SE) of the reference method must be known before undertaking 
a calibration experiment. The NIR calibration is only as good as the reference values from 
which it was generated. ln addition to the aforementioned selection criteria, the SEE of the 
calibration must be compared to that of the reference method. If the calibration SEE is 
better than the reference SE, the model may be overfilled and may not accurately predict 
unknown samples. For comparative purposes, the ratio of bias/standard error of the bias 
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Table 14. Single wavelength regression for Avicel/CTM tablets: Prediction Results 
Geometry & molt r SEE Val.File bias/SEB molt r SEP 
wavelen th (nm) 
AC-1884+1926 0.988 0.648 NS/S 1.484 0.992 0.595 
AC-1884 0.987 0.672 NS/S 2.014 0.989 0.701 
AC-1926 -0.986 0.700 NS/S 2.118 0.988 0.748 
AC-2236 0.969 1.030 NS/S 2.442 0.975 1.120 
AC-2270 -0.983 0.765 NSIS 0.801 0.980 0.919 
AN-1884 0.982 0.775 Nonscored l.603 0.990 0.709 
AN-1926 0.981 0.806 Non scored 1.824 0.989 0.761 
AN-2236 0.951 1.270 Non scored 1.714 0.972 1.270 
AN-2270 -0.970 0.995 Non scored 1.000 0.986 0.769 
AS- 1926+1884 0.990 0.612 Scored 0.152 0.987 0.678 
AS-1884 0.984 0.745 Scored 0.517 0.987 0.786 
AS-1926 -0.982 0.793 Scored 0.595 0.985 0.854 
AS-2236 0.960 1.180 Scored 0.546 0.962 1.220 
AS-2270 -0.980 0.839 Scored 0.740 0.982 0.826 
AF-1884 0.980 0.847 Flat 0.218 0.984 0.791 
AF-1926 -0.974 0.967 Flat 0.033 0.979 0.893 
AF-2236 0.957 1.250 Flat 0.158 0.972 1.000 
AF-2270 -0.975 0.960 Flat 0.089 0.984 0.775 
Legend: 
AC A vicel/CTM mixed nonscored/scored 
AN Avicel/CTM nonscored 
AS A vicel/CTM scored 
AF A vicel/CTM flat 
NS/S mixed nonscored/scored 
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Table 15. Summary of NSAS Emcompress®/CTM regression coefficients at single 
wavelengths. 
matrix geometry A. (nm) slope intercept r2 
EMC flat 1430 -709.667 -28.643 0.983 
flat 1898 404.347 -25.595 0.977 
flat 1926 -180.258 -25.931 0.979 
flat 1430+1926 -533.31 I -28.067 0.983 
NS/S 1430 -584.592 -21.888 0.916 
NS/S 1898 489.262 -30.458 0.949 
NS/S 1926 -193.118 -26.636 0.948 
NS/S 1926+1430 -303.484 -28.492 0.953 
Nonscored 1430 -581.375 -21.502 0.912 
Nonscored 1898 440.558 -26.879 0.947 
Nonscored 1926 -177.071 -23.924 0.946 
Nonscored 1898+1926 709.504 -28.669 0.947 
Nonscored 1926+1430 -418.038 -25.383 0.963 
Scored 1430 -601.056 -22.962 0.929 
Scored 1898 507.493 -31.808 0.939 
Scored 1926 -200.179 -27.869 0.943 
Scored 1430+1926 -102.358 -27.253 0.943 
204 
Table 16. Single wavelength regression for Emcompress/CTM tablets-
Prediction Results 
Geometry & molt r SEE Validation bias/SEB molt r SEP 
wavelen th (nm) File 
EC-1926+1430 0.953 0.771 NS/S 0.625 0.973 0.606 
EC- 1430 -0.916 J.000 NS/S 0.544 0.962 0.742 
EC- 1898 0.949 0.789 NS/S 0.643 0.976 0.569 
EC-1926 -0.948 0.793 NS/S 0.686 0.976 0.572 
EN-1898+1926 0.963 0.641 Non scored 2.118 0.959 0.935 
EN-1926+1430 0.947 0.770 Nonscored 2.153 0.971 0.790 
EN-1430 -0.912 0.960 Nonscored 0.018 0.976 0.559 
EN-1898 0.947 0.754 Nonscored 2.102 0.971 0.783 
EN-1926 -0.946 0.757 Nonscored 1.981 0.970 0.777 
ES-1430+1926 0.943 0.870 Scored 0.045 0.976 0.559 
ES-1430 -0.929 0.952 Scored 0.308 0.956 0.747 
ES-1898 0.939 0.882 Scored 0.198 0.974 0.586 
ES-1926 -0.943 0.856 Scored 0.018 0.976 0.559 
EF-1430+1926 0.983 0.738 Flat 0.643 0.995 0.380 
EF-1430 -0.983 0.733 Flat 0.579 0.996 0.364 
EF-1898 0.977 0.845 Flat 0.768 0.991 0.519 
EF-1926 -0.979 0.809 Flat 0.755 0.992 0.491 
Legend: 
EC Emcompress/CTM mixed nonscored/scored 
EN Emcompress/CTM nonscored 
ES Emcompress/CTM scored 
EF Emcompress/CTM flat 
NS/S mixed nonscored/scored 
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(bias/SEB) was included in the summary tables. It is desirable that this ratio be less than 
3.0 for best model fit. 
It is complicated to compare equations on an individual basis, since each was 
generated independently. Each was developed from a unique combination of wavelengths 
and calibration samples. For instance, while developing one equation, an outlier may be 
detected which was not an outlier for another calibration. This calibration set may work 
well at a particular wavelength as a second derivative, but the raw data from the same 
calibration set may regress at a different wavelength. Tb.is resulted in a unique set of 
calibration samples for that equation. Also, changing the individual samples in a calibration 
set may cause the computer software to select a different wavelength for regression. As 
previously explained, the basis of selection of the regression wavelength (by the NSAS 
software) is the degree of variation at that point. One set of samples may have a greater 
standard deviation at one wavelength; if samples are added or deleted from this set, the 
highest variability may occur at a different wavelength. 
There were no outstanding features to note concerning calibration ofEmcompress® 
based tablets in comparison to Avicel® based tablets. The process was the same, and 
similar patterns of behavior were noted for both matrices. 
1 .4.5.J Hardness Calibration o/SRC Avicel®!CTMTablets 
General calibration equations were developed for SRC tablets using several 
different calibration, or training, sets. All four replicates of NIR tablet scans were averaged 
(AC data set) and subject to random sample selection for the calibration set. MLR and PLS 
regression were used to develop equations using raw and second derivative spectral data. 
Improvement of the MLR models was obtained by regressing on more than one 
wavelength. ln some cases, the first regression wavelength. was preselected based on 
spectral information, or to provide a basis of comparison to the other groups of calibrations 
(e.g. , scored, nonscored, mixed). 
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Table 17 summarizes the calibration and validation process for the AC data set. 
Seven MLR equations were developed using second derivative spectra. Several of these 
predictions resulted in good agreement (r= 0.991 or better) and two predictions resulted in 
agreement of r= 0.981 or better. When the same AC calibrations were applied to data sets 
consisting solely of nonscored or scored data, a large bias resulted. Linearity was still 
0 .989 or better, but large values for bias and bias/SEB ratio were observed. Two AC 
calibrations were able to satisfactorily predict values from an AN (nonscored) data set and 
an AS (scored) data set. 
Four MLR equations were developed using the raw AC data. A series of three of 
these equations was applied to one validation set. The first model was based on one 
wavelength (2422 nm), the second on two wavelengths (2422 nm + 2378 om), and the 
third equation was based on three wavelengths ( 1460 om + 1740 nm + 2040 nm). The 
best prediction came from the two-term equation. The prediction values for r were as 
follows: one-term, r= 0.997, two-term, r= 0.992 and three-term, r= 0.994. 
Four PLS calibrations were developed using the second derivative AC data. All 
four of these fit the two validation sets well. As expected, increasing the number of factors 
improved the calibration. When AC calibrations were applied to AN or AS validation sets, 
only one calibration gave acceptable results, with values for bias and bias/SEB within 
specified tolerances. Results were slightly better for the nooscored validation set (bias/SEB 
= 0.63) versus the scored data set (bias/SEB = 1.53). 
Two calibrations were developed using raw AC data in a PLS regression. Both 
equations accurately predicted the validation set. The two equations were unable to predict 
values from the AN or the AS validation sets. The first calibration employed the full 
spectral range of 1100 nm to 2500 om. The second was restricted to the range of 1500 nm 
to 2150 nm. The SEE' s were very close (0315 versus 0312), and the validation of the 
first equation (SEP = 0.349) was slightly better than the second (SEP= 0369). 
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To summarize the calibration process for AC data sets, all of the AC calibrations 
were able to predict AC validation sets with a good degree of accuracy. None of the 
calibrations based on raw data were able to sufficiently predict AN or AS data. One second 
derivative PLS calibration was able to predict an AN (r2= 0.994) as well as an AS 
(r2=0.995) validation set. Two second derivative MLR equations adequately fit both AN 
and AS data from one validation set. ln general , a higher bias/SEB value resulted when an 
model was used to predict an AN or AS model. There did not appear to be a difference in 
performance between PLS models developed from raw data versus second derivative data. 
MLR models were slightly better when second derivative data was used. 
Table 18 summarizes the validation of nonscored Avicel®/CTM tablets (AN) using 
MLR. Using second derivative spectral data, six out of seven equations successfully 
(SEP<0.5) predicted the AN validation set. The r2 value was consistently 0.994 to 0.995. 
The equation that did not fit the validation set was a calibration based on 1930 nm, the 
water band. The SEE at this wavelength was 0.8 l. However, when using 1930 run with a 
second wavelength (1456 nm), the equation was able to fit the validation data (SEE= 
0.375 and SEP = 0.500) . 
AN calibrations using second derivative data were only marginally successful at 
fitting AS or AC validation sets. One equation fit the AC data, and two others were 
marginally acceptable. When applying AN calibrations to scored data sets (AS), two out of 
seven equations produced a fair prediction. Performance of the models appeared to be the 
same between raw and second derivative data for both PLS and MLR models. 
Calibrations based on spectral data from scored (AS) tablets followed the same 
pattern as the nonscored (AN) tablets: equations developed specifically for AS data were 
able to fit AS validation sets but not AN or AC validation sets. Calibration and validation 
results are summarized in Table 19. Performance of raw data PLS models was slightly 
better than second derivative. Raw and second derivative MLR models were about equal in 
performance. 
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Table 17. Summary of hardness calibration/validation summary for AC (combined 
scored and nonscored) tablets. Reference SE for all A vicel/CTM SRC 
tablets is 0.68 kg. 
MLR- 2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
acm-call -0.994 0.468 NS/S 1.14 0.982 0.780 
acm-ca12 0.997 0.326 NS/S 1.45 0.997 0.341 
Nonscored 0.67 0.997 0.382 
Scored 0.01 0.996 0.414 
acm-cal3 0.996 0.402 NS/S 0.92 0.997 0.310 
Nonscored 11.00 0.998 0.300 
Scored 10.81 0.997 0.317 
ac-call -0.983 0.790 NS/S 0.00 0.995 0.439 
Nonscored 0.995 0.451 
Scored 0.994 0.495 
ac-cal2 0.996 0.408 NS/S 0.997 0.350 
Nonscored 0.997 0.369 
Scored 0.995 0.456 
ac-cal3 0.997 0.327 NS/S 0.991 0.571 
Nonscored 0.994 0.512 
Scored 0.07 0.993 0.513 
acm-ca14 0.992 0.529 NS/S 0.62 0.983 0.810 
Non scored 8.19 0.989 0.632 
Scored 8.28 0.986 0.687 
MLR-Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB mult r SEP 
ac-cal4 0.971 0.976 NS/S 0.04 0.969 1.060 
acm-cal5 0.993 0.490 NS/S 0.84 0.992 0.555 
acm-ca16 0.998 0.268 NS/S 2.72 0.997 0.342 
Non scored 6.42 0.996 0.405 
acm-cal7 0.995 0.423 NS/S 0.14 0.994 0.468 
Non scored 7.98 0.997 0.355 
Scored 4.26 0.991 0.568 
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Table 17. Calibration and validation summary of AC hardness (continued). 
PLS- 2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
acm-plsl 0.996 0.363 NS/S 0.99 0.996 0399 
Non scored 3.51 0.993 0.646 
Scored 2.24 0.996 0.470 
acm-pls2 0.997 0.348 NS/S 0.60 0.995 0.443 
Nonscored 8.24 0.995 0.907 
Scored 6.67 0.995 0.753 
ac-plsl 0.997 0.317 NS/S 0.47 0.994 0.516 
Nonscored 0.63 0.994 0.588 
Scored 1.53 0.995 0 .449 
ac- ls2 0.998 0.296 NS/S 0.21 0.995 0.417 
PLS-Raw hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
acm-pls3 0.998 0.315 NS/S 0.21 0.997 0.349 
Non scored 4.09 0.997 0.313 
Scored 3.10 0.995 0.405 
acm-pls4 0.998 0.312 NS/S 0.65 0.996 0.369 
Non scored 5.42 0.997 0.315 
Scored 4.35 0.995 0.423 
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Table 18. Summary of hardness calibration and validation results for AC (nonscored) 
tablets. Reference SE for A vicel/CTM SRC tablets is 0.68. 
MLR· 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acn-call -0.992 0.512 NSIS 7.50 0.995 0.435 
Non scored 0 .40 0.995 0.456 
Scored 11.80 0.993 0.488 
acn-cal2 0.997 0.345 NS/S 0.90 0.995 0.419 
Nonscored 0.97 0.995 0.456 
Scored 0.10 0.993 0.522 
acn-ca13 -0.996 0.370 NS/S 0.14 0.994 0.455 
Non scored 1.40 0.994 0.502 
Scored 0.14 0.993 0.515 
acn-ca14 -0.980 0.811 NS/S 8.70 0.987 0.707 
Nonscored l.80 0.989 0.705 
Scored 13.70 0.984 0.937 
acn-cal5 -0.996 0.375 NS/S 0.70 0.995 0.439 
Nonscored 0.84 0.994 0.500 
Scored 0.91 0.993 0.518 
acn-ca17 0.989 0.597 NSIS 7.90 0.992 0.567 
Nonscored 0.85 0.995 0.445 
Scored 12.70 0.988 0.678 
MLR-Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acn-cal8 0.997 0.303 NSIS 3.7 0.997 0.377 
Nonscored l.9 0.995 0.448 
Scored 6.5 0.993 0.609 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acn-plsl 0.997 0.313 NSIS 3.60 0.997 0.352 
Non scored 0.23 0.995 0.470 
Scored 6. IO 0.995 0.438 
acn-pls2 0.998 0.310 Nonscored 0.90 0.997 0.317 
Scored 4.50 0.996 0.412 
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Table 19. Summary of hardness calibration and validation results for ACS (scored) 
tablets. Reference SE for Avicel/CTM SRC tablets is 0.68. 
( 
MLR- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acs-call -0.994 0.455 NS/S 5.90 0.995 0.463 
Nonscored 12.76 0.994 0.458 
Scored 1.23 0.993 0.541 
acs-ca12 0.997 0.310 Non scored 0.994 0.468 
Scored 1.72 0.996 0.385 
acs-cal3 -0.994 0.472 NS/S 6.36 0.995 0.456 
Non scored 0.995 0.436 
Scored 1.04 0.993 0.527 
acs-cal4 0.996 0.399 Scored l.09 0.994 0.458 
MLR-Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acs-cal5 0.993 0.513 NS/S 6.11 0.991 0.603 
Scored 0.13 0.985 0.728 
acs-cal6 0.995 0.416 Scored 0.84 0.992 0.531 
acs-cal7 0.997 0.360 Scored 1.05 0.992 0.519 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acs- Isl 0.998 0.281 Scored 2.28 0.996 0.430 
PLS- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acs- ls2 0.999 0.250 Scored 0.81 0.994 0.498 
212 
These findings conclude that separate calibrations are needed for an accurate 
prediction of scored tablets. This further indicates that there is a difference in the NIR 
signal due to scoring of Avicel®/CTM tablets. 
1.4.5.2 Hardness CalibraJion of FF Avice/®/CTMTablets 
Table 20 summarizes the calibration and validation process for FF Avicel®/CfM 
tablets using MLR and PLS regression. The equations developed for the flat tablets were 
able to adequately predict AF validation sets. The SEE values for three out of four MLR 
models were far below the reference SEE (AF SEE = 0.66 kg) , which raises the suspicion 
of overfitting the model. These models also produced SEP's that were less than the SEE, 
an unexpected result since SEP's are normally greater than SEE' s. 
None of the AF equations were able to predict AC data sets. There did not appear 
to be a significant difference in calibration performance using raw data versus second 
derivative data for either MLR or PLS models. 
1.4.5.3 Hardness Calibration of Mixed FF & SRC Avice/®/CTMTab/ers 
Table 21 summarizes the results of calibrations developed for spectral data 
consisting of mixed AC and AF samples (ACAF). Lo general , it was possible to model the 
combined sets of Avicel® tablet data. PLS calibrations were better than MLR for these 
samples, and raw data produced slightly better results than second derivative data. 
The calibrations performed best when applied to validation sets of mixed samples. When 
applied to sets of flat, scored or nonscored tablet data, a large bias value resulted. 
Better calibrations resulted from data sets that excluded AF hardness levels 2 and 4. 
These two sample sets were very close to the "adjacent" sample sets in spectral appearance. 
These findings provide valuable information about the suitability of the calibration sample 
set. 
The effect of increasing the number of regression wavelengths can be observed in 
the first three MLR second derivative calibrations of Table 21 . Regression at 2054 nm 
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Table20. Summary of hardness calibration/validation results for AF (flat-faced) 
tablets. Reference SE for Avicel/CTM FF tablets is 039. (#denotes a 
deleted sample). 
MLR-2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
afcl-cl 0.9955 0.405 NS/S 4.6 0.939 2.160 
Rat 0.48 0.997 0.359 
afcl-c2 0.9975 0.309 NS/S 7.09 0.966 2.130 
Flat 0.7 0.998 0.275 
afcl-c3 NS/S 8.05 0.969 2.250 
NS/SI 0.49 0.973 0.962 
Flat 0.11 0.999 0.250 
afcl-c4 -0.993 0.509 NS/S 25.17 0.928 9.550 
Flat 0.51 0.993 0.519 
afcl-c5 0.9978 0.288 NS/S 21.58 0.966 5.710 
Flat 0.95 0.998 0.296 
MLR-Raw hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
afclr-cl 0.9986 0.229 NS/S 14.11 0.983 2.740 
Flat 0.56 0.999 0.231 
afclr-c2 0.9957 0.396 NS/S 44.38 0.990 6.410 
Flat 0.38 0.998 0.304 
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Table 20. Summary of AF calibration and validation results (continued). 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
afcl-pl 0.9979 0.2945 NS/S 10.89 0.971 2.820 
afcl-p2 0.9982 0.2727 Flat 0 .67 0.998 0.277 
NS/S 24.2 0.940 8.390 
Flat 0.7 0.998 0.258 
PLS- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
afclr-pl 0.9978 0.2874 Flat 0.25 0.9980 0.277 
afclr-p2 0.9987 0.2359 NS/S 9.60 0.995 1.070 
Flat 0.65 0.999 0.235 
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Table 21. Summary of hardness caJjbration/validation results for ACAF 
(combined FF and SRC) tablets. Reference SE for all (flat and SRC) 
Avicel/CTM tablets is 0.54. 
MLR-2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
acf2d-cl -0.990 0.644 ACAF 0.62 0.991 0.619 
NS/S 0.99 0.969 1.050 
Flat 1.69 0.994 0.541 
acf2d-c2 0.992 0.566 ACAF 0.17 0.993 0.539 
acf2d-c3 0.994 0.505 ACAF 0.05 0.993 0.521 
acf2d-c4 0.995 0.467 ACAF 0.09 0.996 0.426 
acf2d-c5 0.997 0.347 ACAF 0.67 0.996 0.393 
MLR- Raw hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
acf2-cl (h135) 0.992 0.586 NSIS 0.11 0.991 0.659 
Flat 0.80 0.994 0.513 
ACAF 1.24 0.991 0.624 
acf2-c2 (h 13 5) 0.995 0.461 Flat 0.03 0.735 0.224 
Scored 0.57 0.992 0.841 
ACAF 0.60 0.992 0.579 
NS/S 0.70 0.991 0.696 
AatH2 9.22 0.899 0.342 
Non scored 10.62 0.996 1.080 
amix-call 0.998 0.264 ACAF 4.23 0.981 1.020 
Flat 16.20 0.996 1.410 
amix-cal2 0.993 0.482 ACAF 8.05 0.837 4.380 
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Table 21 . Summary of calibration/validation results of ACAF hardness (continued). 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acf2d-pl 0.997 0.386 ACAF 1.21 0.997 0.396 
acf2d-p2 0.998 0.334 ACAF 0.13 0.997 0.388 
Scored 1.19 0.995 0.455 
NS/S 1.92 0.993 0.598 
Nonscored 5.29 0.995 0.705 
PLS- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
acf2-p I (h 135) 0.998 0.331 ACAF 0.51 0.997 0.340 
acf2-p2 (h 135) 0.998 0.265 ACAF 0.04 0.998 0.279 
amixplsl 0.999 0.213 ACAF 6.04 0.929 2.300 
amixpls2 0.998 0.271 ACAF 7.08 0.976 1.560 
amix ls3 0.997 0.313 ACAF 8.04 0.884 3.670 
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(calibration filename acf2d-cl) produced a satisfactory calibration, with an SEEof0.644 
kg. The addition of a second regression term at 2136 nm (calibration filename acf2d-c2) 
improved the SEE to 0.566. The SEP improved from 0.619 to 0.539, and the bias was 
significantly reduced. The addition of a third wavelength (2460 nm, calibration filename 
acf2d-c3) further improved the model. Linearity improved only slightly with the addition 
of the second and third wavelengths. 
Figures 42 to 46 display the residual versus NIR calculated hardness plots for 
several unsuccessful Avicel®/CTM calibration models. Each of the models produced a 
high degree of bias in the validation process. The bias is obvious in each of the plots, as 
there appeared to be two distinct populations. Further analysis showed that this was indeed 
the case, leading to the conclusion that the residual data are segregated by geometry. 
1 .4.5.4 Hardness Calibration of SRC Emcompress®ICTM Tablets 
Hardness calibration and validation results for EC (combined scored and nonscored 
data) tablets are summarized in Table 22. The reference SE for hardness of EC tablets was 
0.55 kg. Second derivative models came closest to this value in the SEE's. Linearity was 
also slightly better in second derivative calibrations. Second derivative models were used 
to predict three types of validation sets: nonscored, scored and mixed (nonscored plus 
scored) data. The best performance (SEP values) resulted unexpectedly from validation 
sets containing only scored data. Since scoring is probably responsible for much of the 
variability factor in the calibrations, we might conclude that some of the calibration samples 
contain too much variability, and the calibration set should be reevaluated. Remembering 
that both calibration and validation sets are representative of the entire sample population, 
we would ideally want outliers excluded, and our validation sets to be similar to the 
calibration samples. If they are not, then a new calibration set should be selected, which 
more closely resembles the entire population to be modeled. The present calibration set is 
not realistic, from a manufacturing perspective, since we would probably not use mixed 
data of this type. 
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Table22. Summary of calibration/validation results of EC (combined) hardness data. 
Reference SE is 0.55 for Emcompress/CTM SRC tablets. 
MLR- 2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
ecacal2 0.984 0.465 Non scored 0.61 0.969 0.677 
Scored 0.79 0.967 0.666 
NSIS 0.02 0.933 0.933 
ecaca13 0.963 0.674 Nonscored 2.31 0.971 0.758 
Scored 0.91 0.978 0.548 
NS/S 0.70 0.968 0.655 
MLR- Raw hardness data 
Cal.file mult r SEE Val.File bias/SEB molt r SEP 
ecacall 0.952 0.745 NS/S 0.39 0.972 0.624 
PLS- 2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mult r SEP 
ecapls4 0.9869 0.442 Nonscored 2.19 0.977 0.676 
Scored 0.85 0.977 0.566 
NS/S 0.22 0.936 0.911 
PLS· Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecapls2 0.960 0.695 NS/S 0.74 0.968 0.680 
eca ls3 0.973 0.568 NS/S 0.15 0.974 0.589 
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Results of hardness calibration and validation for ECN (nonscored) tablets are 
summarized in Table 23. Raw MLR calibrations were much better than second derivative 
MLR. The first set of MLR models (second derivative) differs in the number of 
wavelengths regressed. The first was developed at 1752 nm and the second at 1752 and 
1348 nm. Linearity was fair for both, and SEE values were close to the reference SE of 
0.55 kg. Prediction results were not as good, with relatively high bias/SEB and SEP 
values. In fact , these two models were better at predicting scored and mixed (scored with 
nonscored) data. This might be explained by the high regression coefficients obtained for 
each of the models. The regression coefficient for the first equation was 5950, and for the 
second the coefficients were 10,508 and 5,836; over 5,000 is undesirable and indicate 
overfitting. 
In contrast, one of the raw data MLR models had regression coefficient values in 
the low hundreds, and a SEE of 0.552 kg. Prediction based on this model resulted in a 
SEP of 0.353. This was a two-term equation, based on regression at 2492 and 1922 nm. 
The other equation in the raw data MLR section of Table 23 was a one-term model at 2492 
nm. Although prediction with this equation was good (SEP= 0.700 kg), this model was 
deemed unacceptable because the calibration multiple r value was only 0.919 and the SEE 
was 0.923 . 
PLS models for EC nonscored tablets also appear in Table 23. The best calibration 
was a second derivative model with a SEE of 0.$7 kg and a SEP of 0.579 kg. It can be 
noted from the table that these PLS models seemed to fit scored, nonscored and mixed 
(scored with nonscored) data nearly equally. However, the linearity of each of the models 
is marginal, with calibration multiple r value of 0.970 orless. If the calibration sample set 
was changed, linearity might improve. Of the two PLS models developed from raw EC 
nonscored data, one had a SEP of 0.623 kg, although the calibration multiple r value was 
only 0.954. Overall, calibration of nonscored Emcompress®/CTM tablets was only 
moderate! y successful. 
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Table23. Summary of hardness calibration/validation of EC nonscored tablets. 
Reference SE is 0.55 for Emcompress/CTM SRC tablets. 
MLR-2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecncall -0.961 0.643 Nonscored 2.57 0.972 0.844 
Scored 2.36 0.972 0.726 
NS/S 0.12 0.969 0.682 
ecncal2 0.969 0.594 Nonscored 2.35 0.961 0.980 
Scored 3.93 0.961 1.030 
NS/S l.12 0.949 0.877 
MLR- Raw hardness data 
Cal.file multr SEE Val.File bias/SEB molt r SEP 
ecnrcall 0.919 0.923 Nonscored 0.35 0.967 0.700 
ecnrcal2 0.973 0.552 Nonscored 1.91 0.989 0.353 
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Table 23. Summary of hardness calibration/validation of EC nonscored tablets 
(continued). 
PLS· 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecnplsl 0.942 0.787 Scored 0.20 0.975 0.659 
NS/S 1.09 0.976 0.652 
ecnpls2 0.969 0.625 Nonscored 2.52 0.973 0.820 
Scored 0.93 0.955 0.852 
NS/S 1.07 0.967 0.733 
ecnpls3 0.970 0.587 Nonscored 0.75 0.975 0.579 
Scored 0.92 0.975 0.587 
NS/S 0.11 0.976 0.567 
PLS- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecnrplsl 0.969 0.607 Non scored 2.81 0.955 1.010 
ec ls2 0.954 0.784 Non scored 0.07 0.970 0.623 
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Hardness calibration and validation results for ES (scored) tablets are summarized 
in Table 24. A series of second derivative MLR equations was developed by successively 
adding a wavelength term to the model. The first two models were created using one 
wavelength (2172 nm and 2170 nm, respectively). The second model bad a better SEE, 
but the prediction results were better with the first equation (SEP= 0.766 kg versus 
0.872). SEE's were further reduced by the addition of another regression term, but overall 
performance was not as good as expected. Although SEE values were very low, the 
performance of the models was not acceptable (i.e., SEP values were much higher than the 
reference SE). None of the scored MLR models could predict nonscored or mixed data 
sets; all predictions resulted in high bias/SEB and SEP values. 
Two MLR calibrations were created for scored tablets using raw data. The 
wavelengths used were the same as those in the nonscored data, with the same results. The 
two-term equation was better than the one term equation and SEP values were in the same 
range as the reference SE. 
One PLS calibration was developed for scored tablets using second derivative data. 
The SEE was 0 .854 and the SEP was 0.567 for scored tablets. This model predicted 
nonscored and mixed (scored with nonscored) nearly as well as it predicted scored data. 
This result indicates that the PLS model is not precise enough to discriminate the different 
data sets. 
1.4.5.5 Hardness Calibration of FF Emcompress®ICTMTablets 
Table 25 summarizes hardness calibration and validation results for EF (flat-faced) 
tablets. Overall, prediction results (SEP) for EF validation sets were at least as good as the 
reference SE of 0.46 kg. The first section contains two MLR models developed from raw 
data. The difference between them is that the first was constructed with a single 
wavelength (2288 nm, SEE= 0.692 kg) and the second from two wavelengths (2288 + 
1910 nm, SEE= 0.697 kg). lo this case, the addition of a second term did not 
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( Table24. Summary of hardness calibration/validation results for EC scored tablets . Reference SE is 0.55 for Emcompress/CTM SRC tablets. (*denotes an 
adjustment to bias/slope). 
MLR- 2d hardness data 
Cal.file mutt r SEE Val.File bias/SEB mutt r SEP 
ecscall 0.962 0.700 Nonscored 5.00 0.951 l.370 
Scored 0.59 0.955 0.766 
NSIS 3 .05 0.959 0.938 
ecscal2 0.983 0.476 Nonscored 6.71 0.940 1.880 
Scored 1.13 0.948 0.872 
NS/S 2.49 0.952 0.961 
ecscal3 0.988 0.416 Nonscored 7.01 0.929 2.100 
Scored 1.17 0.932 1.000 
NS/S 4.07 0.940 1.330 
ecscal4 0.989 0.397 Non scored 6.47 0.931 1.960 
Scored 1.03 0.935 0.979 
NS/S 3.67 0.942 1.250 
MLR· Raw hardness data 
Cal.file mutt r SEE Val.File bias/SEB mutt r SEP 
ecsrcal 1 0.932 0.933 Scored 1.80 0.967 0.733 
ecsrcal2 0.948 0.830 Scored 0.12 0.975 0.579 
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Table 24. Summary of hardness calibration/validation results for EC scored tablets 
(continued). 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecsplsl 0.943 0.854 Nonscored 
Scored 
NS/S 
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1.52 
0.03 
0.84 
0.967 0.744 
0.975 0.567 
0.976 0.581 
Table25. Summary of hardness calibration/validation results for EF (flat-faced) 
tablets. Reference SE for Emcompress/CTM flat-faced tablets is 0.46. 
MLR-Raw hardness data 
Cal.file mnlt r SEE Val.File bias/SEB molt r SEP 
efr-call 0.985 0.692 NS/S 8.09 0.951 1.870 
efr-cal2 0.985 0.6<n Flat 1.22 0.996 0.377 
MLR-2d hardness data 
Cal.file mult r SEE Val.File bias/SEB mutt r SEP 
ef-call -0.985 0.688 Flat 0.71 0.994 0.471 
ef-cal2 0.990 0.583 Flat 0.26 0.994 0.440 
ef-cal3 0.988 0.620 Flat 0.98 0.993 0.516 
PLS- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
efr-plsl 0.984 0.700 NS/S* 9.12 0.949 2.120 
Flat 1.30 0.996 0.366 
PLS- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ef-plsl 0.980 0.800 Flat 0.73 0.993 0.473 
ef- ls2 0.987 0.680 Flat 0.81 0.995 0.415 
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significantly improve the model. The SEP obtained upon prediction of an EF validation set 
using the two-term model was 0.377 kg. 
The second section of Table 25 contains MLR models developed from second 
derivative (2d) data. These were based on one, three, and two terms, respectively. The 
three-term model produced the best SEE (0.583 kg) and SEP (0.440 kg). 
PLS models follow the MLR results in Table 25. The raw data PLS model uti lized 
one factor and produced acceptable results (SEE= 0.700 kg, SEP= 0366 kg). The 
second derivative models varied in the number of factors, which were one and three, 
respectively. The three-factor model had a better SEE (0.680 kg) than the one-factor model 
(SEE= 0.800) and a better SEP (from 0.473 to 0.415 kg). It appeared that PLS and MLR 
models performed equally well, and second derivative models were slightly better than raw 
data models (bias/SEB ratios were lower for second derivative models). 
1.4.5.6 Hardness Calibration of Mixed FF & SRC Emcompress®/CFMTablets 
Numerous calibration equations were generated for Emcompress®/CTM tablets of 
mixed geometry (ECEF). Results of hardness calibration and validation for ECEF data are 
summarized in Table 26. Raw data and second derivative data performed equally well for 
ECEF data sets. All of the MLR and PLS models adequately fit validation sets of mixed 
EC and EF spectra. The addition of a second or more regression wavelengths improved 
the models. This point is illustrated by calibration files ecef-p3, ecef-p4, ecef-c5 and ecef-
c7 in Table 26. Ele ecef-p3 is based on one wavelength (1824 nm). The next three 
calibration files include the successive addition of regression wavelengths 2436 nm, 1620 
nm and 2236 nm, respectively. Each additional wavelength resulted in an improvement in 
both correlation coefficient (from 0.9'8:77 to 0.9957) and SEE (from 0.500 to 0.306). 
However, the SEP's did not improve as expected in the validation process. In this case, 
the SEP increased with each additional wavelength, and leveled out after three terms. 
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Table26. Summary of hardness calibration/validation of ECEF tablets. 
( Reference SE is 0.50 for all Emcompress/CTM tablets. 
MLR- 2d hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
ecef-cl 0.969 0.823 ECEF 0.34 0.981 0.618 
NS/S 0.47 0.946 0.818 
Nonscored 2.18 0.956 0.913 
Scored I. I 0.969 0.659 
ecef-<:2 0.982 0.602 NS/S 0.27 0.939 0.894 
ECEF 1.21 0.981 0.653 
ecef-p3 0.988 0.500 ECEF 1.57 0.981 0.681 
ecef-p4 0.993 0.390 ECEF 1.91 0.982 0.702 
ecef-c5 0.995 0.319 NS/S l.86 0.939 1.050 
ECEF 1.83 0.980 0.732 
ecef-c7 0.996 0.306 NS/S 1.68 0.940 l.040 
ECEF 1.62 0.979 0.754 
ecef-<:6 0.990 0.471 ECEF 1.83 0.979 0.763 
MLR- Raw hardness data 
Cal.file molt r SEE Val.File bias/SEB molt r SEP 
emixcall 0.964 0.893 ECEF 0.2 0.980 0.634 
NS/S 0.59 0.967 0.780 
Flat 1.6 0.995 0.458 
emixcal2 0.971 0.810 ECEF 0.27 0.985 0.550 
emixcal4 0.980 0.690 ECEF 0.52 0.986 0.550 
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Table 26. (continued) Summary of hardness calibration/validation of ECEF tablets. 
( PLS- 2d hardness data 
Cal.file mutt r SEE Val.File bias/SEB mutt r SEP 
ecef-pl 0.974 0.779 ECEF O.Q3 0.986 0.542 
Nonscored 1.25 0.961 0.792 
Scored 0.25 0.974 0.606 
ecef-p2 0.983 0.647 ECEF 0.54 0.974 0.749 
ecef-pl3 0.982 0.654 ECEF 0.65 0.986 0.548 
ecef-pl4 0.993 0.420 ECEF 1.32 0.975 0.814 
ecef-pl5 0.981 0.674 ECEF 1.09 0.983 0.626 
Non scored 2.28 0.961 1.050 
Scored 2.88 0.971 0.905 
ecef-pl6 0.985 0.595 ECEF 1.63 0.981 0.706 
Nonscored 1.59 0.960 1.140 
ecef- 17 0.992 0.460 ECEF 2.07 0.980 0.759 
PLS- Raw hardness data 
Cal.file mutt r SEE Val.File bias/SEB mutt r SEP 
emix Isl 0.980 0.689 ECEF 0.51 0.985 0.552 
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1.4.6 Calibration of Compression Force 
Upper and lower punch compression forces were calibrated against NIR data for 
flat faced tablets using both raw and second derivative data. As with hardness calibrations, 
the addition of a second regression term tended to improve a MLR model. Tablet matrix 
appeared to be a factor in the success of the calibrations, as it was possible in this study to 
calibrateAvicet® /CTM but not Emcompress® /CTM tablets. 
1.4.6.J Compression Calibration of FF Avicel®!CTMTab/ets 
The upper compression force (UC) calibration and validation results for A vice!® 
/CTM tablets are summarized in Table Tl. The reference SEE for flat A vice!® /CTM tablets 
was 0.099 kN (the overall SEE for A vice!® /CTM flat and convex tablets was 0.118 kN) 
for upper compression force. Regression coefficient values were under 2000 for second 
derivative data, and in the hundreds for raw data models. Two PLS models were 
developed for each type of data, using the full spectral range for one (1100 to 2500 nm) 
and a restricted range for the other model ( 1500-1990). Reducing the wavelength range 
improved the calibration statistics but did not improve prediction performance. Both of the 
raw data calibrations made adequate predictions of the validation set. Comparisons of raw 
data versus second derivative models were inconclusive, since there were only two models 
for each data type. 
Table 28 summarizes the calibration and validation efforts for lower compression 
(LC) force data. The reference SE for Avicel®/CTM LC flat tablets was 0.075 kN, and the 
overall SE for A vice!® /CTM flat and convex tablets was 0.086 kN. The same wavelengths 
as the UC calibrations were used for LC MLR models. Calibration statistics for LC data 
were slightly better than for UC data, with linearity being equal . 
Overall, calibration of Avicel®/CTM upper and lower compression force with NIR 
absorbance was successful despite the small number of samples in the calibration set. 
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Table27. Near-infrared calibration/validation of upper compression force for Avicel® 
/CTM tablets. 
MLR- 2d UC data 
Cal.file multr SEE Val .File bias/SES multr SEP 
afc2-cl -0.991 0.121 afcval2d 0.963 0.993 0.121 
afc2-c2 0.995 0.097 afcval2d 1.797 0.988 0.179 
MLR-Raw data 
Cal.file rnultr SEE Val.Ftle bias/SES multr SEP 
afc2r-cl 0.978 0.195 afc-val 0.304 0.979 0.196 
afc2r-c3 0.993 0.116 afc-val 0.654 0.993 0.128 
PLS-2d data 
Cal.file rnultr SEE Val.Ftle bias/SES multr SEP 
afc2-pl 0.999 0.052 afcval2d 0.214 0.989 0.144 
afc2- 2 0.993 0.112 afcval2d 1.606 0.995 0.114 
PLS- Raw data 
Cal.file multr SEE Val .File bias/SES multr SEP 
afc2r-pl 0 .991 0.129 afc-val 0.35 0.993 0.118 
afc2r- 2 0.993 0.116 afc-val 1.818 0.989 0.167 
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Table28. Near-infrared calibration and validation of lower compression force for 
Avicel®/ CTM tablets. 
MLR-2ddata 
Cal.ftle multr SEE Val.File bias/SEB multr SEP 
afc3-cl -0.991 0.103 afcval2d 0.312 0.992 0.099 
afc3-c2 0.995 0.080 afcval2d 1.461 0.988 0.136 
afc3-c3 0.997 0.059 afcva12d 2.024 0.992 0.123 
MLR-Raw data 
Cal.file multr SEE Val.File bias/SEB multr SEP 
afc3r-cl 0.977 0.163 afc-val 0.066 0.978 0.165 
afc3r-c2 0.992 0.097 afc-val 0.032 0.992 0.106 
PLS-2d data 
Cal.file multr SEE Val.File bias/SEB multr SEP 
afc3-pl 0.990 0.111 afcval2d 0.448 0.988 0.122 
afc3- 2 0.993 0.090 afcval2d 0.862 0.995 0.084 
PLS- Raw data 
Cal.file multr SEE Val.File bias/SEB multr SEP 
afc3r-pl 0.991 0.107 afc-val 0.253 0.991 0.107 
afc3r- 2 0.997 0.066 afc-val 1.795 0.989 0.135 
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1.4.6.1 Compression Calibration of FF Emcompress® /CFM Tablets 
Results of the upper punch calibration and validation for Emcompress® /CTM 
tablets are summarized in Table 29. The reference SE was an inflated l.T77 kN. This 
value dropped to 0.226 kN with the exclusion of level EFl data. Since the models were 
created using all five compression force levels, 1.277 kN is the relevant value. 
MLR models constructed from second derivative data had very high regression 
constants, despite conformance to acceptable SEE and SEP levels. These findings indicate 
the presence of high variability or an outlier in the calibration set. Emcompress® /CTM 
spectral and reference data contained more variability than theAvicel® /CTM tablets. 
Lower punch calibration and validation results appear in Table 30. Again, the 
reference SE for this data inflated to 0.925 kN with all data included, and 0.141 kN 
without EFl data SEE and SEP values fell below the reference SE, but there was a high 
amount of bias in the validations. Raw data models were slightly better than second 
derivative models. 
Due to the small sample size (n=20) and high amount of variability, the calibration 
of Em compress® /CTM flat tablets was deemed unsatisfactory. The process might be 
improved by using a larger calibration set and excluding the EFl tablet data. It bas been 
shown in other studies 7 that a greater matrix variability requires that many more samples be 
included in order to have a valid calibration. It is evident from the Avicel® /CTM results 
that compression force can be modeled using NIRS, however improper selection of the 
calibration set can produce inadequate results. 
1. 7 Conclusions 
These results describe the utility of the hardness/NIR relationships for different 
formulations. The NIR/hardness relationship established in Manuscript II still holds true 
for other matrices: an increase in tablet compression force resulted in an increased NIR 
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Table29. Near-infrared calibration and validation of upper compression force for 
Emcompress® /CTM flat tablets. 
MLR-Raw data 
Cal.file multr SEE Val.file bias/SES SEP multr 
efr2-cl 0.985 0.938 efc-val 0.129 0.439 0.993 
efr2-c2 -0.990 0.793 efc-val* 0.856 0.572 0.997 
efc2r-cl 0.998 0.296 efc-val 1.09 1.280 0.936 
efc2r-c2 -0.996 0.372 efc-val 1.336 0.702 0.997 
efc2r-c3 0.999 0.227 efc-val 0.035 1.570 0.976 
*restored deleted samples 
MLR-2ddata 
Cal.file multr SEE Val.file bias/SES SEP multr 
efc-call -0.994 0.583 efcval2d 1.536 0.708 0.997 
efc-cal2 0.997 0.436 efcval2d 4.835 0.950 0.999 
efc2-cl -0.999 0.225 efcval2d 1.167 0.357 0.995 
efc2-c2 0.999 0.183 efcval2d 2.026 0.425 0.995 
PLS- Raw data 
Cal.file multr SEE Val.file bias/SEB SEP multr 
efc2r- I 1.000 0.150 efc-val 4.338 0.278 0.999 
PLS-2d data 
Cal.file multr SEE Val.file bias/SEB SEP multr 
efc-plsl 0.985 1.030 efcval2d 3.063 1.230 0.992 
efc2- I 0.999 0.226 efcval2d 2.207 0.321 0.998 
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Table30. Near-infrared calibration/validation of lower compression force for 
Emcompress® /CTM tablets. 
MLR-Raw data 
Cal.file multr SEE Val.File bias/SEB SEP multr 
efc3-cl 0.985 0.693 efc-val 1.35 0.513 0.997 
efc3-c2 -0.989 0.597 efc-val 0.142 l.160 0.976 
MLR-2ddata 
Cal.file multr SEE Val.File bias/SEB SEP multr 
efc-cal3 -0.973 0.915 efcval2d 2.222 0.933 0.995 
efc-cal4 -0.995 0.403 efcval2d 1.439 0.531 0.997 
efc-cal5 0.997 0.319 efcval2d 3.993 0.679 0.998 
efc-cal6 0.998 0.269 efcval2d 4.44 0.773 0.998 
PLS- Raw data 
Cal.file multr SEE Val.File bias/SEB SEP multr 
efc3- I 0.984 0.718 efc-val 1.105 0.512 0.997 
PLS-2d data 
Cal.file multr SEE Val.File bias/SEB SEP multr 
efc- ls2 0.985 0.751 efcval2d 3.199 0.893 0.993 
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absorbance. There is a matrix effect involved in the NIR calibration of hardness and 
compression force. Calibration models must be formulation (matrix) specific. 
Tablet geometry also bas an effect on the NIR calibration of hardness. CaHbration 
models designed specifically for one geometry type did not fit another shape of tablet 
surface. Raw data models bad smaller regression coefficients than second derivative 
models, suggesting an increase in the amount of noise in the second derivative models. 
Mixed geometry models gave variable results, supporting the assertion that calibration 
models should contain samples of homogeneous composition. 
The NIR spectra of scored sides of tablets contained more variability between 
replicates (higher standard deviation) than the nonscored sides of tablets. This study did 
not find a statistical difference in NIR response to hardness due to scoring of 
Erncompress®/CTM tablets, possibly due to the higher variability in reference and spectral 
data versus tbeAvicel®/CTM data. There was a significant difference in NIR response due 
to scoring of the Avicel® /CTM tablets. This portion of the study suggests that separate 
calibrations should be developed for scored and nonscored tablets. 
This document described the determination of several tablet properties and 
subsequent caHbration using NIRS. Further work may lead to an explanation of the 
mechanism behind changing NIR absorbance in response to increased tablet hardness. 
Specific studies may be undertaken to determine which features of the tablet surface are 
most responsible for the change in NIR response to increased compression force. 
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Addendum to Manuscript IV 
The following observations were made with regard to the results of Manuscripts Ill 
and IV. 
Data from two tablet presses 
There was a difference in the NIR spectra between two batches of CTM 6% tablets 
manufactured with two different tablet presses. One batch was produced at the University 
of Rhode Island (URI), using one station of a sixteen-station Stokes Rotary Tablet Press. 
The second batch was made at Pfizer Central Research, using a Korsch six-station tablet 
press. The same raw materials were used in both blends. The same NlR 
spectrophotometer was used to obtain the reflectance spectra of all of the samples. When 
the spectra were plotted together, there was one region (Figure I a) where the spectra were 
different; the plot was essentially the same for the remainder of the spectra. 
This finding has implications in the validation process of a NIR hardness testing 
method. The spectral variation may be due to inhomogeneity of the blend or differences in 
the concentration of one or more of the components. As the URJ press was not 
instrumented, upper and lower punch data were not available for comparison to the Pfizer 
press data. In any case, a good NIR calibration set for this product would include this type 
of variation if a company produced these tablets at several manufacturing sites. 
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Figure la. Comparison of Nl R spectra of cWorpheniramine maleate 6%/ Avicel®/magnesium stearate tablets 
manufactured on two different tablet presses. 
Data from two hardness testers 
The overall standard error of the Pfizer hardness tester was 0.50 kg, as compared to 
032 kg for the Erweka hardness tester at URI. This difference may be attributed to the 
number and type of samples available for calculation. The error calculation for the Erweka 
Hardness Tester was based on sampling 20 flat faced, nonscored tablets from 20 batches of 
300. All of these samples were of the same excipient matrix, so the calculation was based 
on the testing of 400 similar samples. 
The calculation of the overall standard error of the hardness tester at Pfizer was 
based on a combination of flat faced and standard round convex tablets (with one scored 
side) and two different excipient matrices. Ten tablets from each batch of200 tablets were 
included in the calculation, for a total of 200 samples tested. Hardness testing of the flat 
tablets resulted in a much lower (0.41 kg) standard error than convex tablets (0.60 kg). 
This difference should be considered when calibrating hardness with NIRS. The standard 
error for all batches containing Avicel® was 0.52 kg, while that for Emcompress® was 
0.49 kg. This finding was unexpected, since NIR spectral data for the Avicel® -containing 
tablets appeared to be less variable than the Emcompress® tablet data. 
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SUMMARY OF CONCLUSIONS 
I) Near-infrared (NIR) spectrophotometric methods are becoming increasingly utilized 
by the pharmaceutical industry. However, the appearance of NIR methods in the 
pharmaceutical literature has been sparse, and indicates the reluctance of the industry to 
accept the technology. 
2) Although the potential of NIR to predict tablet parameters has been suggested, the 
published literature appears to have little data in this area. The present work appears to be 
the first study to evaluate the practical utility of the NIR/compression force relationship. 
3) Feasibility studies using chlorpheniramine/Avicel and bydrochlorothiazide/Avicel 
tablets indicated that a relatively simple relationship may exist between NIR absorbance and 
tablet hardness. An increase in tablet compression force resulted in a consistent increase in 
NIR absorbance. 
4) Chlorphenirarnine/Avicel and hydrochlorothiazide/Avicel tablets of increasing 
hardness levels were successfully differentiated by principal component analysis. This 
result indicates the potential use of NIR as a useful and non-destructive, quality control 
mechanism. The NIR signal responded in the same way to a change in hardness, 
regardless of the drug. 
5) A series of formulation specific equations was developed by calibrating tablet 
hardness data against NIR reflectance response (absorbance) for each formulation. The 
results of NIRS hardness prediction were at least as precise as the reference hardness test 
(SE= 0.32). 
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6) Calibration models developed using the calculated tablet density were better than 
those from hardness data. This was probably due to the accuracy of weight and thickness 
measurements and the high quality tablet press tooling. However, the predictive ability 
(SEP) of the hardness models was better than the density models. These results indicate 
that the hardness models contained built in variability and were thus more rugged. 
Conversely, the density models may have been overfitted. 
7) Separate calibration models are required for scored versus nonscored tablets, 
regardless of the tablet matrix. Mixed models consisting of scored and nonscored tablets 
adequately predicted mixed validation sets, but better predictions resulted when the 
calibration and validation sets contained only scored or nonscored tablets. 
8) NlR spectra are different for tablets of different excipient matrices, thus separate 
calibration models are required. 
9) Tablets composed of the same excipient matrix required slightly different calibration 
equations when the geometry was changed. Mixed models, composed of both nat and 
convex tablets, satisfactorily predicted mixed validation sets, but better predictions resulted 
when the calibration and validation sets contained tablets of only one type of geometry. 
10) It may be possible to predict tablet hardness using a NlR model based on only one 
wavelength. Good linearity and SEP values were obtained from simple linear regression 
equations from one or two wavelengths. 
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11) NIR calibrations for tablet hardness performed best when formulation specific 
models were constructed. Ruggedness was improved when all expected types of 
variability were included in the model. Linearity and SEE were improved when the 
calibration and validation sets contained a single type of product. 
12) The key factor in calibration development is the selection of the calibration set. It 
was illustrated in this work that careful selection of representative samples is imperative to 
the successful performance of the calibration model. 
13) This project demonstrated that it is possible to calibrate various tablet parameters 
with NIR absorbance data and achieve successful predictions of those parameters. NIR 
models for tablet hardness, density , upper and lower compression force data were 
developed using several different tablet matrices. 
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SECTION III 
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Appendix A. List of terms used in Statistical Summary Report! 
(*reprinted with permission of Paul Entrap, Marketing Manager, Perstorp Analytical Co., 
Silver Spring, MD) 
Bias 
Standard Error of Bias 
(SEB) 
Standard Error of 
Difference(SDD) 
Root Mean Square (RMS) 
Slope Adjustment 
Standard Error of Slope 
lnterceptAdjustment 
Standard Error of 
Performance 
Simple Correlation 
Achievable Standard Error 
of Prediction (achievable 
SEP) 
Prediction Stability 
Coefficient 
The average difference between the calculated and reported 
results. 
The standard error expressing the confidence interval of the 
reported bias. 
The bias corrected estimate of random errors. 
A non-bias corrected estimate of random errors. RMS will 
be equal to the SOD when the bias is zero. 
Factor by which the slope and bias terms are multiplied to 
adjust the existing equation to fit the current data. 1.00 = 
no adjustment. 
Estimate of the error on the computed slope. 
Adjustment to be made to the intercept term of the 
calibration when a slope adjustment is made. 
0 is equivalent to no adjustment. 
Estimate of the error in the computed values using a slope 
and bias corrected equation. 
Correlation between the calculated and reported values 
using the slope and bias corrected equation. 
The best estimate of the achievable standard error of 
performance using the available data from each group. 
Ratio of the achievable SEP to the actual root mean square 
deviation (SEP). Thus, the achievable is more often less 
than the actual SEP. 
I Reference Manual for Near Infrared Spectral Analysis Software (NSAS) Version 330a, 
NIRSystems, lnc./Perstorp Analytical Co. , Silver Spring, MD, pp.3-1to3-62, 1995. 
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APPENDIX B. 
Hardness calibration results for chlorpheniramine maleate (CTM), hydrochlorothiazide (HCTZ) and placebo tablets in Manuscript Ill. 
Table la. 
Legend: MLR 
PLS 
SEE 
* 
# 
Multiple linear regression 
Partial least squares regression 
Standard error of estimation (or calibration) 
deleted outlier 
nonrandom sample selection in calibrati on set 
CTM 2% MLR Calibration 
Cal.file k(O) k(I) k(2) k(3) A.nm 
ctm2cal -24.582 -4985.83 0 0 1458 
ct2cal4* -24.244 -4934.89 0 0 1458 
ct2ca12 -2.81 -4284.59 !075.8 0 1458+1528 
ct2cal3 1.266 4039.43 1231.8 - 117.2 1458+1528+1728 
ct2ca15 -2.461 -4300.2 11 02.4 0 1458+ 1528 
multr SEE 
-0.986 0.51 
-0.9878 0.482 
0.9905 0.423 
0.9912 0.411 
0.9929 0.372 
APPENDlX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript Ill. 
Table lb. CTM 2% PLS calibration 
Cal. file #factors MSECV (min) /...range nm multr SEE 
pls2ctm2 2 0.071 l.25 1100-2500 0.9871 0.4902 
pls3ctm2 2 0.069 l.24 1300-2350 0.9873 0.4857 
~ plsctm2 3 0.077 1.23 1100-2500 0.9884 0.4738 pls4ctm2 l 0.055 l.04 1300-2500 0.9903 0.4258 
pls5ctm2 3 0.055 l.23 ll74-1414 0.9906 0.4306 
[llls6ctm2 4 0.062 l. l 7 1950-2360 0.9911 0.4171 
APPENDIX B (continued) 
Hardness calibration results for CTM, Herz and Placebo tablets in Manuscript III . 
Table2a. CTM 6% MLR Cali bra ti on 
Cal.file K(O) K(I) k(2) k(3) k(4) A nm multr SEE 
c6sscall0 -18.86 -396.54 -536.9 1 -422.92 0 2236+1932+1436 0.976 0.554 
c6sscal6 35.81 14.04 0 0 0 155811784 0.987 0.394 
N 
~ c6sscall -28.37 -5523.27 0 0 0 1784 -0.989 0.365 
c6sscal8 -29.83 -441.25 -7523.23 0 0 2236+1780 0.992 0.325 
c6ssca12 -23.53 -3084.61 0 0 0 1590+1760 -0.992 0.318 
ctm6cal -28.37 -5520.97 0 0 0 1784 0.992 0.313 
c6sscal3 -28.58 -5579.67 -229.45 0 0 1784+2254 0.993 0.298 
c6sscal9 -29.77 -947.64 -6894.04 -992.57 0 2236+ 1780+2078 0.993 0.291 
c6ssca17 22.47 12.77 4527.15 0 0 1558/ l 784+ 1698 0.994 0.285 
c6sscal5 -35.59 -5934.56 -314.08 2686.51 -1113.249 1784+2254+ 1180 0.994 0.271 
+1720 
APPENDIX B (continued) 
Hardness calibration results for CTM, Herz and Placebo tablets in Manuscript Ill. 
Table2b. CTM 6% PLS Calibration 
Cal. file #factors MSECV (min) A. range nm multr SEE 
pls4ctm6 5 0.023 1.21 1300-2350 0.9942 0.2771 
~ pls3ctm6 5 0.022 1.06 1100-2500 0.9944 0.2721 
pls2ctm6 7 0.022 1.10 1100-2500 0.9961 0.2237 
1£!slctm6 8 0.024 1.06 1100-2500 0.9969 0.20~ 
~ 
APPENDIX B (continued) 
Hardness calibration results for CTM, Herz and Placebo tablets in Manuscript III. 
Table3a. CTM 2 & 6% MLR Calibration 
Cal.file K(O) K( I) k(2) A. range nm A.nm multr 
ct26cal5 -24.826 -1325.83 - 1930. 18 1100-2500 2018+1436+2236+2268 0.9439 
ct26cal I -33.124 -5821 .95 0 1100-2500 1824 -0.951 
ct26cal3 -32.4 152.738 -7151.95 1930 1930+1824 0.9538 
ctm26cal2 -20.653 -9243.32 1510.452 1100-2500 1824+2324 0.9676 
Table3b. CTM 2 & 6% PLS Calibration 
Cal. file #factors I MSECY (min) A range nm I mult r SEE 
c26olsl II I 0.064 1.18 l 100-2500 I 0.9908 0.4121 
" 
SEE 
0.982 
0.912 
0.887 
0.746 
~. 
APPENDIX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript Ill. 
Table4a. HCTZ 15% MLRCalibration 
Cal.file K(O) K(I) K(2) K(3) A. nm mull r SEE 
hctl5c2# -2 1.81 511.34 0.00 0 1998 0.944 1.010 
6hc15cal 21.54 - 139.21 0.00 0 157211998 -0.985 0.513 
4hc15cal -9.21 235.44 -2027.65 0 1998+1578 -0.959 0.441 
~ hct15cal# -31.17 -1399.01 0.00 0 2076 -0.984 0.547 
2hc15cal -29.89 -1345.28 0.00 0 2076 -0.983 0.541 
5hcl5cal -27.78 -992.8 1 771.80 0 2076+1316 0.989 0.445 
3hl5cl * -29.37 -1323.68 0.00 0 2076 -0.991 0.412 
3h15c2* -26.25 -896.24 - 1232.31 0 2076+1822 0.994 0.330 
3hl5c3 -22.25 -479.63 -2172.43 292.36 2076+1822+1902 0.996 0.295 
7hcl5cal -2. 11 -955.78 0.00 0 1360+2262 0.990 0.502 
9hc15cal 71.97 -51.69 0.00 0 1580/1676 -0.989 0.430 
8hc15cal -25.11 -1372.35 908.01 0 2320+1328 0.990 0.417 
10hc15ca -12.16 -63 1.55 -3582.01 0 1520+1576 0.991 0.393 
APPENDIX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript Ill. 
Table4b. HCTZ 15% PLS Calibration 
Cal. file #factors MSECV A. range nm (min) multr SEE 
pls2hc15* 4.00 0.03 1100-2500 1.13 0.995 0.301 
pls4hcl5 4.00 0,03 1300-2350 1.18 0.995 0.294 
7hcl5pls 6.00 0.04 1100-2500 1.21 0.994 0.341 
~ plshct15 6.00 0.04 1100-2500 I.OJ 0.995 0.310 ~hi~ 4.00 0.06 1100-2500 l.12 0.996 0.289 
~ 
APPENDIX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript lll . 
Table Sa. HCTZ 20% MLR Calibration 
Cal.file K(O) K(I) K(2) A. nm multr SEE 
Shc20cal -13.7 499.789 0 1394 0.9799 0.446 
6hc20cal -14.002 73.401 760.654 1930+1390 0.9808 0.442 
hc20cal2 -14.801 120S.Oll 0 1334 0.9871 0.426 
hc20cal3 -14.613 1203.062 0 1332 0.989 0.38S 
hct20cal# -14.39S 1184.126 0 1332 0.99 0.356 
hc20cal4# -14.636 1204.486 0 1332 0.991 0.354 
Table Sb. HCTZ 20% PLS Calibration 
Cal. file #factors MSECV A. range nm multr SEE 
pls2bc20 3 0.054 1100-2500 0.9882 0.4142 
pls4hc20 3 0.054 1300-2350 0.9893 0.393 
pls3h20 3 0.046 1100-2500 0.99 0.3743 
1£!shct20# 3 O.Q38 1100-2500 0.990S 0.3588 
APPENDIX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript Ill. 
Table 6a. HCTZ 15% & 20% MLR Calibration 
Cal.file K(O) K(I) k(2) A. nm multr SEE 
hcAcall -26.655 -1101.81 0 2262 -0.971 0.665 
hcAcal2 -26 - 1077.04 0 2262 -0.977 0.575 
hcAcal4 -26.585 -1098.62 0 2262 -0.979 0.556 
~ hcAcal3 -25.747 - 1067.43 0 2262 -0.979 0.551 
hcAcal5 -18.999 - 129.26 -2503.1 14 1930+1820 -98.41 0.464 
Table 6b. HCTZ 15% & 20% PLS Calibration 
Cal. file #factors MSECV A. range nm multr SEE 
plslhcA 7 0.065 1100-2500 0.9877 0.4478 
pls2hcA 4 0.052 1100-2500 0.988 0.4075 
pls3hcA 5 0.043 1100-2500 0.9905 0.3615 
1£!s4hcA 5 0.042 1100-2500 0.991 0.3502 
APPENDIX B (continued) 
Hardness calibration results for CTM, HCTZ and Placebo tablets in Manuscript lll. 
Table 7a. MLR Calibration of Placebo ( 1200-24.SOnm) 
Cal.file K(O) K(l) k(2) k(3) k(4) A.nm multr SEE 
pl3cl -15.47 8077.78 -3246.33 621.31 0 1320+222o+2400 0.99 0.400 
pl3c2* - 15.24 8246.67 -3307.55 601.46 0 1320+2220+2400 0.993 0.338 
1£!4cl -19.24 7123.99 2160.32 -2683.24 666.02 1320+1700+2220+2400 0.991 0.383 
~ 
Table 7b. PLS Calibration of Placebo ( 1200-24.SOnm) 
Cal. file #factors MSECV (min) multr SEE 
pl2p2 7 0.034 I 0.9936 0.3144 
pl2p3 6 0.043 1.25 0.9921 0.3452 
pl2p4 6 0.046 1.2 0.9914 0.3593 
pl2p5 7 0.031 I 0.9942 0.3006 
pl2p6 6 0.043 1.38 0.9928 0.3294 
p12p7 6 0.o3 1.24 0.9939 0.2949 
1£!2£§_ 5 0.043 1.77 0.9894 0.382 
APPENDIX C. 
The following tables contain density calibration coefficients and other data from 
Manuscript Ill. 
Table la. MLR density calibration results for CTM 2% in Manuscript III. 
Cal.file K(O) K(l) k(2) A. nm multr SEE 
dct2cl -0.671 444.071 0.000 1292 0.9778 0.0204 
dct21sc2 -0.89 1 272.346 21.136 1292+2228 0.9867 0.0159 
dct2c3 2.071 0.213 0.000 152411292 0.9821 0.0182 
dct2c4 -0.235 -6.208 0.000 1292/1524 -0.9815 0.0187 
Table lb. PLS density calibration results for CTM 2% in Manuscript lU. 
Cal. file #factors MSECV (min) A. range nm multr SEE 
dct2pll 5 0 1.20 1100-2500 0.9938 0.0112 
dct2pl2 4 0 1.18 1100-2500 0.9927 0.0118 
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APPENDIX C (continued) 
Table 2a. MLR density calibration results for CTM 6% in Manuscript Ill. 
Cal .tile K(O) K( I ) k(2) A.nm multr SEE 
dct6cl -1.156 -96.739 0.000 2352 -0.9779 0.0224 
dct6c2 -0.922 -74.151 93.802 2352+2172 0.9826 0.0200 
dct6c3 2.228 3 .409 0.000 1.568/2352 0 .9832 0.0195 
dct6c4 2.036 -0.338 0.000 2352/1454 0 .9860 0.0179 
Table 2b. PLS density calibration results for CTM 6% in Manuscript Ill. 
Cal. file #factors MSECV (min) A. range nm multr SEE 
dct6pll 6 0 1.00 1100-2500 0.9956 0.0104 
dct~2 6 0 1.00 1100-2500 0.9958 0.0100 
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APPENDCX C (continued) 
Table 3a. MLR Density calibration results for HCTZ 15% in Manuscript III. 
Cal.file K(O) K(I) k(2) A.nm multr SEE 
dhl5cl -0.161 -201. 146 0.000 1820 -0.9850 0.0217 
dh\5c3 -0.093 -2.339 0.000 1820/1556 -0.9943 0.0135 
dh\5lsc2 0.760 -187.750 -70.132 1820+1558 0.9951 0.0127 
Table 3b. PLS Density calibration results for HCTZ 15% in 
Manuscript m. 
Cal. file #factors MSECV (min) A.range nm multr SEE 
dhcl5pll 5 0 1.24 1100-2500 0.9966 0.0109 
dhl5pl2 5 0 1.16 1100-2500 0.9972 0.0098 
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APPENDIX C (continued) 
Table 4a. MLR Density calibration results for HCTZ 20% in Manuscript Ill. 
Cal.file K(O) K(I) k(2) A.nm multr SEE 
dh20cl 0.300 -82.442 0.000 2318 -0.9740 0.0178 
dh20c2 0.155 -73.691 -82.157 2318+1814 0.9887 0.0119 
dh20c3 0.602 -0.469 0.000 231811568 0.9680 0.0197 
dh20c4 1.709 0.641 0.000 156812318 0.9832 0.0144 
Table 4b. PLS Density calibration results for HCTZ 20% in Manuscript Ill. 
Cal. file #factors MSECV (min) A. range nm multr SEE 
dh20pll 6 0 1.00 1100-2500 0.9972 0.0062 
dh2_2E!2 6 0 1.00 1100-2500 0.9984 0.0048 
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